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1 Introduction  
1.1 Taxonomy of Streptococcus pyogenes (S. pyogenes) 
S. pyogenes belongs to the genus Streptococcus, the family Streptococcaceae and to the 
order Lactobacillales. The order Lactobacillales belongs to the class Bacilli and to the 
phylum Firmicutes. Firmicutes included all gram-positive bacteria. Gram-positive 
bacteria are divided into two separate phyla: the Firmicutes (low G+C gram-positive 
bacteria) and the Actinobacteria (high G+C gram-positive bacteria) (Rocha, 2002; 
Patterson., 1996). Several members of the genus Streptococcus are pathogenic for humans 
and animals. Some species are proven or suspected to be zoonotic. Several members are 
commensal species. S. pyogenes is a human pathogen and has a worldwide distribution 
(Fulde & Valentin Weigand, 2013). 
1.2 General properties of Streptococcus pyogenes  
S. pyogenes is a fermentative, aerotolerant, catalase negative, beta hemolytic, nonmotile, 
non-spore-forming gram-positive coccus. S. pyogenes has a hyaluronic acid capsule. It 
occurs in chains or pairs (Patterson., 1996). It grows under aerobic and anaerobic 
conditions. S. pyogenes is a lactic acid bacterium and generates energy through acid-
generating fermentation pathways. It converts carbohydrates to lactic acid by 
fermentation (Murdoch, 1998; Steele, et al., 1953; Pancholi & Caparon, 2016). 
Streptococcus is considered as a low G+C content genus (Gao, et al., 2014; Rocha, 2002). 
1.3 Classification  
Streptococci are classified based on hemolysis into three groups according to their 
appearance on blood agar: α-hemolytic, β-hemolytic and γ-hemolytic. α -hemolysis, 
which is observed as green zones around colonies, is caused by oxidation of the 
hemoglobin by bacterially produced H2O2. β -hemolysis appears as clear zones 
surrounding the colonies, and is due to the lysis of red blood cells by secreted hemolysin. 
Streptococci that display no zones or haloes around their colonies are called γ-hemolytic 
(Becker, 1916). They are also classified based on serologic specificity. In the early 20th 
century, Rebecca Lancefield described a serological classification of streptococci based 
on the carbohydrate composition of bacterial antigens found  in the cell walls of β-
hemolytic streptococci (Lancefield, 1933a). The Lancefield serological grouping system 
for identification of streptococci is based on the immunological differences in their cell 
wall polysaccharides (group A, B, C, F and G) or lipoteichoic acids (group D) 
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(Cunningham, 2000). S. pyogenes is known as group A streptococci (GAS) and appears 
as beta-hemolytic on blood agar. 
S. pyogenes is further subdivided into different serotypes based on the highly variable N-
terminal sequence of the cell surface M protein as described by Rebecca Lancefield 
(Lancefield, 1962b). Currently, there are over 190 types of M-protein genes (emm) 
identified in S. pyogenes (Maripuu, et al., 2008). This typing system is based on a 
sequence at the 5' end of emm that is present in all isolates. The targeted region 
of emm displays the high level of sequence polymorphism. There are four main 
subfamilies of emm genes which are distinguished by sequence variations in the 3´end, 
encoding the peptidoglycan-spanning domain. emm subfamily genes are arranged in the 
chromosome in 5 different patterns from A to E (McGregor & Spratt, 2004).   
 
1.4 Clinical manifestation 
Group A streptococci colonize the skin or throat and lead to several suppurative infections 
and non-suppurative sequelae. They have developed different virulence mechanisms to 
avoid host immune system (Cunningham, 2000). Acute Streptococcus 
pyogenes infections may take the form of pharyngitis, scarlet fever (rash), impetigo, 
cellulitis, or erysipelas. Invasive infections can result in life-threatening diseases like 
necrotizing fasciitis, myositis, bacteremia and streptococcal toxic shock syndrome 
(Cunningham, 2008; Stevens, 2000). Rheumatic fever, Pediatric Autoimmune 
Neuropsychiatric Disorders Associated with Streptococcal infections (PANDAS) and 
glomerulonephritis are autoimmune post infectious sequelae of S. pyogenes infections 
(Benedek, 2006; Cunningham, 2016; Swedo, et al., 1998). S. pyogenes is sensitive to β-
lactam antibiotics. The number of strains resistant to macrolide antibiotics is rising 
(Logan, et al., 2012). Macrolides, chloramphenicol, teicoplanin, vancomycin, and 
levofloxacin are considered as alternative therapies of S. pyogenes infections (Camara, et 
al., 2013). 
 
1.5 Virulence factors of S. pyogenes 
Different virulence factors of group A streptococci have been studied. Streptococcal 
adhesins such as M protein and lipoteichoic acid are important factors which mediate 
attachment to the host epithelial cell (Courtney & Podbielski, 2009; Ryan & Juncosa, 
2016). The M protein and the hyaluronic acid capsule are factors that inhibit phagocytosis 
(Fischetti, 2016). All S. pyogenes infections are established firstly by attachment of the 
bacterial organism to human epithelial cells, including those in the oral and nasal cavities 
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and the skin. Lipoteichoic acid (LTA) was the first streptococcal adhesin to be identified 
that reacted with fibronectin on the host cell (Hanski , et al., 1992). At least 24 other 
adhesins have been identified after LTA such as M protein, SpeB, FbaA, FbaB, protein 
F1 and protein F2, Cpa, Lmb, Sfbx, which bind to human extracellular matrix proteins, 
including collagen, fibronectin (Fn), and laminin (Courtney & Podbielski, 2009; Fischetti, 
2016; Walker, et al., 2014; Fiedler, et al., 2010). Oligocomponent pilus structures 
represent a class of virulence factors with adhesive and matrix protein-binding activity. 
These extended surface structures play key roles in host cell and tissue adherence in S. 
pyogenes (Kreikemeyer, et al., 2011c). Streptodornase (DNase), streptokinase 
(plasminogen activation), and streptolysine S biosynthesis proteins (hemolysis) have been 
proved as virulence factors in S. pyogenes (Patterson., 1996; Winter & Berwheimer, 1963; 
Fiedler, et al., 2010).  
Once streptococci have attached to the epithelium, different events can occur: in one 
pathway, the activation of nonspecific, innate, and specific host defense mechanisms or 
potential induction of bacterial “apoptosis” will happen. These phenomena lead to the 
limitation of infection and clearance of the bacteria from host cells. The other pathway is 
to prevent the primary immune responses of host and a successful colonization of the 
host's tissues (Courtney & Podbielski, 2009). Extracellular products, such as pyrogenic 
(erythrogenic) toxins are essential factors to destroy host cells and to colonize suitable 
sites in the host, resulting in the spreading of the bacteria to a new site in the host. 
Subsequently streptococci can proliferate and spread to adjacent host tissues. S. pyogenes 
possesses many virulence factors, which are mediators of infection and survival within 
the host (Figure 1-1), (Courtney & Podbielski, 2009; Podbielski & Kreikemeyer, 2004b). 
 
 
 
Figure 1-1. Model of the impact of adhesion, invasion, and intracellular persistence on the 
pathogenesis of streptococcal infections (Courtney & Podbielski, 2009). 
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1.6 Regulation of gene expression  
During the infection process, expression of pathogenicity factors is precisely controlled 
by a network of protein and RNA regulators. Precise regulation is essential for responding 
to the host conditions for avoidance of the host immune system. These responses are 
mostly provided by two main types of regulators: approximately 30 stand-alone response 
regulators (RRs) and up to 13 two-component signal transduction systems (TCSs) 
(Fiedler, et al., 2010; Parkinson & Kofoid, 1992; Kreikemeyer, et al., 2003b). 
During the first decade of 21th century, RNAs were discovered as important regulatory 
factors in eukaryotes as well as in prokaryotes. Among them, miRNAs, sRNAs and 
riboswitches have been investigated in all three domains of life (Patenge, et al., 2015). 
RNA-mediated regulation confers the ability of fast adaptation of cell growth in response 
to environmental stress. Bacterial sRNAs are composed of 30 to 500 nucleotides and 
influence gene expression (inhibition or activation) in response to environmental signals 
through different mechanisms at both transcriptional and translational level (Landt, et al., 
2008).  
Bacteria produce three types of non-coding regulatory RNAs:  
(A) Cis-encoded antisense RNAs; a cis-encoded antisense RNA (as RNA) has only one 
target mRNA. It is encoded on the opposite strand of the target mRNA and its sequence 
is complementary to the respective target mRNA. Naturally, cis-acting antisense RNAs 
pair to the target RNA at specific regions of high complementarity over a small region of 
6 to 8 nt to control biological function by regulating gene expression at the post-
transcriptional level. Specific and fast recognition is attained with a short binding site. An 
asRNA-mediated regulation generally inhibits mRNA transcription and/or translation or 
induces their rapid mRNA degradation. In fewer cases, asRNAs activate expression of 
mRNAs (Cho & Kim, 2015) (Figure 1-2.A).  
(B) Trans-acting small non-coding RNAs; trans-acting small non-coding RNAs (sRNAs) 
have multiple target mRNAs. They are encoded in intergenic regions on the chromosome 
in a distinct locus from the target mRNAs. As an outcome, its sequence is similar to 
targets but not identical and can pair to more than one target. After binding to target it 
controls translation or degradation of target mRNAs (Cho & Kim, 2015) (Figure 1-2.B). 
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Figure 1-2. Schematic representation of gene regulation at translational level by cis-encoded 
antisense RNA and Trans-acting small non-coding in bacteria. A) Cis- encoded asRNA has a high 
complementarity to the target mRNA. B) Trans- acting small non-coding RNAs are encoded on 
a locus distinct from their target mRNAs. They are similar to their targets but not identical. In 
some cases, trans-acting small non-coding RNAs need Hfq to facilitate binding to the targets 
(Saberi, et al., 2016). 
 
(C) Cis-acting 5′ element non-coding RNAs; since ribosomes can bind mRNA before the 
transcription of DNA to mRNA is complete, most cis-regulatory signals are found within 
the 5′ untranslated region (UTR) of mRNAs. These regulatory regions contain structures 
which sense environmental signals (riboswitches or thermosensors) or are potential 
binding sites for trans-acting regulators (non-coding RNAs or proteins). In riboswitches, 
binding of small metabolites leads to a structural change that influences transcription or 
translation of the downstream gene(s) in an operon (Cho & Kim, 2015) .  
In comparison to transcriptional regulation mediated by protein–DNA interaction and to 
post-translational regulation exerted by protein–protein interaction, regulation by non-
coding RNAs is profitable when fast responses to environmental signals are needed 
(Shimoni, et al., 2007). As non-coding RNAs are not translated, it is beneficial to cells to 
use sRNA-mediated regulation, so the energetic cost of their synthesis is lower than 
synthesis of regulatory proteins (Altuvia & Wagner, 2000). Regulation by non-coding 
RNAs at the translational level results in a quicker effect than at the transcriptional level 
since mRNA is the direct target (Cho & Kim, 2015; Sharma, et al., 2007). Some sRNA 
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molecules bind to proteins and affect transcription or translation. For example, CsrB or 
RsmA sRNA family inhibit RNA binding regulatory proteins (Babitzke & Romeo, 
2007). The Csr system also modulates gene expression post-transcriptionally by affecting 
mRNA stability in E. coli (Esquerré, et al., 2016). sRNAs can protect bacteria against 
foreign and invasive DNAs and phages as a part of the CRISPR system which is known 
as immune system for bacteria (Jiang & Doudna, 2015).  
 
1.6.1 Regulation by sRNAs in S. pyogenes 
A few sRNAs with regulatory functions have been identified and described in S. 
pyogenes. Pel/sagA RNA (pleiotropic effect locus/streptolysin-associated gene A) and 
RivX RNA and FasX (fibronectin/fibrinogen-binding/hemolytic-activity/streptokinase-
regulator-X) have been described and shown to play critical roles in the expression of 
virulence factors in S. pyogenes (Kreikemeyer, et al., 2001a; Mangold, et al., 2004; 
Ramirez-Peña, et al., 2010; Le Rhun, et al., 2016; Roberts & Scott, 2007).  
Pleiotropic effect locus (pel) which contains sagA, the structural gene for streptolysin S, 
is an effector of virulence factor expression in S. pyogenes. Regulation by pel RNA occurs 
at both transcriptional (emm, sic, nga) and post-transcriptional (SpeB) levels (Li, et al., 
1999; Mangold, et al., 2004).  
RivX is an sRNA that has been studied in the M1T1 serotype. RivX is putatively involved 
in the regulation of the Mga (multiple gene activator) regulon that controls the expression 
of a number of virulence-associated factors (Roberts & Scott, 2007; Le Rhun, et al., 
2016).  
FasBCA is a growth phase-associated two component system (fibronecin/fibrinogen 
binding/hemolytic activity/streptokinase regulator) that has been studied in detail in S. 
pyogenes. The fas operon is transcribed as polycistronic message (fasBCA) and contains 
genes encoding two potential histidine protein kinases (FasB and FasC) and one response 
regulator (FasA). Downstream of fasBCA, a 300 nucleotide monocistronic transcript 
(fasX) is located that does not encode any peptide sequences (Kreikemeyer, et al., 2001a). 
FasX affects virulence factor expression using at least three distinct known mechanisms: 
(A) FasX positively regulates streptokinase gene expression by stabilizing the ska mRNA 
(Ramirez-Peña, et al., 2010). (B) FasX negatively regulates pilus expression and 
adherence in S. pyogenes. It base pairs to the 5′ end of mRNA of the pilus biosynthesis 
operon. RNA:RNA interaction destabilizes the mRNA and subsequently reduces the 
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ability of adherence to human keratinocytes (Liu, et al., 2012). (C) FasX also negatively 
controls cpa mRNA encoding a pilin protein and inhibits the translation of cpa and leads 
to the negative regulation of pilus expression (Danger, et al., 2015; Liu, et al., 2012).  
1.6.2 Riboswitches as regulatory elements 
Riboswitches were first discovered in 2002, when the first RNA-based intracellular 
sensors of vitamins were found (Mironov, et al., 2002; Nahvi, et al., 2002; Winkler, et al., 
2004). They are present in all three domains of life. Riboswitches are regulatory non-
coding RNA structures and are mostly found within the 5′ untranslated regions of 
mRNAs. They play a crucial role in adaptive responses through sensing environmental 
signals. Known riboswitches sense different biological signals such as amino acids and 
their derivatives, carbohydrates, coenzymes, thiamin pyrophosphate, nucleobases and 
their derivatives (Serganov & Nudler, 2013b), inorganic ligands including metals (Mg2+ 
cations) (Cromie, et al., 2006), and anions (Baker, et al., 2012).  
1.6.3 Structure and function of riboswitches 
Most riboswitches are composed of two distinct functional domains, the aptamer(s) and 
the expression platform. The aptamer is the sensor domain of the riboswitch and very 
conserved in sequence and structure across bacterial species, because it is involved in the 
recognition of the signal (Serganov & Nudler, 2013b). Riboswitch classes have evolved 
by alteration of their metabolite specificity, accommodating a different ligand or signaling 
compound. Different variants are known for riboswitch classes that recognize different 
signaling molecules (Weinberg, et al., 2017). 
The second domain of a riboswitch is an expression platform that is located immediately 
downstream of the aptamer domain (Figure 1-3). Ligand binding to the aptamer domain 
induces a conformational change in an expression platform, resulting in transcriptional or 
translational regulation. Regulation sometimes leads to RNA processing or affects mRNA 
stability (Serganov & Nudler, 2013b). 
 
 
Figure 1-3. Schematic representation of the arrangement of aptamer domain and expression 
platform in a riboswitch in an mRNA transcript. The aptamer domain and the expression platform 
overlap through a sequence that can base pair with either domain (yellow bar). 
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1.6.3.1 Transcriptionally acting riboswitch 
The presence of a signal either induces a Rho-independent terminator or exposes Rho 
binding site and leads to premature transcription termination. Consequently, synthesis of 
the full-length mRNA will be inhibited (Serganov & Nudler, 2013b). If formation of an 
anti-terminator hairpin is promoted, RNA polymerase completes transcription of the 
gene. The Gly riboswitch in B. subtilis is one example of this type (Phan & Schumann, 
2007). 
1.6.3.2 Translationally acting riboswitch 
Signal detection by the sensor domain of the riboswitch leads to either sequestering of the 
ribosome binding site (RBS or Shine-Dalgarno sequence: SD) and subsequently 
repression of ORF expression or facilitating the access of ribosome to the RBS by 
formation of SD antisequester hairpin and translation initiation (Serganov & Nudler, 
2013b). 
1.6.3.3 Induction of mRNA degradation 
mRNA degradation as a mechanism for riboswitch function was observed in gram-
positive bacteria in 3 different fashions.  
(A) Ligand binding promotes cleavage by riboswitch-ribozyme. An open 5′-OH is 
created, which stimulates RNase J, and leads to degradation of mRNA (Bastet, et al., 
2011). 
(B) Self-splicing and simultaneous translation activation was determined as a riboswitch 
mechanism in C. difficile. Self-splicing occurs in the presence of ligand. Somehow the 
complete SD will be accessible by the ribosome and translation will be proceed. In the 
absence of ligand, SD can be removed from the mRNA resulting in repression of 
translation initiation (Chen, et al., 2011). 
(C) In the absence of the metabolite, an anti-terminator structure forms and transcription 
proceeds. In the presence of a ligand, formation of a terminator structure inhibits 
transcription initiation. There is one hypothesis that truncated RNA will bind to the 5´-
UTR of the corresponding mRNA and RNA:RNA interaction will reduce RNA stability. 
This kind of modulation was observed in L. monocytogenes (Serganov & Nudler, 2013b). 
1.7 Glycine (Gly) riboswitch  
Gly riboswitches commonly consist of two adjacent homologous aptamers, linked by a 
short linker region preceding Gly catabolism and efflux genes in different groups of 
bacteria (Barrick, et al., 2004; Mandal, et al., 2004; Ruff & Strobel, 2014; Phan & 
Schumann, 2007). They regulate the expression of downstream genes that are involved 
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in transport or degradation of Gly to balance the concentration of Gly in bacterial cells 
(Kazanov, et al., 2007). Studies have shown that two aptamers function cooperatively. It 
means Gly binding to one aptamer increases the affinity for Gly of the other aptamer 
(Mandal, et al., 2004; Butler, et al., 2011). However, a full-length derivative of the Gly 
riboswitch containing its extended 5′ leader, did not show cooperative binding (Sherman, 
et al., 2012). 
In Gly riboswitches ligand binds to both aptamers in ligand-binding pockets which have 
nearly identical and conserved sequence features. Nucleotide positions near the ligand 
binding pocket at positions 32, 35, and 69 are a base for classifying Gly riboswitches to 
different variant groups. In one variant key nucleotides are G, G, U. The other variant is 
D, G, A that D identify every nucleotide but not C (Weinberg, et al., 2017) (Figure 1-4). 
 
 
 
Figure 1-4. Consensus nucleotides in the Gly riboswitch in B. subtilis. Circles and thick lines in 
black show not conserved sequences. P1 through P4 identify common base-paired elements. 
Nucleotide positions at 32, 35, and 69 are defined in green (Mandal, et al., 2004). 
 
 
 
1.7.1 Function and structure of the Gly riboswitch in B. subtilis  
The Gly riboswitch in B. subtilis is located in the the 5´-UTR of three-gene operon gcvT–
gcvPA–gcvPB (Mandal, et al., 2004). Computational analysis of atomic-resolution 
structures proved that the Gly riboswitch in B. subtilis belongs to the GGA variant 
(Weinberg, et al., 2017). Nucleotide positions revealing the variant are marked with green 
circle (Figure 1-4). The Gly riboswitch in B. subtilis is selectively induced by Gly. It is a 
switch for gcvT operon which codes for the Gly cleavage system proteins that are 
responsible for degradation of Gly as an energy source. Gly degradation leads to the 
formation of 5-10-methylene-tetrahydrofolate, ammonia and CO2 (Kikuchi, 1973). 
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Frequently, the gcvT element is located adjacent to genes for putative Na+/Alanine 
symporters (Barrick, et al., 2004). 
The absence of Gly leads to the formation of a Rho-independent terminator and attenuated 
transcript. In presence of Gly and binding simultaneously to the aptamers, allosteric 
modulation of the secondary and tertiary structure of the 5´-UTR directs to the formation 
of an anti-terminator structure and transcription of the full-length mRNA transcript 
(Mandal, et al., 2004; Phan & Schumann, 2007) (Figure 1-5).  
 
Figure 1-5. Mechanism of regulation of gene expression mediated by Gly riboswitch in B. subtilis 
(Serganov & Patel, 2009a).  
 
The Gly riboswitch in B. subtilis is composed of two aptamer domains (I and II) that are 
connected by a short linker. The interaptamer linker forms helix P0 with the 5′ region of 
the first aptamer domain (Baird & Ferre-Damare, 2013). P0 folds into a kink-turn and 
supports partial prefolding of Gly-free aptamers. P0 kink-turn helps to organize more 
compact structure that enhances glycine binding and facilitates other interaptamer 
interactions (Baird & Ferre-Damare, 2013). P0 helix is connected to P1. Tertiary contact 
occurs between P3 of the second aptamer and P1 of the first aptamer and causes aptamer 
dimerization. Previous report showed that dimerization of t he two aptamers is dependent 
on Gly binding in at least one aptamer (Ruff & Strobel, 2014). Aptamer dimerization 
stabilizes the P1 stem of aptamer II, that controls the expression platform (Ruff & Strobel, 
2014). Interaptamer interactions and dimerization can increase the glycine-binding 
affinities of the individual aptamers (Figure 1-6) (Ruff & Strobel, 2014; Baird & Ferre-
Damare, 2013; Sherman, et al., 2012).  
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Figure 1-6. Schematic representation of the Gly riboswitch in B. subtilis. It is composed of 
aptamer (I) and aptamer (II). P1 through P3 represent common base paired elements. P0, K-turn 
sequence in B. subtilis is presented (Baird & Ferre-Damare, 2013).  
 
1.7.2 Gly riboswitch in S. pyogenes 
55 putative sRNAs were identified in S. pyogenes M49 (Patenge, et al., 2012). Among 
those, a putative Gly riboswitch (ribogly) was found, which is located within the 5´-UTR 
of a putative Na+/Alanine symporter gene that is preceding a cation efflux system protein 
gene (Table 1). 
  
Table 1. Characteristics of ribogly upstream and downstream genes in S. pyogenes 
M49.  
Identification ribogly Upstram gene Downstream genes 
DNA helicase 
pcrA 
Na+/Alanine 
symporter 
cation efflux system 
protein 
Old locus tag - Spy49_1007c Spy49_1008 Spy40_1009 
Locus tag - Spy49_RS05030 Spy49_RS05035 Spy49_RS05040 
Location 1000814-
1000899 
998180-1000498 1001027-1002349 1002469-1003704 
Rfam RF00504 - - - 
 
Provided by: https://www.ncbi.nlm.nih.gov/nuccore/209558587  
                     http://rfam.xfam.org/family/RF00504 
 
The putative Gly riboswitch is annotated by NCBI      
(https://www.ncbi.nlm.nih.gov/nuccore/209558587) (Figure 1-7) , and Rfam database 
using Rfam web service (http://rfam.xfam.org/family/RF00504).  
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Figure 1-7. Representation of the location of the Na+/Alanine symporter gene and the cation efflux 
system protein gene as well as the upstram gene (pcrA) from NCBI. pcrA is located on the 
opposite strand. The ribogly is depicted in green. 
 
1.8 CRISPR system 
Another family of sRNAs is involved in CRISPR systems (Clustered Regularly 
Interspaced Short Palindromic Repeats), which play a key role in bacterial defense against 
viruses, transposable elements and conjugative plasmids. CRISPR systems are found in 
approximately 90% of sequenced archaeal genome and approximately 40% of 
sequenced bacterial genome (Marraffini & Sontheimer, 2010). CRISPR systems are 
considered as RNA-guided adaptive immune systems which target and inactivate 
plasmids and bacteriophages.  They consist of short foreign DNA sequences that are 
separated by repeat sequences adjacent to CRISPR-associated (cas) genes. ∼30 base pair 
foreign DNA fragment from viruses or mobile elements integrates into the bacterial 
genome at CRISPR loci and served as a memory for the next encountering with invading 
viruses. Bacteriophages and plasmids are detected and removed by CRISPR system 
composed of Cas proteins and a library of small CRISPR RNAs (crRNAs) (Jiang & 
Doudna, 2015). The CRISPR-Cas complex targets non-self DNA through base pairing 
with the crRNA guide sequence, leading to Cas protein-mediated DNA cleavage and 
degradation (van der Oost, et al., 2014). 
CRISPR-Cas systems differ in the number and sequences of the associated cas genes, the 
repeat sequence and the number of repeat-spacer units (Kunin, et al., 2007). CRISPR-Cas 
systems have been classified based on their cas gene content, in three main types, each 
containing different subtypes that demonstrate different mechanisms of targeting of the 
invasive nucleic acid (van der Oost, et al., 2014) (Appendix 7-1). 
In general, the mechanism of the CRISPR system consists of three stages. The first stage 
is the acquisition step. An invading genetic element is fragmented and integrated as a new 
spacer at the leader end of the CRISPR array. The second stage is named expression step. 
The CRISPR locus is transcribed and pre-crRNA is processed into small crRNA by 
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CRISPR-associated (Cas6) and/or housekeeping ribonucleases (such as RNase III) and 
the mature crRNAs together with Cas proteins form a crRNP complex (CRISPR 
ribonucleoprotein). The third step is known as degradation step. The crRNP scans foreign 
nucleic acid for a complementary sequence and the target is degraded by Cas nucleases 
(Heler, et al., 2014; van der Oost, et al., 2014) (Figure 1-8).  
 
Figure 1-8. Schematic illustration of the function of CRISPR-Cas system which consists of three 
steps. The first step (yellow box) is considered as spacer acquisition. Short fragment of invading 
DNA is integrated into the genome at the end of CRISPR array. At the second step (pink box), 
when transcription of CRISPR array is complete, it is processed into small crRNAs. The 
combination of crRNAs and Cas proteins forms crRNP. During the third step, crRNP complex 
scans invading nucleic acid for a complementary sequence and Cas nucleases mediate degradation 
of the target (van der Oost, et al., 2014). 
 
CRISPRs also are known to play a role in regulating self-gene expression by utilizing 
spacers that target self-genes. One hypothesis suggests that self-targeting is a 
consequence of autoimmunity (Stern, et al., 2010). The CRISPR immune system also 
helps the bacterium to bypass the human immune system. It was revealed that CRISPR 
can change the pathogenic behavior of Campylobacter jejuni (Louwen, et al., 2013). 
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1.9 CRISPR system in S. pyogenes 
S. pyogenes strains usually have two CRISPR-Cas loci in their genomes: type II-B, which 
has been shown to be functional, and type I-C (Hatoum-Aslan & Marraffini, 2014). 
Beside these findings, there are some strains which lack CRISPR systems. These strains 
have more prophages than CRISPR harboring strains (Nozawa, et al., 2011). 
In one study, (Patenge, et al., 2012) in S. pyogenes M49, one sRNA gene belonging to the 
CRISPR system was identified. It was named moses16, with ID number 
sRNASpy491206c (Raasch, et al., 2010). Moses16 was expressed during growth in 
culture media as well as in blood. In another study in S. pyogenes serotype M1 it was 
silent (Perez, et al., 2009). In the present work, it was named candidate34 (cand34).  
cand34 is an sRNA annotated as CRISPR RNA and located adjacent to the cas genes 
annotated as CRISPR I-C associated proteins. The order of cas2, cas1, cas4, cas7/csd2, 
cas8/csd1, cas5, cas3 is in accordance to CRISPR system I-C (Figure 1-9). 
 
 
Figure 1-9. Pictorial representation of the location of CRISPR system I-C RNA and cas genes. 
https://www.ncbi.nlm.nih.gov/nuccore/209539788?report=graph. 
 
 
Aim of this work 
The aim of this study was the investigation of two potential regulatory RNAs in S. 
pyogenes serotype M49 strain 591. In Part I, functional characterization of a cis-
regulatory RNA which is annotated as a putative riboswitch and is encoded upstream of 
an open reading frame annotated as Na+/Alanine symporter (Spy49_1008) was 
performed. Clarifying the regulatory function of the ribogly is a prerequisite of its 
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potential use for recombinant gene expression purposes. Due to the mechanism of 
riboswitches with allosteric properties, sensing a specific metabolite and modulating the 
expression of downstream operons, production of recombinant proteins can be controlled 
using riboswitches as was established previously (Phan & Schumann, 2007). 
Another potential application can be using riboswitch elements as targets for therapeutic 
agents. Effector-analogues can be used as artificial riboswitch ligands to restrict bacterial 
growth. (Soukup & Breaker, 2000). In Part II, the influence of a CRISPR element on the 
virulence of S. pyogenes was studied. 
Objectives 
Part I: Investigating the mechanism of a glycine-dependent riboswitch 
❖ To creat and test a luciferase-based reporter gene assay in the presence and 
absence of glycine. 
❖ To analyze the transcripts of the putative riboswitch and the corresponding 
operon by RT-PCR and Northern blotting to clarify the mechanism of the cis-
regulatory RNA in response to the ligand and its regulatory effects on the 
Na+/Alanine symporter gene transcript.  
❖ To investigate the stability of the putative riboswitch and Na+/Alanine symporter 
gene transcripts. 
❖ To investigate the native promoter activity in  the metabolite-dependent induction 
and influence on the respective operon, by fusing endogenous promoter to the 
reporter gene.  
❖ To determine the operon structure of downstream gene(s) by RT-qPCR and 
Northern blotting. 
 
Part II: Investigating the influence of the cand34 on the virulence of S. pyogenes M49.  
❖ To construct a deletion mutant of the cand34 in S. pyogenes M49. 
❖ To construct a complementation and an overexpression strain for comparison. 
❖ To perform human blood survival assay with the different strains.  
❖ To determine the adherence to and internalization into human keratinocytes of 
the different strains.  
❖ To identify potential regulatory targets of the sRNA using bioinformatic target 
analyses and to evaluate predicted targets using RT-qPCR transcript analyses.  
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2 Material and Methods 
2.1 Materials 
Table 2. Chemicals and enzymes 
Chemicals and enzymes Manufacturer 
Agar (Agar technical No.3) Oxoid Ltd., Basingstoke, England 
Agarose Standard  Carl Roth GmbH & Co. KG, Karlsruhe 
Alanine Sigma-Aldrich Chemie GmbH, Steinheim 
Arginine-Hydrochloride Sigma-Aldrich Chemie GmbH, Steinheim  
Asparagine  Sigma-Aldrich Chemie GmbH, Steinheim 
Biotin Sigma-Aldrich Chemie GmbH, Steinheim 
Calcium chloride-Hexahydrate Merck KGaA, Darmstadt 
Casein Hydrolysate Merck KGaA, Darmstadt 
Columbia Agar with 5% Sheep Blood  BD, Maryland, USA 
10x Coral Load PCR Puffer Qiagen GmbH, Hilden 
Cysteine Sigma Aldrich Chemie Gmbh, Steinheim 
Cystine Fluka Chemie AG, Buchs, Schweiz 
DIG Easy Hyb Roche Diagnostics GmbH, Mannheim 
Dipotasium hydrogen phosphate AppliChem GmbH, Darmstadt 
Disodium hydrogen phosphat-Dihydrat Merck KGaA, Darmstadt 
D-Luciferin Molecular Probes, Eugene, Oregon, USA 
dNTP Mix  Qiagen GmbH, Hilden 
Diethylpyrocarbonat Sigma-Aldrich, St. Louis, MO, USA 
DMEM (Dulbecco's Modified Eagle 
Medium), 
high glucose, GlutaMAXTM 
GIBCO, Life Technologies, Paisley, Scotland 
 
EDTA-Na2 x 2 H2O Merck KGaA, Darmstadt 
Ferrous sulfate heptahydrate (FeSO4 · 7H2O) Fluka Chemie AG, Buchs, Schweiz 
Iron(III) nitrate nonahydrate Merck KGaA, Darmstadt 
Acetic acid AppliChem GmbH, Darmstadt 
Erythromycin  Fluka Chemie AG, Buchs, Schweiz 
Ethanol (absolute)  Zentralapotheke der Universitätsklinik 
Rostock 
Ethidium bromide (1 % [w/v] in H2O) Carl Roth GmbH & Co.KG, Karlsruhe 
10x FastDigest® Buffer  Thermo Fisher Scientific, Dreieich  
10x FastDigest® Green Buffer Thermo Fisher Scientific, Waltham, USA 
FastDigest® Restriktion enzymes  Thermo Fisher Scientific, Waltham, USA 
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Table 2. Chemicals and enzymes (Continued) 
 
Chemicals and enzymes Manufacturer 
Folic acid Fluka Chemie AG, Buchs, Schweiz 
Formaldehyde 37% Baker, Deventer, Holland 
Glucose Merck KGaA, Darmstadt 
Glutamine Sigma-Aldrich Chemie GmbH, Steinheim 
Glutamic acid Sigma-Aldrich Chemie GmbH, Steinheim 
Glycerin (99 %)  Carl Roth GmbH & Co.KG, Karlsruhe 
Gly  Carl Roth GmbH & Co.KG, Karlsruhe 
Glycyl-Glycin Fluka Chemie AG, Buchs, Schweiz 
Guanine-Hydrochloride-Monohydrate Fluka Chemie AG, Buchs, Schweiz 
Yeast extrakt Oxoid Ltd., Basingstoke, England 
Histidine-Hydrochloride-Monohydrate Sigma-Aldrich Chemie GmbH, Steinheim 
HaCat DKFZ, Heidelberg (Boukamp, et al., 1988) 
Hydroxyproline Sigma-Aldrich Chemie GmbH, Steinheim 
IRDye® 800CW Streptavidin LI-COR Biotechnology GmbH, Germany 
Isoleucine Sigma-Aldrich Chemie GmbH, Steinheim 
6x Loading Dye  Thermo Fisher Scientific, Waltham, USA 
LB Broth Base Invitrogen, Carlsbad, California, USA 
Leucine Sigma-Aldrich Chemie GmbH, Steinheim 
Luciferin Sigma-Aldrich, St. Louis, MO, USA 
Lysine Merck KGaA, Darmstadt 
Magnesium sulfate heptahydrate Merck KGaA, Darmstadt 
Manganese(II) sulfate Fluka Chemie AG, Buchs, Schweiz 
Maxima SYBR Green/ROX qPCR Master 
Mix  
Thermo Fisher Scientific, Waltham, USA 
Millennium™ RNA Marker  Applied biosystem (Ambion) 
Methionine Sigma-Aldrich Chemie GmbH, Steinheim 
MOPS  Fluka Chemie AG, Buchs, Schweiz 
NADH Sigma-Aldrich Chemie GmbH, Steinheim 
Nicotinamide Fluka Chemie AG, Buchs, Swiss 
O´ GeneRuler™ 1 kb DNA Ladder Thermo Fisher Scientific, Waltham, USA 
Odyssey® Blocking Buffer Li-cor Bioscience-GmbH, Bad Homburg 
Penicillin/Streptomycin-stock solution (1%)  Invitrogen GIBCO, Fisher Scientific, 
Schwerte  
Potassium chloride Merck KGaA, Darmstadt 
Potassium dihydrogen phosphate Merck KGaA, Darmstadt 
Potassium hydroxide Merck KGaA, Darmstadt 
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Table 2. Chemicals and enzymes (Continued) 
Chemicals and enzymes Manufacturer 
Primer Eurogentec Germany GmbH, Cologne 
Pantothenic acid Fluka Chemie AG, Buchs, Swiss 
Phenylalanine Sigma-Aldrich Chemie GmbH, Steinheim 
Phusion® DNA Polymerase Thermo Fisher Scientific, Waltham, USA 
5x Phusion® High-Fidelity PCR Buffer Thermo Fisher Scientific, Waltham, USA 
Proline Sigma-Aldrich Chemie GmbH, Steinheim 
Pyridoxal hydrochloride Sigma-Aldrich Chemie GmbH, Steinheim 
Pyridoxamine-Dihydrochloride Sigma-Aldrich Chemie GmbH, Steinheim 
Riboflavin Fluka Chemie AG, Buchs, Swiss 
RiboRuler Low Range RNA Thermo Fisher Scientific, Waltham, USA 
Rifampicin Riemser, Greifswald 
2X RNA loading dye Thermo Fisher Scientific Inc. 
Serine Sigma-Aldrich Chemie GmbH, Steinheim 
Sodium acetate Merck KGaA, Darmstadt 
Sodium chloride Carl Roth GmbH & Co.KG, Karlsruhe 
Sodium hydrogen carbonate Merck KGaA, Darmstadt 
Sodium hydroxide Merck KGaA, Darmstadt 
Sodium dihydrogen phosphate Merck KGaA, Darmstadt 
Sodium dodecyl sulfate SERVA, Heidelberg, Germany 
Spectinomycin dihydrochloride pentahydrate MP Biomedicals LLC, Illkirch, France 
10x T4 DNA Ligase Buffer Thermo Fisher Scientific, Waltham, USA 
T4 DNA Ligase  Thermo Fisher Scientific, Waltham, USA 
Taq-Polymerase Qiagen GmbH, Hilden 
Thiamine-Hydrochloride Fluka Chemie AG, Buchs, Swiss 
Threonine Sigma-Aldrich Chemie GmbH, Steinheim 
Trypsin – EDTA (0,25%), phenol red GIBCO by Life Technologies, Paisley, 
Scotland 
Tryptophan Sigma-Aldrich Chemie GmbH, Steinheim 
Tris-HCl Carl Roth GmbH & Co.KG, Karlsruhe 
Todd Hewitt Broth  Oxoid Ltd., Basingstoke, England 
Tween® 20 Serva, Heidelberg, Germany 
Tyrosine Sigma-Aldrich Chemie GmbH, Steinheim 
Uracil Sigma-Aldrich Chemie GmbH, Steinheim 
Valine Sigma-Aldrich Chemie GmbH, Steinheim 
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Table 3. Materials 
Consumable supplies Manufacturer 
Cell culture flask (75 cm2)  
 
Greiner Bio-One, Kremsmünster,  
Österreich  
Cell culture 24 well-plate Greiner Bio-one, Kremsmunster, Osterreich 
Disposable Plastic Vacuum Filters 150 and 
500 ml (0,22 µm) 
Corning incorporated, Kaiserslautern 
Disinfectants AHD 2000 Lysoform Dr. Rosemann GmbH, Berlin 
Disinfectants Bacillol® AF Bode Chemie, Hamburg 
Disposable Inoculation Loops Greiner Bio-One, Kremsmünster, Austria 
Electroporation cuvettes peqLab Biotechnologie GmbH, Erlangen 
Falcon Tube Cellstar® (15 ml, 50 ml) Greiner Bio-One, Kremsmünster, Austria 
GENbox anaer (bag) Biometra, Göttingen 
Glass beads (0.10-0.11 mm) Sartorius, Gottingen 
Glass beads (2.85-3.3 mm)   Carl Roth GmbH & Co. Karlsruhe 
Hybridization bottle Thermo Fisher Scientific, Waltham, USA 
MicroAmp® Fast 96-Well Reaction Plate Thermo Fisher Scientific, Waltham, USA 
Parafilm Bemis Company, Wisconsin, USA 
PCR Soft tubes (0.2 ml) Biozym, Hessisch Oldendorf 
Pipettes (10, 20, 100, 200, 1000 µl)   Gilson, France 
Pipette tips (10, 20, 100, 200, 1000 µl)   Greiner Bio-One, Kremsmünster, Austria 
Pipetting aids  Eppendorf, Hamburg 
Plastik pipets Cellstar® (5, 10, 25 ml) Greiner Bio-One, Kremsmünster, Austria 
RNA Nano Chips  Agilent Technologies, Inc. Santa Clara, USA 
Rotilabo®-Blotting Papers, Thickness 1.0 mm Carl Roth GmbH & Co. KG, Karlsruhe 
Roti®-Nylon 0.2, pore size 0.2 µm Carl Roth GmbH & Co. KG, Karlsruhe 
Round bottom test tubes (12 x 75 mm) Roche Diagnostics GmbH, Mannheim 
Safe-Lock tubes (0.5, 1.5, 2 ml) Eppendorf AG, Hamburg 
Sterilfix® Injection filter (0.2 µm)  Braun, Melsungen 
UVpette tips Biozym, Hessisch Oldendorf 
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Table 4. Devices  
Devices Manufacturer 
Agilent G2565AA Scanner Agilent Technologies, Inc. Santa Clara, USA 
Anaerocult® Jar Merck KGaA, Darmstadt 
Analytical balance BP 4100S, Sartorius, Göttingen 
Biological safety cabinet class ll Thermo Fisher Scientific, Waltham, USA 
Centrifuge Biofuge pico Heraeus, Hamburg 
Centrifuge Biofuge fresco  Heraeus, Hamburg 
Refrigerated centrifuge Type 5417R Eppendorf, Hamburg 
Centrifuge Varifuge 3.OR Heraeus, Hamburg 
Centrifuge Megafuge 1.0R Heraeus, Hamburg 
Centrifuge Sorvall Lynx 4000 Thermo Fisher Scientific, Waltham, USA 
Eddy Jet Spiralplater1.22  IUL Instruments GmbH, Königswinter 
Electroporator ECM 399 Harvard Apparatus, Holliston, USA 
Freezer -80 °C Type Hera freeze Heraeus, Hamburg 
Fume hood 
 
Gel documentation system Intas Science GmbH, Göttingen 
GENbox anaer System  biomérieux Deutschland GmbH, Nürtingen 
GS Gene Linker® UV Chamber Bio-Rad Laboratories GmbH, California, USA 
Horizontal electrophoresis system Bio-Rad Laboratories GmbH, Munich 
Hybridization oven Biometra, Ma, USA 
Incubator B6060 Heraeus, Hamburg 
Luminometer Lumat LB 9501 Berthold Technologies GmbH Bad Wildbad 
Microscope CKX41 Olympus Deutschland GmbH, Hamburg  
Mini-Vacuum pump E1 Axon Lab AG, Baden-Dättwil 
Odyssey® Imager      Li-cor Bioscience-GmbH, Bad Homburg 
pH-Meter WTW Serie Type pH 720 WTW GmbH, Weilheim 
Picodrop Microliter Spectrophotometer  Biozym, Oldendorf 
Power supply Model 200/20 Bio-Rad-Laboratories GmbH, Munich 
Power supply, Power Pac 3000 B Bio-Rad-Laboratories GmbH, Munich 
Qubit®2.0 Fluorometer Life Technology (Invitrogen), Schwerte 
Ribolyser  Peqlab Biotechnologie Gmbh, Erlangen 
Spectrophotometer SmartSpecTM 3000   Bio-Rad-Laboratories GmbH, Munich 
Thermocycler Type T3 Biometra GmbH, Göttingen 
Thermomixer  Comfort Eppendorf, Hamburg 
GS Gene Linker® UV Chamber Bio-Rad-Laboratories GmbH, Munich 
ViiA™ 7 Real-Time PCR System Thermo Scientific, Waltham, USA 
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Table 4. Devices (Continued)  
Devices Manufacture 
Vortex-Genie Touch Mixer  Scientific Industries, Bohemia, NY, USA 
Water mantel incubator with regulated CO2 
and O2 pressures  
Heraeus, Hamburg 
 
Table 5. Bacterial strains  
Bacterial Strain Plasmid Resistance Strain* Source 
E. coli DH5α 
 
- -  GibcoBRL 
Eggenstein 
E. coli DH5α 
 
pFW11-luc2 Spectinomycin 1985 IMIKRO 
(Podbielski, et al., 
1999a) 
E. coli DH5α 
 
pFW11-
ribogly-luc2 
Spectinomycin 4863 IMIKRO 
(Popp, 2015) 
S. pyogenes M49 
strain 591**                         
- - 4588 R. Lütticken 
(Aachen) 
S. pyogenes M49/  
pFW11-ribogly-luc2 
pFW11-
ribogly-luc2 
Spectinomycin 4864 IMIKRO 
(Popp, 2015) 
 
 
*Strain number of IMIKRO strain collection. 
** In following text, short form; S. pyogenes M49 refers to this strain. 
 
Table 6. Antibiotics 
 
 
 
Antibiotics* Solvent Concentration 
for S. pyogenes 
Concentration  
for E. coli 
Spectinomycin Ultra pure water 60 µg/ml 100 µg/ml 
Erythromycin Ethanol absolute 5 µg/ml 150 µg/ml 
Rifampicin Dimethyl sulfoxide 
(DMSO) 
200 µg/ml (not used at this study) 
Penicillin/Streptomycin: Ready to use for cell culture 5000 U/ml 
*Sterilization was performed with filtration through Sterifix ® Injection filter 0.2 µm. 
Solutions containing Ethanol were not sterilized.  
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Table 7. Plasmid 
Plasmid (Size)     Antibiotic  
    resistance  
 Origin 
pFW11-luc2 (4210 bp)   Spectinomycin    IMIKRO (Podbielski, et al., 1999a) 
pFW11-ribogly-luc2 (5107 bp) 
 
  Spectinomycin                IMIKRO (Popp, 2015) 
pAT19 (6600 bp)   Erythromycin                (Trieu-Cuot, et al., 1991) 
 
 
 
Table 8. Oligonucleotides and their sequences 
Oligonucleotide Sequences 5´-3´ 
Gly_luc_xho_rv CCTCGAGCTCCTAAAAGTCATCGAAGACG 
Ribo.prom. BamHl-fwd TCGGATCCATGCGCTTCATCAACG 
Ribo.prom. xhol-rev CCTCGAGAATTAGGACTATCATACCTC 
Luc-check-rev CCATGATAATAATTTTCTGGA 
RT_Luc_for GAGACATAGCTTACTGGGACG 
RT_Luc_rev TATCGACTCCAATTCAGCGGG 
5s-RNA-RT-fwd AGCGACTACCTTATCTCACAG   
5s-RNA-RT-rev GAGATACACCTGTACCCATG 
groES-M49-for TCGGGTGTTCGCACTATTACA G 
groES-M49-rev CATGCCCATTTTCAACTAAAACC 
A 
RT_ribogly_for CTGGAGAGACCTTATTAGGC 
RT_ribogly_rev GAGAGATTGAGCAGTATGCC 
B 
RT_AASymporter_for AATCAGCCTTCACTCCGACAGC 
RT_AASymporter_rev ACTCATTGGAGAAGACACCGCG 
C 
Efflux.fwd GTCTCAACGAGCTAGGACC 
Efflux.rev GGCAGGCTCAACGTGAATG 
D Ribo.J.fwd TCAGGCAAAAGGACAGAAGG 
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Table 8. Oligonucleotides and their sequences (Continued) 
Nucleotides Sequences 5´-3´ 
AA.J.rev CGAGTGCTATCATCTTTCTCTCC 
E 
AA.Efflux.joint.fwd   CGCCAGTTGTTATTTTAGAAACC 
AA.Ffflux.joint.rev GATTGGCATCGGCTGGTTGGC 
T7.ribogly_rev(2) cttaatacgactcactataggGAGAGATTGAGCAGTATGCC  
AAsymorter_fwd (4) GGACGGGGATTTACCTTACC 
T7. AASymporter_rev (4) cttaatacgactcactataggCAGTTCCGACAGTAGCGGC 
T7.5s-RNA-RT-fwd cttaatacgactcactataggAGCGACTACCTTATCTCACAG 
T7.Efflux.rev cttaatacgactcactataggGGCAGGCTCAACGTGAATG 
BamHI_cand34_5`flanking_fwd AGGATCCTTCCAAGGTCGGAGTAAACG 
SalI_cand34_5´flanking_rev GCGTCGACAGCCTTTTTATCTCCATTTCGC 
Ncol_cand34-3´ flanking-fwd GATCCATGGCCTGACCTCATTAAAAGAGAG 
PstI_cand34-3´ flanking-rev GACTGCAGAGCTGCCATGCTCATCTTGTCCT 
Compl _M16/c34_Bam_fwd AGGATCCAATCTCTTGTGCGAAGCTAGC 
Compl _M16/c34_Sall_rev GCGTCGACCTTGAATTTGATACGCTATCAG 
Spec-weg-FOR ATATTGAATGGACTAATGAAA ATG 
RT-cyto-fwd GCATTGAACAAACCGTTGCG 
RT-cyto-rev GGTACTTACTGGGAGCCG 
RT-cas2-fwd CCAAGTGTTTCCACACGCC 
RT-cas2-rev CGTCATGTTGCCAAACTCTG 
RT-ABC-fwd GGGTTTACCCTTGAGCATTACC 
RT-ABC-rev GGATAAAGATAGCTCCAAAGGTCC 
RT-NAD Synthetase-fwd GCTTGATCACTTGTTTCCTCC   
RT-NAD Synthetase-rev GGCATTTCTGGAGGTCAGG 
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• Restriction sites are underlined. Nucleotide sequences of the T7 promoter are given 
in lower case letters. 
• Primer sets A, B, C and D amplified fragments which are shown in (Figure 3-6).       
• All primers were synthesized by "Eurogentec Deutschland GmbH" (Cologne). 
 
Table 9. kits 
Kit Supplier 
QIAquick® PCR Purification Kit (250) Qiagen GmbH, Hilden 
QIAprep® Spin Miniprep Kit (250) Qiagen GmbH, Hilden 
TURBO DNA-free™ Kit Life Technologies (Ambion), Schwerte 
SuperScript™ First-Strand Synthesis System 
for RT-PCR 
Life Technologies (Invitrogen), Schwerte 
Colony Fast-Screen™ Kit Epicentre Biotechnologies, Madison, USA 
MEGAscript® T7 Transcription Kit     Life Technologies (Invitrogen), Schwerte 
RNA Clean & Concentrator™-5 kit Zymo Research, USA 
RNA Clean & Concentrator™-25 kit Zymo Research, USA 
Pierce™ RNA 3' End Biotinylation  Thermo Scientific, USA 
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2.2 Methods 
2.2.1 Media preparation 
Broth media were prepared by suspending the defined amount of component as following 
in 1 L of Ultra-pure water in screw capped bottles. Autoclave cycle conditions were 
121°C (250 F), 15 psi for 15 min.  
Solid media were prepared by adding 1.5% agar to broth media. Sterilized media were 
poured in Petri dishes. S. pyogenes was cultivated in THY medium and E. coli was grown 
in LB medium. 
Addition of antibiotics to media was carried out after cooling the sterilized media to 
approximately 50°C. The respective concentrations of antibiotics are given in Table 6. 
After pouring the media in plates these were allowed to solidify. The plates were stored 
at 2-8°C in a plastic bag to avoid drying out. 
 
 CDM 
Chemically Defined Medium (CDM) was used as described (van de Rijn & Kessler, 
1980). Solutions were prepared as described in 2.2.1 and sterilized using 0.22 µm filters. 
CDM was prepared according to Table 10. pH 7,4 was adjusted with NaOH. The 
solution was diluted to the final volume of 1000 ml using Ultra pure water. CDM was 
sterilized by filtration through a 0.22 µm filter. 
 
▪ Solutions for CDM 
Phosphate Buffer: 100 ml  
KH2PO4 2 g 
K2HPO4 10 g 
Ultra pure water to final volume  
 
 LB-Medium (Lennox L Broth Base):  
LB-Broth-Base                                                                 20g
NaCl                                                4.5g 
Sterilization with autoclave  
 THY-Medium (Todd Hewitt Yeast):  
Todd-Hewitt-Broth                            36.4g 
Yeast-Extract                                5 g 
Sterilization with autoclave  
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Asparagine: 200 ml  
Asparagine 1 g 
Ultra pure water to final volume  
 
 
L-Leucine: 100 ml  
Was heated not higher than 57 °C  
L-Leucine 1 g 
Ultra pure water to final volume  
 
 
D/L-Alanine: 200 ml  
D/L-Alanine 4 g 
Ultra pure water to final volume  
Amino Acid Mix: 400 ml  
Was not heated higher than 57 °C  
L-Aspartic Acid 2 g 
L-Phenylalanine 2 g 
L-Serine 2 g 
L-Proline 4 g 
L-Hydroxyproline 4 g 
Gly 4 g 
2.5 N NaOH 6.4 ml 
Ultra pure water to final volume  
L-Glutamic acid : 200 ml  
L-Glutamic acid 6 g 
2.5 N NaOH 19.2 ml 
Ultra pure water to final volume  
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L-Isoleucine: 200 ml  
Was heated not higher than 57 °C  
L-Isoleucine 2 g 
Ultra pure water to final volume  
 
L-Methionine: 200 ml  
Was heated not higher than 57 °C  
L-Methionine 2 g 
Ultra pure water to final volume  
 
L-Threonine: 100 ml  
Was heated not higher than 57 °C  
L-Threonine 2 g 
Ultra pure water to final volume  
 
L-Argenine HCl: 200 ml  
L-Argenine HCl 4.84 g 
Ultra pure water to final volume  
 
L-Histidine HCl H2O: 200 ml  
L-Histidine HCl H2O 5.4 g 
Ultra pure water to final volume  
 
L-Thryptophan: 200 ml  
L-Thryptophan 4 g 
2N HCl 20 ml 
Ultra pure water to final volume  
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L-Valine: 100 ml  
L-Valine 2 g 
Ultra pure water to final volume  
 
L-Lysine: 100 ml  
L-Lysine 2.76 
Ultra pure water to final volume  
 
Riboflavin:100 ml  
Riboflavin 8 mg 
conc. Acetic Acid 0.1 ml 
 
Vitamin Mix: 250 ml  
Nicotinamide 11 mg 
Thiamine HCl 20 mg 
Aminobenzoic Acid 4 mg 
Pantothenic Acid 40 mg 
Ultra pure water to final volume  
 
 
 
 
 
 
Folic Acid: 250 ml   
Folic Acid 5 mg 
2.5 N NaOH 0.1 ml 
Ultra pure water to final volume  
Material and Methods 
- 34 - 
 
Biotin: 200 ml 
Storage in brown bottle 
Solution 1:  Biotin 5 mg 
95% EtOH 1 ml 
0.01N HCl 49 ml 
Solution 2:  Solution 1 20 ml 
0.01N HCl 180 ml 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Salts: 100 ml  
FeSO4 x 7 H2O 100 mg 
CaCl2 x 6 H2O 200 mg 
MnSO4 100 mg 
Pyridoxamine 2HCl: 100 ml  
Pyridoxamine 2HCl 23 mg 
Ultra pure water to final volume  
MgSO4 x 7 H2O: 50 ml  
MgSO4 x 7 H2O 7 g 
2 N HCl 1 ml 
Ultra pure water to final volume  
AGU Mix: 500 ml  
Adenine sulfate 435 mg 
Guanine HCl H2O 310 mg 
Uracil 250 mg 
2 N HCl 50 ml 
Ultra pure water to final volume  
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Fe(NO3)2 x 9 H2O 20 mg 
2 N HCL 1.2 ml 
Ultra pure water to final volume  
 
 
Sodium Bicarbonate: 10 ml  
Was prepared freshly before use and not heated higher than 57°C 
Sodium Bicarbonate 1.25 g 
Ultra pure water to final volume  
 Solution was sterilized using Sterifix ® Injection filter 0.2 µm. 
 
 
L-Cysteine: 5 ml 
 
L-Cysteine 2.5 mg 
Ultra pure water to final volume   
  Solution was sterilized using Sterifix ® Injection filter 0.2 µm. 
 
 
 
 
L-Glutamine: 200 ml  
L-Glutamine 
Ultra pure water to final volume 
4 g 
L-Tyrosine: 400 ml  
L-Tyrosine 4 g 
2.5 N NaOH 16 ml 
Ultra pure water to final volume  
 
L-Cystine: 400 ml 
 
L-Cystine 4 g 
2 N HCl 80 ml 
Ultra pure water to final volume  
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Table 10. Components for 1000 ml Chemically Defined Medium 
Component Amount 
Glucose  10 g 
Na2HPO4 7.35 g 
NaH2PO4 3.2 g 
Na(CH3COO)  4.5 g 
Phosphate Buffer 10 ml 
Asparagine 20 ml 
Amino Acid Mix 20 ml 
L-Leucine 20 ml 
L-Glutamic Acid 3.4 ml 
D/L-Alanine 5 ml 
L-Isoleucine 10 ml 
L-Methionine 10 ml 
L-Threonine 10 ml 
L-Argenine HCl 5 ml 
L-Histidine HCl H2O 5 ml 
L-Thryptophan 5 ml 
L-Valine 5 ml 
L-Lysine 5 ml 
Riboflavin 25 ml 
Vitamin Mix 25 ml 
Biotin 20 ml 
Folic Acid 40 ml 
Pyridoxamine 2HCl 6.25 ml 
L-Glutamine 10 ml 
L-Cystine 5 ml 
L-Tyrosine 10 ml 
AGU Mix                                                                    44 ml
MgSO4 x 7 H2O 5 ml 
Salts 5 ml 
Pyridoxal HCL 1 mg 
NADH 2.5 mg 
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Following components were added to the medium before use. 
Sodium Bicarbonate 200 µl  for 10 ml CDM 
L-Cysteine 100 µl 
 
2.2.2 Overnight culture 
2.2.2.1  E. coli overnight culture  
To prepare an overnight culture of E. coli strain a single colony from LB agar plate was 
removed using a sterile loop and transferred to a tube containing 10 ml LB broth. In 
plasmid carrying strains respected antibiotic was added to the media. The tube was 
loosely closed and incubated in shaking incubator at 37℃ and 180 rpm (revolutions per 
min) overnight. After incubation the culture was used for next experiments (2.2.3).  
2.2.2.2  S. pyogenes overnight culture 
An overnight culture of S. pyogenes was prepared by transferring a single colony from 
THY agar plate to a tube containing THY broth using a sterile loop. To culture mutant 
strains carrying antibiotic resistance cassette respected antibiotic was added to the media. 
The tube was loosely closed and incubated at 37℃ and 5% CO2 overnight. The culture 
was used for the subsequent experiments (2.2.3). 
2.2.3 Strain maintenancece 
650 µl overnight culture of the respective strain was mixed with 350 µl sterile Glycerol 
(99%) and stored at -20°C. 
2.2.4 Measuring optical density 
To plot standardized growth curves of the respective bacterial strain (absorbance versus 
time) 1 ml of overnight culture was inoculated in 19 ml of broth media. Samples were 
collected at hourly intervals. The optical density at a wavelength of 600 nm (OD600) was 
measured using a spectrophotometer and recorded.  
2.2.5 Reporter gene assay 
 Luciferase assay 
Bacteria were grown overnight in THY. Cells were pelleted and washed with PBS. 
Washed cells were inoculated into 6 tubes containing CDM with different concentrations 
of Gly; 0 mM, 0.01 mM, 0.1 mM, 1 mM, 2.6 mM and 10 mM to OD600≈ 0.08- 0.1. Tubes 
were incubated at 37°C, 5% CO2. In one-hour intervals and once after 24 hours, the OD600 
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of each sample was measured and luciferase activity was monitored. A 150 μl aliquot of 
culture was mixed with 150 μl 1 x assay buffer in a test tube (12x75 mm). 150 μl luciferin 
was added to the mixture. The tube was placed in the luminometer immediately and 
emitted light was measured for 15 seconds at room temperature. 
Assay buffer  
Glycyl-Glycin 4.1 g 
MgCl2 2.54 g 
Ultra pure water 500 ml 
  pH 7.8 adjusted with Mg(OH)2 
   
D- Luciferin solution 
 D-Luciferin (33 mM)                
 KH2PO4 buffer (10mM), pH 6.5 
After preparation, 50 µl aliquots were stored at -20 °C. For every experiment, D- 
Luciferin solution was diluted in ratio of 1:100 with sterilized Ultra pure water. 
DNA manipulation and analysis 
2.2.6 Chromosomal DNA isolation 
Chromosomal DNA of S. pyogenes was obtained from 5 ml overnight culture in THY 
broth. Cells were harvested by centrifugation at 4000 rpm for 5 min. Pellets were 
resuspended in 1 ml 1X PBS in a 1.5 ml microcentrifuge tube containing beads (0.1-0.11 
mm) and mechanical cell (lysis) disruption was achieved using a ribolyser (6000 upm, 
40 s, 1-times). This step was followed by centrifugation at 13000 rpm for 10 min. 100 µl 
of supernatant was transferred to a 1.5 ml microcentrifuge tube. DNA was purified with 
the QIAquick® PCR Purification Kit according to the manufacturer´s instruction. DNA 
was stored at -20 °C. 
2.2.7 Plasmid DNA isolation 
Plasmid isolation was performed using the QIAprep® Spin Miniprep Kit according to 
the manufacturer´s instruction. Plasmid solutions were stored at -20°C. 
2.2.8 Primer design 
Primers were designed considering: 1) the optimal length of 18-20 nucleotides, 2) GC 
content between 40 - 60 % and balanced distribution of A, T, G and C, 3) avoiding intra 
primer homology and inter primer homology, 4) adding the corresponding restriction site 
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to the primer followed by suggested extra base (s) at the beginning of the restriction site 
according to the restriction enzyme´s manufacturer. To calculate oligonucleotide melting 
temperature, self-complementarity, and hairpin formation estimation, OligoCalc (Kibbe, 
2007) was used which is available at following link: 
http://biotools.nubic.northwestern.edu/OligoCalc.html. 
2.2.9 PCR (Polymerase Chain Reaction) 
PCR Components are given in Table 11. The Phusion polymerase was used for low error 
rates. It has a 3'-5'-Proofreading exonuclease activity (Thermofisher® Inc) (Mullis, et al., 
1986). 
 
Table 11. PCR reaction components 
Component Volume Final 
Concentration 
5x Phusion® High-Fidelity Buffer 4 µl 1 x 
   
5x Phusion® High-Fidelity DNA-
Polymerase 
0.2 µl 0.02 U/µl 
dNTPs (10 mM) 0.4 µl 200 µM 
Forward primer (10 µM) 1 µl 0.5 µM 
Reverse primer (10 µM) 1 µl 0.5 µM 
Genomic DNA template  1 µl (1 ng/ µl) 
Aquabidest.    To final volume of 20 µl   
 
Thermocycling conditions  
Step Temperature Time 
Initial denaturation 95°C 5 min 
Denaturation 95°C 10 s      
Annealing Primer  30 s                   25X 
Extention 72°C 30 s/kb 
Final Extention 72°C 10 min 
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2.2.10 Agarose gel electrophoresis  
Agarose gels were prepared using 1% agarose (w/v) in TAE buffer. The agarose/buffer 
mixture was melted by heating in a microwave until the agarose was completely 
dissolved. The gel was poured into the gel casting tray with an appropriate comb to create 
wells. After setting the gel at room temperature and solidification, the comb was 
removed. The Casting tray was placed in a gel box with 1X TAE buffer and the gel was 
covered by the buffer. The marker O´ GeneRuler™ 1 kb DNA Ladder was loaded in one 
well. Samples were mixed with 0.2 vol, 6X loading dye and loaded in the wells. The lid 
of gel box was closed. Power supply settings were at 5 V/cm. After completing 
electrophoresis, the gel was immersed in 0.15 µl/ml ethidium bromide solution for 10 
min. The gel was exposed to UV light and a photo was taken for documentation (Lee, et 
al., 2012).  
50 X TAE Buffer  
Tris-HCl 2.0 M 
Accetic acid 1.0 M 
EDTA-Na2-2 H2O 50 mM 
pH 7.5 
 
 
6X loading dye  
Bromphenol blue 0.25% (w/v) 
Cyanol 0.25% (w/v) 
Glycerol 30% (v/v) 
EDTA-Na2-2 H2O 50 mM 
 
To estimate the size of double-stranded DNA on agarose gels, O´ GeneRuler™ 1 kb DNA 
Ladder from Thermo Fisher Scientific was used (Figure 2-1). 
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Figure 2-1. O´ GeneRuler™ 1 kb DNA Ladder (Thermo Fisher Scientific). 
 
2.2.11      Molecular cloning 
2.2.11.1 Restriction digest  
Restriction digests were performed according to the instructions of the supplier.  
Table 12. Restriction digest components 
Components Plasmid DNA  Purified PCR product 
10X FastDigest Buffer 2 µl 2 µl 
DNA 1000 ng 200 ng 
FastDigest enzyme1* 1 µl 1 µl 
FastDigest enzyme2* 1 µl 1 µl 
Aquabidest. to 20 µl to 30 µl 
*Thermo Scientific™ FastDigest™  
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Table 13. Restriction digest conditions  
 
Restriction 
Enzyme 
 
Restriction 
site 
 
Incubation 
Temperature 
 
 
Incubation 
Time(min) 
 
Inactivation 
PCR 
Product 
Plasmid 
DNA 
BamHI G↓GATCC 37°C 5 5 80°C; 5 min 
Nhel G↓CTAGC 37°C 5 15 65°C; 5 min 
Sall G↓TCGAC 37°C 60 5 65°C; 10 min 
XhoI C↓TCGAG 37°C 10 10 80°C; 5 min 
Pstl CTGCA↓G 37°C 30 5 Purification* 
Ncol C↓CATGC 37°C 10 10 65°C; 15 min 
*Enzyme inactivation was performed using QIAquick® PCR Purification Kit.                     
Digests were performed with two restriction enzymes simultaneously in one reaction 
tube. Incubation time was set according to longer incubation time.   
 
 
2.2.11.2 Ligation  
Ligation was performed considering molecular sizes of the fragments. A molar ratio of 
1:5 vector to insert according to DNA fragment sizes was calculated via NEBioCalculator 
(https://nebiocalculator.neb.com/#!/ligation). Reactions were set up in a microcentrifuge 
tube on ice. The T4 DNA Ligase Buffer was thawed and resuspended at room 
temperature. Reaction mixture was prepared (Table 14) and spun briefly. The tube was 
incubated at 16°C overnight. The product was used directly for transformation in E. coli. 
Table 14. Components and their volumes for a ligation reaction 
Component Volume 
T4 DNA Ligase Buffer (10X) 2 µl 
Vector DNA 50 ng 
Insert DNA Molar ratio of 1:5 vector to insert according to 
fragment size  
Aquabidest. to 20 µl 
T4 DNA Ligase 1 µl (0.1U/ µl) 
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2.2.11.3 Transformation of E. coli DH5α 
2.2.11.3.1  Preparing chemically competent cells    
E. coli DH5α competent cells were prepared for general cloning purpose via CaCl2 
method (Hanahan, 1983).  
E. coli DH5α was streaked on LB plate and incubated at 37°C overnight. 5 ml LB medium 
was inoculated with a single colony and incubated at 37°C and 180 rpm overnight. 1 ml 
overnight culture was used to inoculate 100 ml LB medium and incubated at 37°C and 
180 rpm until OD600 = 0.4. The Culture was chilled for 5 min on ice and swirled 
occasionally to ensure cooling. All bottles and solutions which were used in the process, 
were precooled. The cell suspension was centrifuged for 5 min at 4°C and 4000 rpm. The 
supernatant was decanted, and the pellets were carefully resuspended in 30 ml ice-cold 
buffer 1. The cell suspension was incubated for 90 min on ice.  This step was followed 
by centrifugation for 5 min at 4°C and 4000 rpm .The supernatant was decanted, and the 
pellets were carefully resuspended in 4 ml ice-cold buffer 2. 100 µl aliquots were 
transferred in sterile, cold, 1.5 ml microfuge tubes as quick as possible and snap frozen 
in liquid nitrogen. The tubes (aliquots) were stored at -80°C.  
           
Buffer1  Buffer2  
RbCl 100 mM MOPS 10 mM 
MnCl2 50 mM RbCl 10 mM 
Potassium acetate       30 mM CaCl2 75 mM 
CaCl2 10 mM Glycerol 15% 
pH 5.8 Adjusted with HCl pH 8  Adjusted with KOH 
 
Buffers were sterilized by filtration using a 0.22 μm filter and were stored at room 
temperature. 
2.2.11.3.2  Heat shock transformation  
Chemically competent cells were thawed on ice. 10 µl ligation mixture was added to the 
thawed cells. Cells were incubated for 30 min on ice. This step was followed by 60 
seconds incubation at 42°C. Tubes were transferred on ice for 2 min. 1 ml warm LB 
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medium was added and tubes were incubated at 37°C and 450 rpm for 1 hour in a 
Thermomixer (Comfort Eppendorf). Cells were centrifuged at room temperature for 5 
min and 4000 rpm. The supernatant was decanted and 300 µl LB medium was added 
carefully. 50 µl, 100 µl, and 150 µl were plated on each LB-Agar medium plate which 
contained the appropriate antibiotics. Plates were incubated overnight at 37°C. To check 
for the presence of a plasmid in the transformants colony fast screening was performed. 
To evaluate the identity of the construct, plasmids were extracted (2.2.7) and cut with the 
appropriate restriction enzymes (2.2.11.1). 
2.2.11.3.3 Colony fast screening  
As a rapid procedure for identifying recombinant plasmids in DH5α colonies, colony fast 
screening was performed using Colony Fast-Screen™ Kit (epicentre®, Illumina 
company®). 10 µl of Restricti-Lyse™ Solution was distributed into a 0.5 ml 
microcentrifuge tube for each colony to be screened. Bacterial colonies were picked using 
a sterile loop and as much of the colony as possible was transferred to the microcentrifuge 
tube containing the lysis buffer. A sample of each colony was spotted onto a master plate. 
2 µl of gel loading solution was added to each tube and mixed well using vortex 
vigorously (10-60 seconds). Tubes were incubated at 75°C for 15 min in a thermocycler. 
Each tube was centrifuged briefly. 15 µl reaction sample was analyzed by agarose gel 
electrophoresis.  
2.2.11.4 Transformation of S. pyogenes 
2.2.11.4.1 Preparing S. pyogenes electrocompetent cells  
S. pyogenes was streaked on THY plate and incubated at 37°C and 5% CO2 overnight. A 
single colony was inoculated in 3 ml THY broth/20mM Gly and incubated at 37°C and 
5% CO2 overnight. 500 μl of overnight culture was inoculated in 30 ml THY broth/20mM 
Gly at 37°C and 5% CO2 to an OD600 of 0.2. The culture was chilled for 30 min on ice 
and swirled occasionally to ensure cooling. All bottles and the ultra pure water which 
were used in the process were precooled. Cells were collected by centrifugation at 4°C 
and 4000 rpm for 5 min. The supernatant was discarded, and cells were washed in 30 ml 
ice-cold ultra pure water. The cells were pelleted by centrifugation for 5 min at 4°C and 
4000 rpm. The supernatant was decanted, and cells were resuspended in 30 ml ice-cold 
ultra pure water. Cells were collected by centrifugation at 4°C and 4000 rpm for 5 min. 
The supernatant was discarded and 500 μl ice-cold ultra pure water was added to the 
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pellet. Cell suspension was distributed in 160 µl aliquots in cold cuvettes appropriate for 
electroporation (Dunny, et al., 1991). 
2.2.11.4.2  Electroporation 
10-30 μg plasmid was added to an ice-cold cuvette containing 160 µl S. pyogenes 
suspension. The cuvette was placed in the electroporation device. Transformation was 
performed with 1750 V. 1 ml THY medium was added to the mixture immediately. Cells 
were incubated at 37°C and 5% CO2 for 1 hour. 250 µl suspension were plated on each 
selective THY plate containing appropriate antibiotics. Plates were incubated in an 
anaerobic jar containing S. pyogenes pack at 37°C for 72 hours.  
2.2.12  RNA analysing methods 
2.2.12.1 RNA isolation  
RNA was isolated from S. pyogenes M49. 700 μl of overnight culture was added to 10 
ml of fresh CDM and incubated at 37°C and 5% CO2 for 3 hours. Cells were pelleted by 
centrifugation at 4000 rpm at 4°C for 5 min. The supernatant was discarded. 1 ml 
TRIzol® was added to the pellets and incubated at room temperature for 5 min. 
Resuspended cells were transferred to the tube containing beads (0.1-0.11mm). Sample 
tube was processed in a ribolyser for 40 seconds at 6000 rpm. This step was followed by 
centrifugation at 13000 rpm at 4°C for 5 min. 750 μl of supernatant was transferred to a 
microfuge tube containing 600 μl acid phenol and 20 μl sodium acetate. Homogenization 
was achieved in a ribolyser at 4000 rpm for 2 x 10 seconds. The tube was centrifuged at 
7500 rpm and 4°C for 15 min. The upper phase was transferred to a 2-ml tube without 
disturbing the interphase. This step was repeated to increase RNA purity. The upper 
phase was transferred to a 2-ml tube containing 1 ml ice-cold absolute ethanol. Sample 
was incubated at -20°C overnight. Centrifugation was performed at 13000 rpm for 60 
min. To remove residual phenol 1 ml ethanol 70% in DEPC treated H2O was added to 
the pellets. This process was followed by spinning at 13000 rpm for 5 min. Pellets air-
dried at room temperature for 10 min and were resuspended in 50 μl DEPC treated H2O. 
RNA concentration and purity were determined from a 1:10 diluted sample using a 
Picodrop Microliter spectrophotometer. The RNA sample was stored at -80°C. 
2.2.12.2 DNase treatment 
Genomic DNA contamination was removed from RNA using TURBO DNA-free™ Kit 
according to the kit manufacturer´s instruction. RNA concentration and purity were 
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determined using a Picodrop Microliter spectrophotometer. The RNA sample was stored 
at -80°C. 
2.2.12.3  RNA quality assessment 
RNA integrity was determined using Agilent G2565AA Scanner. Sample preparation 
was performed in accordance with the instructions of the manufacturer.  
2.2.12.4  cDNA synthesis  
cDNA was synthesized from the total RNA using “SuperScript™ First-Strand Synthesis 
System for RT-PCR" kit according to the manufacturer's instructions.  
2.2.12.5  Real-time quantitative PCR (qPCR)  
Real-time PCR was performed using a 96 well plate format in the ViiA™ 7 Real-Time 
PCR System. Each sample was prepared in duplicate as follows (Table 15). Two types 
of negative controls were included in each qPCR experiment: A no template control 
(NTC) and a no reverse transcriptase control (NRT) in which reverse transcriptase was 
omitted from the reverse transcription step. This control evaluates the presence of DNA 
contamination in an RNA sample.  
Table 15. Components and their volume to establish one qPCR reaction 
Component Single rxn Notes 
SYBR® GreenER™ qPCR SuperMix Universal 10 μl 1X final conc. 
Forward primer, 10 μM 1.5 μl 300 nM final conc. 
Reverse primer, 10 μM 1.5 μl 300 nM final conc. 
Template: Test well (20 ng of cDNA) 
NRT (20 ng of RNA) 
4 μl - 
DEPC-treated water  3 μl  - 
Final volume  20 μl - 
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Thermocycling conditions  
Step Temperature (°C) Time (min) Cycles 
Hold Stage 50 2:00  
 95 10:00 1 
 95 0:15  
PCR-Stage 90 0:15 40 
 60 1:00  
Melt Curve Stage 90 0:15 1 
 60 1:00  
 
2.2.12.6  Comparative method or ΔΔCT method of relative quantification 
Data from qPCR were analyzed using relative quantification method. The 2-ΔΔCt Method 
analyses the relative changes in gene expression from qPCR experiments (LIvak & 
Schmittgen, 2001). This method relies on direct comparison of Ct values between the 
sample and a calibrator (control group). The target and reference gene (housekeeping 
gene) were amplified from the same sample. 5S rRNA was used as an endogenous 
reference gene, which is present in constant levels in S. pyogenes.  
The ΔCt value for each sample was achieved by determining the difference between the 
Ct value of the target gene and the Ct value of the reference gene for each unknown 
sample as well as for the calibrator. 
• ΔCt (sample) = Ct target gene – Ct reference gene  
• ΔCt (calibrator) = Ct target gene – Ct reference gene 
In the next step, the sample was normalized to the calibrator sample. At the end, the 
relative quantification (RQ) of the target gene in the sample group in comparison to the 
calibrator was calculated. 
• ΔΔCT = ΔCt (sample) – ΔCt (calibrator) 
• RQ=2–ΔΔCt   
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2.2.12.7  Confirmation of primer specificity and linearity 
All real-time PCR primers were validated experimentally with two assays. First; 
Synthesis of a single amplicon was verified with a melting program which was run on 
the real-time PCR instrument at the end of the cycling program. The size of the RT–PCR 
product was analyzed by agarose gel electrophoresis. The second assay verified an 
amplification efficiency > 90 %. Serial dilution of known concentrations of DNA was 
performed and measured in duplicate (Pfaffl & Pfaffl, 2001). Ct values were plotted 
versus the initial amounts of the DNA concentrations. The data were fitted to a straight 
line and the slope was calculated. The efficiency was calculated through following 
formula: 
𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%) = 10
−
1
𝑆𝑙𝑜𝑝𝑒 − 1 ∗ 100 
Efficiencies between 90% -100% were accepted (-3.6 ≥ slope ≥ -3.3). 
 
2.2.12.8  RNA stability test  
700 μl of an overnight culture was added to 10 ml of fresh CDM containing 0.1 mM or 
10 mM Gly and incubated at 37°C, 5% CO2 for 3 hours. 5 ml of sample was recovered, 
and de novo synthesis of RNA was stopped by the addition of 1 mg/ml rifampicin 
(Ramirez-Peña, et al., 2010). Samples were recovered after 1, 2, 5, and 10 min to monitor 
degradation of mRNA over time. Recovered samples were added to two volumes of 
RNAprotect, incubated at room temperature for 5 min. Samples were pelleted by 
centrifugation at 4000 rpm, 4°C for 5 min and quick frozen in liquid nitrogen. RNA was 
isolated from each sample as explained (2.2.12.1). Reverse Transcription was performed 
as described (2.2.12.4). qPCR was carried out as explained (2.2.12.5). 
 
2.2.12.9  Northern blotting 
2.2.12.9.1 RNA probe generation 
 Primer design considerations 
To detect mRNA, “antisense” probes were designed, i.e. complementary to the target 
mRNA. T7 RNA polymerase promoter site (see below) was added to the 3' end of the 
reverse primer.  
cttaatacgactcactatagg 
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 In-vitro transcription 
In-vitro transcription of gene of interest was performed using MEGAscript® Kit 
according to the kit manufacturer´s instruction. The DNA template was created by PCR 
as described (2.2.7). The PCR product was purified using PCR purification kit in 
accordance with the instructions of the manufacturer. The purified PCR product was used 
as T7-DNA template for in-vitro transcription.  
 
 RNA recovery 
The product of in-vitro transcription was purified using the RNA Clean & 
Concentrator™-5 kit according to the kit manufacturer´s instruction. The quantity of 
purified RNA was measured using Qubit®2.0 Fluorometer. The integrity of purified 
RNA was assessed using the Agilent G2565AA Scanner and an Agilent RNA 6000 Nano 
kit according to the kit manufacturer´s instruction. 
 
 Biotin labeling of the 3' terminal end of RNA probe 
Labeling reaction was performed using the Pierce™ RNA 3' End Biotinylation Kit  
according to the kit manufacturer 's instruction. 
 
 Biotin labeled probe purification 
Biotin labeled RNA probe was purified using the RNA Clean & Concentrator™-5 kit in 
accordance with the instructions of the manufacturer. Quality of purified RNA was 
assessed utilizing using the Agilent G2565AA Scanner and an Agilent RNA 6000 Nano 
kit according to the kit manufacturer´s instruction. Concentration was measured using 
Qubit®2.0 Fluorometer. 
 
2.2.12.9.2 Denaturing agarose gel electrophoresis 
 Formaldehyde-agarose gel preparation 
Agarose (1.5%) was heated in 1X MOPS until dissolved. The gel was cooled to 60˚C. 
All subsequent steps were performed in a chemical hood. 2.2 M formaldehyde 37% was 
added to the solution. After gentle mixing, the gel was cast into the gel casting tray with 
an appropriate comb. After solidification, the comb was removed. 
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 Sample preparation 
Total RNA was isolated as explained (2.2.12.1). Isolated RNA quality was tested using 
Agilent G2565AA Scanner. RNA integrity number 9-10 was accepted.  
Samples were prepared by mixing a sufficient amount of RNA with the same volume of 
2X RNA gel loading dye (Thermo Fisher Scientific Inc.) in a RNase free microfuge tube. 
Samples were incubated at 70°C for 10 min and immediately chilled on ice.  
 
 RNA marker preparation 
Millennium™ RNA Marker was thawed on ice and mixed well by pipetting. 3 μl of 
2X RNA gel loading dye was mixed with 3 μl marker in an RNase free microfuge tube. 
The tube was incubated at 70°C for 10 min. It was chilled immediately on ice.  
 
 Pre-run 
The gel was pre-run submerged in 1x formaldehyde gel-running buffer for 30 min at 
5V/cm in a chemical hood. 
 
 Main run 
Samples and ladder were loaded in to the wells. The gel was run in 1x formaldehyde gel- 
running buffer for 180 min at 5V/cm. 
 
 Buffers and solutions  
5X MOPS  
Morpholinopropansulfonic acid (MOPS)                         0.1 M 
Sodium Acetate                                                                 40 mM  
EDTA DEPC treated                                                         5 mM                                                         
DEPC treated water                                                           800 ml    
pH 7.0 adjusted using 2 N NaOH 
The solution was sterilized by filtration through a 0.2-micron Millipore filter, was stored 
at room temperature and protected from light.  
 
1x formaldehyde gel-running buffer 
1 x MOPS  
Formaldehyde 37%                        2.2 M 
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 Visualizing the Formaldehyde/Agarose gel on a UV transilluminator 
Transparent ruler was aligned with the gel. The gel was photographed. The distance of 
migration from the loading well was measured. 
 
2.2.12.9.3 Blotting  
 Installation of the Northern blotting stack 
20 Extra thick blot papers (PROTEAN®XL siz) were placed. 3 strips of Whatman 1 mm 
paper were cut to the width and length of the gel. Strips were placed over the stack. A 
strip of pre-wet Whatman paper with 10 X SSC was placed over the strips. Prewet Roti®-
Nylon 0.2, pore size 0.2 µm was added. A pipette was rolled over the membrane to 
remove bubbles. Gel was placed on the membrane. A pipette was rolled over the gel. 3 
prewet strips of Whatman 1 mm paper were placed over the gel. A bridge (a long stripe 
the width of the gel) of Whatman 1mm paper was prewet in 10X SSC. Both ends of the 
bridge were soaked in two containers located one on each side of the prepared stack. A 
piece of light plastic was placed on the top of the stack to prevent the bridge from drying. 
Transfer was allowed for 4 hours. Well positions were marked in ink. Upper part of the 
blot was marked by cutting.  
 
 
20X SSC 
NaCl    3.0M 
Sodium citrate 0.3M      
Adjusting pH 7.0  
Ultra-pure water to 1 L  
DEPC-treated with 1ml/L incubated overnight at room temperature. 
The solution was sterilized by autoclave and stored at room temperature. 
 
 Immobilization 
Membrane was exposed to UV150 mJoule/cm2 to immobilize RNA on the membrane 
using UV-cross linker. 
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2.2.12.9.4 Hybridisation  
 Step 1 
Prehybridization was performed by adding 5ml/100 cm2 membrane of DIG Easy Hyb 
buffer to the membrane in a hybridization tube and incubated for one hour at 50°C while 
rotating constantly in a hybridization oven. 
 Step 2 
RNA probe (100 ng/ml hybridization solution) was added to DIG Easy Hyb buffer (3.5 
ml/100cm2 membrane). Prehybridization solution was poured off. RNA probe/DIG Easy 
Hyb buffer was immediately added to the membrane and incubated overnight at 50°C 
while rotating constantly in the hybridization oven. 
 
2.2.12.9.5 Stringency wash 
Hybridization solution was removed. The blot was washed twice in the hybridization 
tube with 50 ml of 2X Wash solution for 15 min per wash at room temperature. 100 ml 
of 0.5X Wash solution was heated to 65°C in a water bath. 50 ml of it was added to the 
membrane in the hybridization tube. The tube was placed in hybridization oven, which 
has been heated to 65°C, and incubated for 15 min. This step was repeated once.  
 
2.2.12.9.6 Biotin detection  
 
 Blocking 
1 mL of 10% SDS was added to 9 mL Odyssey® Blocking Buffer (PBS) to a final 
concentration of 1% SDS. In a container, the blot was covered with the solution with 
gently shaking at room temperature for one hour. 
 
 Streptavidin incubation     
IRDye® IRDye 800CW Streptavidin was diluted with Odyssey Blocking Buffer (PBS) 
and 1% SDS to a concentration of 1:3000. The blocking buffer was removed and the blot 
was covered with the diluted IRDye Streptavidin solution. 5 mL of buffer/10 cm2 of 
membrane was used. The container was incubated for one hour at room temperature with 
gentle agitation protected from light. 
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 Washing   
The blot was washed 3 times in 1X PBS-Tween (0.1% Tween® 20) with shaking for 5 
min each at room temperature and protected from light. The blot was rinsed with 1X PBS 
with shaking for 5 min at room temperature in darkness.  
 
 Scanning of the blot with the Odyssey® Imager      
The blot was scanned on an Odyssey® Imager according to the Odyssey Operator’s 
Manual. 
 
2.2.13   Eukaryotic cell culture 
To study the adherence and internalization of S. pyogenes to human keratinocytes, the 
HaCaT cell line (human adult skin keratinocytes) was used.  
2.2.13.1 HaCat cell line cultivation 
HaCat cells were cultured in cell culture flask (75 cm2, Bio-Greiner) containing DMEM 
(Dulbecco’s modified Eagle’s medium) supplemented with 10% (v/v) FCS (fetal calf 
serum) at 37°C and 5% CO2. Media was renewed three times a week. For this purpose, 
DMEM medium was discarded from the cell culture flask by pipette and the bottle was 
subsequently washed using 2 ml of 0.25% trypsin/EDTA. A new 2 ml trypsin/EDTA 
solution was added to the flask and incubated at 37°C and 5% CO2 for 10 min. It was 
checked for detaching cells from the inner surface of the flask. 8 ml of DMEM/FCS 
solution was added to the suspension. Afterward live cells were counted. 25 μl of cell 
suspension and 25 μl of trypan blue were placed on a cell-counting chamber and live 
cells were counted under the microscope (CKX41, Olympus). For following experiments 
monolayer cell line in 24 well-plate was needed. To create a monolayer of HaCat cells 
2ml of 3.5x105 cells/ml suspension was added in a cell culture flask containing 15 ml of 
fresh DMEM/FCS and incubated at 37°C and 5% CO2 for two to three days.  
2.2.13.2 Preparing HaCat cell culture for adherence and internalization 
assay 
A 3.5x105 HaCat cells/ml suspension was aliquoted 1 ml into the 24 well-plate (Greiner 
Bio one) with replicate number 3 for each bacterial strain and incubated at 37°C and 5% 
CO2 overnight for following experiments.  
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2.2.14 Virulence-Relevant assays 
2.2.14.1 Adherence and internalization assay  
Adherence to and internalization into human keratinocytes cells was carried out using 
HaCaT cells (Nakata, et al., 2009). The assays were performed in 24-well plates (Greiner 
bio-one). Three wells were assigned for the adherence and three wells for the 
internalization assay for each strain. Cell culture plates were prepared as described 
(2.2.13.2). After 12-18 hours of incubation, the vitality and confluence of the cells was 
verified using the microscope (CKX41, Olympus). 
Overnight culture (2.2.2.2) from the bacterial strain were transferred to non-selective 
THY medium (1:20). With an OD600 of 0.3, the sample were centrifuged at 4000 rpm for 
10 min. The supernatant was discarded, and the pellet was washed with 5 ml PBS. The 
pellet was resuspended in DMEM and adjusted to an OD600 of 0.5. 1:10 (OD600 = 0.05) 
dilution was performed. 
1 ml bacterial suspension in DMEM solution (OD600 = 0.05) were added to each well 
containing prepared confluent HaCaT cells in 24 well-plate (2.2.13.2). Three wells were 
assigned per strain. One well was used per strain for the B0 sample (bacterial solution 
without HaCaT cells). The 24-well plate was incubated for 2 hours at 37°C, 5% CO2. The 
B0 control was collected. A serial dilution of 10-3 to 10-6 was made and 100 µl plated on 
non-selective THY agar plates using Eddy Jet (IUL Instruments). Subsequently, the plate 
was used for adherence or for the internalization assay: 
Adherence assay:  
The supernatants of the sample (test) were discarded. The wells carefully were washed 
with PBS. 200 μl of 0.25% trypsin-EDTA (1x) was added to each well and incubated 10 
min at 37°C ,5% CO2. The HaCaT cells from the wells were collected in a 2-ml reaction 
tube. The wells were washed with a total 600 μl of 1xPBS and added to the 2ml tube. 
This was followed by centrifugation for 2 min at 10,000 rpm. The supernatant was 
discarded and 1ml ultra pure water was added to the tube. The cells were lysed by 
constant shaking for 10 min. Serial dilution of the suspension was made and 100 µl of 
10-3 to 10-6 were plated on non-selective THY agar plates using Eddy Jet (IUL 
Instruments) and incubated at 37°C, 5% CO2 for 24 hours. 
Internalization assay: 
The supernatant of each well was discarded and replaced with 1 ml of fresh DMEM and 
10 μl of Penicillin/Streptomycin (5000 U/ml) solution per well. A further incubation was 
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carried out for 2 hours at 37°C and 5% CO2. The HaCaT cells were treated as the 
adherence assay. Serial dilution of 10-1 to 10-4 was prepared. 100 μl of each sample were 
plated on none-selective THY agar plates using Eddy Jet (IUL Instruments) and 
incubated at 37°C, 5% CO2 for 24 hours. Analyzing the adherence and internalization 
was carried out through the ratio of colony-forming units (CFU) in comparison to the 
B0-sample. 
2.2.14.2 Blood survival assay  
To study the survival of bacteria in human blood 1 ml overnight culture (2.2.2) of the 
bacterial strain was inoculated into 19 ml of THY broth. Culture was incubated at 37°C 
and 5% CO2 to early exponential growth phase (OD600 ≈ 0.3). A dilution of 1: 10,000 was 
performed in PBS. 100 µl of dilution was plated on the THY agar plate as a control using 
Eddy Jet (control). The test was preceded by inoculating 20 µl of prepared dilution to 
480 µl of heparinized blood. The experiment was carried out in triplicate using blood 
from three independent donors. Inoculated blood was incubated for 3 hours at 37°C and 
800 rpm. 100 µl of samples was plated on THY agar plate using Eddy Jet (IUL 
Instruments). Plates were incubated at 37°C and 5% CO2 for 24 hours. Viable colony 
forming bacteria (CFU) after 3 hours incubation in blood considering the initial quantity 
of bacteria (control) gave the multiplication factor as a measure of survival ability of the 
bacteria (Nakata, et al., 2009).  
2.2.14.3 Oxidative stress 
500 µl overnight culture (2.2.2) of the bacterial strain was inoculated into 9 ml of THY 
broth. The culture was incubated at 37°C and 5% CO2 to early exponential growth phase 
(OD600 ≈ 0.5). Hydrogen peroxide solution was prepared by adding 1µl H2O2 to 99 µl 
DEPC treated water (1:100 dilution). 3 tubes containing 20 ml of bacterial suspension 
were added to (control), 0.5 and 1 mM (tests) H2O2 respectively. Tubes were incubated 
at 37°C and 5% CO2 for 2hours. 1ml of each tube was centrifuged at 4500rpm, for 10 
min. Pellets were washed in 1 ml PBS and resuspended in 1ml PBS. Serial dilution was 
prepared from each sample and100 µl of 10-4, 10-5 and10-6 dilutions were plated in THY 
agar plates. CFUs were counted after 24 hours.
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3 Results 
 Part I 
 
3.1 Investigating Gly as a possible inducer for a putative Gly riboswitch 
Among 22 cis-regulatory RNAs in S. pyogenes M49 (Patenge, et al., 2012) a putative 
Gly riboswitch (ribogly) was identified which is located in the 5′ -UTR of the putative 
Na+/Alanine symporter gene that is preceding a putative cation efflux system protein 
gene (Figure 1-7).  
The secondary structure of ribogly was predicted with the "RNAfold web server" 
(Gruber, et al., 2008). The secondary structure in dot-bracket notation was imported into 
VARNA. VARNA is a tool for the automated drawing, visualization and annotation of 
the secondary structure of RNA designed as companion software for web servers and 
databases (Darty, et al., 2009). The predicted ribogly secondary structure in S. pyogenes 
is shown in Figure 3-1. 
 
 
 
Figure 3-1. Secondary structure of ribogly from S. pyogenes M49 was predicted by RNAfold and 
illustrated using VARNA GUI (Darty, et al., 2009). It is composed of aptamer (I) and aptamer 
(II). Conserved sequences are represented in green  (Esquiaqui, et al., 2014; Mandal, et al., 2004; 
Ruff, et al., 2016). Glycine binding sites are indicated by grey circles. P0 and P1 are boxed in red 
and blue respectively, following the observations from the glycine riboswitch in V. cholerae 
(Esquiaqui, et al., 2014). P1 through P4 represent common base paired elements.  
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The putative Gly riboswitch (ribogly) in S. pyogenes M49 was fused to a luciferase gene 
as a reporter. S. pyogenes M49 was transformed with the plasmid carrying the construct 
PFW11-ribogly-luc2 (Figure 3-2.A) (Popp, 2015). 
 
 
Figure 3-2. Schematic illustration of A) pFW11-ribogly-luc2 B) the location of ribogly in the 
genome of S. pyogenes M49 after transformation with pFW11-ribogly-luc2. 
As first step in this study, the results of the former study were verified. Growth behavior 
of S. pyogenes M49/pFW11-ribogly-luc2 was monitored in CDM deficient in Gly and in 
CDM with different concentrations of Gly (0.01, 0.1, 1, 2.6,10 mM). Growth of S. 
pyogenes M49/pFW11-ribogly- luc2 in CDM in the absence of Gly and in 0.01 mM 
concentration of Gly was poor. Growth behavior was improved at higher concentrations 
of Gly (Figure 3-3). 
 
Figure 3-3. Growth curves of S. pyogenes M49/pFW11-ribogly-luc2 in CDM containing different 
concentrations of Gly. In the absence of Gly and at 0.01 mM Gly, growth of S. pyogenes 
M49/pFW11-ribogly-luc2 was poor (n=3). The data are presented as the mean values ± standard 
deviation. 
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Gly was reported as an essential amino acid (Slade, et al., 1951). In contrast, Levering 
and colleagues observed that repeated re-inoculation of cultures grown in the absence of 
glycine or serine, led to adaptation to the omissions and significant growth of the bacteria 
in the absence of these amino acids (Levering, et al., 2016). Glycine and serine can be 
converted into one another by glycine hydroxymethyltransferase (EC 2.1.2.1). According 
to the biochemical and metabolic database, KEGG (Kanehisaa & Goto, 2000), a glycine 
hydroxylmethyltransferase gene (Spy49_0898) is annotaded in S. pyogenes. However, to 
date the expression of the glycine hydroxymethyltransferase gene and the function of its 
product has not been studied in S. pyogenes. 
For the expression analysis of the luciferase gene, emission of bioluminescence was 
measured using the Luminometer at the same time points as the OD600 nm measurements. 
Luciferin served as a substrate. To compensate the differences in growth behavior in 
different Gly concentrations, light emission data detected by luminometer were divided 
by the corresponding OD600 to determine the relative light units per OD600 (RLU/ OD600). 
After 3 hours of growth in CDM containing 0.01 mM Gly, the highest induction of 
ribogly was observed with 600,000 RLU/OD600 compared to 8000 RLU/OD600 following 
growth in CDM containing 10 mM Gly. Overall, luminescence of bacteria grown in CDM 
containing 0, 0.01, or 0.1 mM Gly was always increased compared to luminescence of 
bacteria grown in CDM containing 1, 2.6 or 10 mM Gly. Wild type S. pyogenes M49 was 
used as a negative control (Figure 3-4). ribogly RNA was specific for Gly and did not 
respond to neither serine nor alanine (Popp, 2015). 
 
Figure 3-4. Relative light units (RLU/OD600) were measured in S. pyogenes M49/pFW11- 
ribogly-luc2 in CDM in the absence of Gly and in CDM containing increasing Gly 
concentrations. (Two-way ANOVA multiple comparisons test: not significant P ≥ 0.05, * p ≤ 
0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** P ≤ 0.0001, n=5). The data are presented as the mean 
values ± standard deviation. 
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3.1.1 Transcription analysis of luc2 in S. pyogenes M49/pFW11-ribogly-luc2  
S. pyogenes M49/pFW11-ribogly-luc2 were grown in CDM containing three different 
concentrations of Gly (0.1 mM, 2.6 mM, and 10 mM Gly) for 3 hours. Total RNA from 
each sample was isolated as explained (2.2.12.1). DNase treatment and cDNA synthesis 
were performed as described in 2.2.12.2 and 2.2.12.4 respectively. Transcript analysis 
was conducted via RT-qPCR as explained (2.2.12.5) to determine the transcript level of 
luc2 in S. pyogenes M49/pFW11-ribogly-luc2 and its results were compared to the results 
of the luciferase assay. All primers used for RT-qPCR are listed in Table 8. 5S rRNA 
served as internal control. Relative expression was calculated as described in 2.2.12.6. 
Transcript level of bacteria grown in CDM complemented with 0.1 mM Gly served as 
calibrator.  
In comparison to the transcript level of luc2 at 0.1 mM Gly, the transcript level decreased 
dramatically at high concentrations of Gly (2.6 mM and 10mM) (Figure 3-5). These 
results show that the reporter gene assay reflects the transcriptional regulation mediated 
by ribogly. 
 
 
Figure 3-5. Transcript level of luc2 in S. pyogenes M49/pFW11-ribogly-luc2 grown in CDM 
complemented with different Gly concentrations (t-test; *** p ≤ 0.001, n=3). The data are 
presented as the mean values ± standard deviation. 
                                                                                                                     
3.2 Transcription analysis via RT-qPCR  
In B. subtilis, binding of Gly to the Gly riboswitch leads to the formation of an anti-
terminator structure and synthesis of the full-length transcript (Phan & Schumann, 2007). 
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To investigate whether ribogly in S. pyogenes M49 functions similarly, transcription 
analyses were performed by RT-qPCR. The transcriptional level of ribogly and the 
Na+/Alanine symporter gene were determined separately. Furthermore, the putative 
cation efflux system gene, which is located immediately downstream of the Na+/Alanine 
symporter gene, was analyzed to investigate whether both genes are transcribed to a bi-
cistronic message. Transcription analyses were performed using total RNA of wild-type 
S. pyogenes M49. 
3 sets of primers were designed according to the arrangement of ribogly and downstream 
genes. To detect attenuation products and the full-length transcript two pairs of primers 
were needed. One set was designed to amplify the putative riboswitch according to the 
Rfam prediction (Figure 3-6. A). This amplicon is part of the truncated as well as of the 
full-length transcript, because it is located in the 5´of the putative terminator structure. 
The second primer pair was designed corresponding to the symporter gene and it is 
specific for the full-length transcript (Figure 3-6.B). A third primer pair was selected 
within the putative cation efflux system protein gene to determine any response to the 
ligand (Figure 3-6. C). All primers used for RT-qPCR are listed in Table 8. 
 
Figure 3-6. Schematic representation of the location of primers to study the transcription 
attenuation model by transcription analyses of ribogly, the Na+/Alanine symporter gene, and the 
putative cation efflux system protein gene.  
 
GAS strains were grown in CDM at the same condition as described in 3.1.1. Total RNA 
was extracted as explained (2.2.12.1). Transcript level of target genes were calculated as 
described (2.2.12.6) compared to 5S rRNA (Figure 3-7). Transcript abundance of ribogly 
remained static at different concentrations of Gly (Figure 3-7). The Na+/Alanine 
symporter and cation efflux system protein transcript levels decreased drastically at 2.6 
mM and 10 mM Gly (Figure 3-7).  
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Figure 3-7. Transcript analysis of ribogly, Na+/Alanine symporter gene, and cation efflux system 
gene. Data are presented as target genes transcript-levels (that are assigned in the graph with their 
name) relative to the amount of transcript at 0.1 mM Gly concentration compared to 5S rRNA. 
(Two-way ANOVA, multiple comparisons; not significant P ≥ 0.05, **** p ≤ 0.0001, n=4). The 
data are presented as the mean values ± standard deviation. 
To verify transcription attenuation, the transcript level of Na+/Alanine symporter gene 
was calculated compared to ribogly as described (2.2.12.6) (Figure 3-8). This result 
shows that the short transcript predominates in all concentrations of Gly and the ratio of 
the full-length transcript to the truncated product dramatically decreased upon addition 
of Gly. 
 
Figure 3-8. Transcript analysis of the Na+/Alanine symporter gene. Data are presented as target 
gene transcript-level relative to the amount of transcript at 0. 1 mM Gly compared to ribogly (t-
test; **** p ≤ 0.0001, n=4). The data are presented as the mean values ± standard deviation. 
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3.2.1 Analysis of the operon transcript 
Transcript levels of the Na+/Alanine symporter gene and the putative cation efflux system 
protein gene were repressed in the presence of high Gly concentrations (Figure 3-7).  
Following experiment was performed to clarify whether the cation efflux system protein 
gene is transcribed as a part of a bi-cistronic mRNA together with the Na+/Alanine 
symporter gene. Two sets of primers to amplify gene junctions were designed: one at the 
junction between the putative riboswitch and the Na+/Alanine symporter gene as a control 
for experiment (Figure 3-6. D) and another at the junction between the Na+/Alanine 
symporter gene and the putative cation efflux system protein gene (Figure 3-6. E). cDNA 
synthesis was performed and followed by PCR as described in 2.2.12.4 and 2.2.9 
respectively. Detection of the PCR product suggested co-transcription of the two genes 
(Figure 3-9). NRT control (no reverse transcriptase control) was included in the test as a 
control using primer set E. Sequencing data of the PCR product support the existence of 
a bi-cistronic message (Appendix 7-9). All primers used for this step are listed in Table 
8. 
 
Figure 3-9. PCR followed by agarose gel electrophoresis to verify whether the cation efflux 
system protein gene is transcribed as a part of a bi-cistronic mRNA together with the Na+/Alanine 
symporter gene. Lane 1; NRT control using RNA sample isolated from S. pyogenes M49 at 0.1 
mM Gly and primer set E. (location of the primer was shown in Figure 3-6). Lane 2; PCR product 
was amplified from cDNA from S. pyogenes M49 at 0.1 mM Gly using primer set E. Lane 3; O´ 
GeneRuler™ 1 kb DNA Ladder. 
 
To prove that the putative riboswitch and Na+/Alanine symporter are transcribed from 
the same operon, RT-PCR was carried out using primer pair D (Figure 3-6). The forward 
primer is specific for a part of the putative riboswitch, located on the aptamer domain, 
and the reverse primer is specific for the Na+/Alanine symporter gene. Amplification of 
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the product determined that riboswitch and the Na+/Alanine symporter gene are 
transcribed from the same operon. No product could be detected at a high concentration 
of Gly (10 mM) (Figure 3-10). 
 
Figure 3-10. Relative expression of the Na+/Alanine symporter gene (using primer pair D shown 
in Figure 3-6) compared to ribogly (t- test; *** p ≤ 0.001, n=3). The data are presented as the 
mean values ± standard deviation. 
3.3 Transcription analysis via Northern blotting 
To confirm the results achieved by RT-qPCR (3.2) and to prove the hypothesis of 
transcription attenuation caused by Gly riboswitch at high Gly concentrations (2.6mM 
and 10mM), Northern blot analyses were performed. The total RNA was extracted as 
explained (3.1.1). 6 μg of each sample was used for the experiment. Northern blotting 
was performed as explained (2.2.12.9). Blots were probed by antisense RNA specific for 
ribogly and were stripped and re-probed with Na+/Alanine symporter-specific probe 
(Figure 3-11). At low concentration of Gly (0.1 mM) a 3 kb band was detected by both 
probes. This size corresponds to the size of a co-transcript of the Na+/Alanine symporter 
gene and the cation efflux system protein gene. In low amount of Gly (0.1mM), both 
probes detected a sharp band about 600 bp. This apparent size corresponds the product 
of a termination at the putative terminator TERM 125 within Na+/Alanine symporter gene 
(TransTermHP v2.07) (Kingsford, et al., 2007). A highly aboundant 200 bp band was 
detectable by the ribogly probe in the presense of high Gly concentrations (2.6 and 10 
mM). This could arise from premature transcription termination or internal processing. 
At high concentrations of Gly no Na+/Alanine symporter gene transcript was detected by 
ribogly probe. A 300 bp band was detected only using the ribogly probe. These results 
fully confirm the data of luc reporter assay (Figure 3-4) and RT-qPCR (Figure 3-7). Gly 
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riboswitch locus and transcript sizes as well as the location of the predicted terminators 
are illusterated in Figure 3-12. 
 
 
Figure 3-11. Northern blot analyses. Total RNA was isolated from S. pyogenes  M49 grown 
in CDM complemented with 0.1mM, 2.6mM and 10 mM Gly concentrations.  6 μg of 
RNA were loaded per well. The Northern blot was probed with antisense RNA complementary 
to the Na+/Alanine symporter and to the ribogly. Transcript size was determined by comparison 
with RNA size marker M1; Thermo Scientific RiboRuler Low range RNA Ladder and M2 
Ambion Millenium TM RNA Marker. 
 
 
 
Figure 3-12. Schematic representation of the Gly riboswitch locus. Gly riboswitch aptamers I and 
II are boxed in yellow. Genes are depicted as green arrows, pointing into the direction of 
transcription. Terminators 1225 and 1227 predicted by TransTermHP (Kingsford, et al., 2007) 
are drawn as stem-loop structures. Transcripts detected by Northern blotting are shown as blue 
lines. 
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3.4 Transcript stability  
Decrease of the Na+/Alanine symporter mRNA level in the presence of 10 mM Gly 
suggests the formation of truncated product caused by transcription termination. Another 
known mechanism of riboswitches for regulation of gene expression in gram-positive 
bacteria is induction of mRNA degradation (Carona, et al., 2012). To investigate the 
stability of ribogly and Na+/Alanine symporter transcript under repressing and non-
repressing conditions, following experiment was performed. 
 S. pyogenes M49 was grown in CDM complemented with two different concentrations 
of Gly (0.1 mM and 10 mM). After 3 hours of growth, one sample from each 
concentration was taken (time point = 0) and cultures were treated with rifampicin to 
inhibit synthesis of RNA. Samples were collected after 1, 2, 5 and 10 min following the 
addition of rifampicin. Procedure was explained in detail in 2.2.12.8. RT-qPCR was 
conducted using primer pairs indicated in Figure 3-6. 5S rRNA and groES mRNA served 
as controls. Samples at time point zero were considered as calibrators. 
5S rRNA was stable over time under both conditions. The groES mRNA transcript was 
degraded at similar rates in the presence of 0.1 mM and 10 mM Gly (half-life 1.8 min 
and 1.9 min, respectively). The ribogly transcript was highly unstable in 0.1 mM and 10 
mM of Gly (half-life 0.4 min under both conditions). The stability of the Na+/Alanine 
symporter mRNA transcript was drastically reduced at 10 mM Gly (half-life 0.5 min). It 
was highly stable in 0.1 mM Gly (half-life 4.2 min) (Figure 3-13). Half-life of the 
respective transcripts has been determined by non-linear regression (least square) curve-
fitting using GraphPad Prism. 
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Figure 3-13. Transcript stability of ribogly, Na+/Alanine symporter (tests), 5S rRNA and groES 
(controls) under low (0.1 mM) and high (10 mM) Gly concentrations via RT-qPCR. Total RNA 
was isolated after rifampicine treatment. Data are presented as percent transcript level relative to 
time point zero (n=3). The data are presented as the mean values ± standard deviation. 
 
3.5 Investigation of the Na+/Alanine symporter gene promoter activity  
To investigate whether the glycine-dependent repression is influenced by the native 
promoter, a 588 bp fragment carrying the promoter region 5′ of ribogly, was fused to the 
luciferase reporter gene. Repression at different concentrations of Gly was assessed via 
RT-qPCR through measuring the transcript level of luc2. 
A 
B 
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3.5.1 Construction of S. pyogenes M49 /pFW11- promoterriboglyluc2  
Endogenous promoter was predicted via online tools; PePPER (de Jong, et al., 2012) and 
BDGP (Adams, et al., 2000). The predicted promoter region (Appendix 7-6) was 
amplified using designed primer pair (Table 8) and fused to luc2 in pFW11-luc2 plasmid 
(Figure 3-14). The resulting plasmid was tested by restriction digest (Figure 3-15). S. 
pyogenes M49 was transformed with pFW11- promoterriboglyluc2. The recombinant strain 
was verified by sequencing (Appendix 7-8). 
 
 
 
Figure 3-14. Schematic representation of pFW11- promoterriboglyluc2 construct.    
            
                    
                                
Figure 3-15. A: Verification of S. pyogenes M49/pFW11- promoterriboglyluc2. Lane 1; S. pyogenes 
M49 control. Lane 2; PCR fragment amplified with primer set Ribo.prom. BamHl-fwd and luc-
check-rev using transformant chromosomal DNA as template. Lane 3; O´ GeneRuler™ 1 kb 
DNA Ladder. B: Verification of the recombinant pFW11-native prompter-luc2 plasmid through 
restriction digest. Lane 1; O´ GeneRuler™ 1 kb DNA Ladder. Lane 2; Recombinant plasmid after 
BamHI restriction digest. Lane 3; Recombinant plasmid after BamHI and XhoI restriction digest 
created pFW11–luc2 and promoterribogly. 
 
 
 
3.5.2 Transcript analysis of luc2 in S. pyogenes M49/ pFW11- 
promoterriboglyluc2 
The transcript-level of luc2 in S. pyogenes M49/ pFW11- promoterriboglyluc2 was assessed 
via RT-qPCR, following growth in CDM with varying concentrations of Gly as explaind 
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(3.1.1). Transcript levels of luc2 showed no Gly-dependent variation. The promoter in 
this construct did not respond to the different concentrations of Gly in the growth medium 
(Figure 3-16). 
 
Figure 3-16. Transcript analysis of luc2 in S. pyogenes M49/ pFW11- promoterriboglyluc2 (n=3). 
The data are presented as the mean values ± standard deviation. 
 
The transcript level of luc2 in the absence of the riboswitch aptamers remains consistently 
(Figure 3-16). The transcript-level of luc2 in S pyogenes M49/ pFW11- 
promoterriboglyluc2 construct was compared to the transcript level of luc2 in S. pyogenes 
M49/pFW11-ribogly-luc2 transformant at non-repressing level of Gly (Figure 3-17). 
Results showed luc2 transcript level in the absence of riboswitch aptamers is significantly 
higher than in the presence of the riboswitch aptamers upstream of the native promoter.  
This outcome is explained by an influence of ribogly on the promoter. Results indicate 
that Gly-dependent expression of the genes located downstream of ribogly is not caused 
by an inducible promoter. 
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Figure 3-17. Comparing transcript level of luc2 in S. pyogenes M49/pFW11- promoterriboglyluc2 
and S. pyogenes M49/pFW11-ribogly-luc2 (t-test; * p ≤ 0.05, n=3). The data are presented as the 
mean values ± standard deviation. 
 
 Part II 
 
3.6 Construction of S. pyogenes M49 cand34 deletion mutant 
cand34 is an sRNA annotated by NCBI as CRISPR RNA belonging to CRISPR I-C and 
is located adjacent to CRISPR associated protein genes (cas genes). ccdA is located 
upstream of cand34, which is annotated as cytochrome C biogenesis protein gene. 
Pictorial representation of CRISPR I-C and upstream gene is provided in 1.9 . 
To study the function of cand34 in S. pyogenes M49 strain 591, a cand34 deletion mutant 
was constructed by replacing cand34 in S. pyogenes M49 chromosome with the 
spectinomycin cassette from pFW11 vector (Appendix 7-3). 5´ (F1) and 3´ (F2) flanking 
regions of cand34 were amplified by PCR (2.2.9). Related primer pairs are listed in Table 
8. The experiment was followed by restriction digests by BamHl/Sall restriction enzymes 
(for amplified F1 fragment) and Ncol/Pstl restriction enzymes (for amplified F2 
fragment) 2.2.11.1). Ligation was performed as described (2.2.11.2). To prove that F1 
and F2 fragments are flanked the spectomycin cassette in PFW11 plasmid, restriction 
digest tests were performed 2.2.11.1). Verification of the recombinant plasmid is shown 
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in Figure 3-18. S. pyogenes M49 was transformed with the recombinant plasmid 
(2.2.11.4). cand34 deletion mutant (Δcand34) was constructed by homologous 
recombination. Chromosomal cand34 was replaced by a spectinomycin cassette from 
pFW11-F1-F2. Δcand34 was selected on a selective THY agar plate (containing 
spectinomycin) and verified by test PCR (2.2.9) (Figure 3-19). To prove that F1 and F2 
were inserted properly, PCR was performed using related primer pairs to amplify F1-
aad9 and aad9-F2 (Table 8). Additional test PCRs are described in the legend of Figure 
3-19. The construct was also confirmed by Sanger sequencing (Appendix 7-10, Appendix 
7-11). 
 
Figure 3-18. Representative agarose gel electrophoresis of the restriction digest products of the 
recombinant pFW11-F1-F2 plasmid. Lane 1; O´ GeneRuler™ 1 kb DNA Ladder. Lane 2; 
pFW11-F1-F2 construct digested by BamHl.  Lane 3; pFW11-F1-F2 construct digested by Pstl. 
Lane 4; pFW11-F1-F2 construct digested by BamHl/Sall and results in pFW11-F2 and F1 
fragment.  Lane 5; pFW11-F1-F2 construct digested by Ncol/Pstl and results in pFW11-F1 and 
F2. Lane 6; pFW11digested by BamHl. 
 
 
 
Figure 3-19. Verification of cand34 deletion in GAS M49 Δcand34 by PCR. Lane1&11: O´ 
GeneRuler™ 1 kb DNA Ladder. Lane2; amplified F1-cand34-F2. lane3&4; amplified F1-aad9- 
F2 fragment from PFW11-F1-F2 construct and Δcand34. Lane5&6; amplified cand34 in WT and 
Δcand34 respectively. Lane7&8; amplified F1-aad9 fragment from PFW11-F1-F2 construct and 
Δcand34 respectively. Lane9&10; amplified F2-aad9 fragment from PFW11-F1-F2 construct 
and Δcand34 respectively. 
A complementation strain of cand34 was constructed. The complete cand34 sequence 
was predicted via online tool PePPER (de Jong, et al., 2012) and inserted into the shuttle 
vector pAT19 (Appendix 7-4) as explained (2.2.11). Δcand34 was transformed with 
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pAT19_cand34. Verification of pAT19-cand34 construct via restriction digest test is 
shown in Figure 3-20. Verification via sequencing is presented in Appendix 7-12. If the 
mutant phenotype was caused by the lack of cand34 expression, ectopic expression of 
cand34 in the complementation strain should restore the WT (wild-type) phenotype. In 
the case of mutations which are unrelated to the cand34 deletion, the phenotype will not 
be restored. An overexpression strain (M49/pAT19_cand34) was constructed via 
transforming pAT19_cand34 into the wild-type strain.  
 
 
 
 
 
 
 
Figure 3-20. Verification of the pAT19-cand34 construct through restriction digest. Lane 1; O´ 
GeneRuler™ 1 kb DNA Ladder. Lane 2; Recombinant plasmid after BamHI/Sall restriction 
digest created linear pAT19 and cand34 fragment. 
 
3.6.1 Transcript analysis of cand34 and its upstream and downstream 
genes  
Transcript analysis of cand34 and its upstream and downstream genes (ccdA and cas2 
respectively) was performed to verify if deletion of cand34 caused any changes in the 
expression of upstream and downstream genes. The location of genes was shown in  
Figure 1-9. ccdA is annotated as Cytochrome C biogenesis protein and its function in S. 
pyogenes has not been studied yet. As mentioned previously, cas2 is a CRISPR 
associated protein. The expression of cand34 and ccdA and cas2 was verified via RT-
qPCR 2.2.12.5) in WT, Δcand34, complementation strain (Δcand34::cand34) and the 
overexpression strain (M49/pAT19_cand34). 5S rRNA served as internal control. 
Transcript level of target genes were calculated as described 2.2.12.6). In the deletion 
mutant strain, the cand34 transcript was absent. Transcript-level of cand34 in the 
complementation strain and in the overexpression strain was drastically higher compared 
to the WT. Results are shown in Figure 3-21.A. No transcript level of ccdA (the upstream 
gene of cand34) was detected in the WT. In Δcand34 and Δcand34::cand34, a high level 
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of ccdA transcript was observed (Figure 3-21.B). The transcript level of cas2 showed no 
significant difference between the tested strains (Figure 3-21.C). 
 
 
 
Figure 3-21. Transcript analysis of cand34 (A), ccdA (B), and cas2 (C) in WT, Δcand34, 
Δcand34::cand34, and M49/pAT19_cand34 (n=3). The data are presented as the mean values ± 
standard deviation. Data are presented as target genes transcript levels relative to the amount of 
transcript level in WT compared to 5S rRNA. 
 
3.6.2  Output from CRISPR finder and blast on the NCBI 
As mentioned (1.9) cand34 is annotated as CRISPR RNA in CRISPR I-C (Dvulg or 
CASS1) in S. pyogenes. Analyses of cand34 sequence with CRISPR web server 
(http://crispr.i2bc.paris-saclay.fr/) (Grissa, et al., 2007) proved its repeat-spacer structure 
as a CRISPR RNA (Figure 3-22). Blast output results for 5 spacers in cand34 shown in 
Table 16 revealed that spacers matched streptococcal phages and prophage regions in 
different S. pyogenes strains. In S. pyogenes NZ131 spacers are involved in CRISPR 
system and none of them matched chromosomal gene sequences in this microorganism. 
This outcome means autoimmunity by self-targeting as was reported previously (Stern, 
et al., 2010) did not happened in S. pyogenes.  
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Figure 3-22. Output of CRISPR web server to indicate repeat-spacer structure of CRISPR RNA.  
 
Table 16. Blast results  of cand34 spacers   
Spacer1 S. pyogenes NZ131 
Streptococcus phage phi3396 
Spacer2 S. pyogenes NZ131 
 S. equi 4042 
Spacer3 S. pyogenes NZ131 
S. pyogenes strain M23ND 
Streptococcus dysgalactica subsp. equisimilis GGS 
Spacer4 S. pyogenes NZ131 
S. pyogenes AP53 
S. pyogenes NGAS743 
S. pyogenes AP1 
S. pyogenes NCTC8198 
S. pyogenes HSC5 
S. pyogenes Alab49 
S. pyogenes Manfredo 
S. pyogenes MGAS10394 
Streptococcus pyogenes prophage phiRamid paratox 
(prx_sda1) 
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Table 16. Blast results  of cand34 spacers (Continued) 
Spacer5 
 
S. pyogenes NZ131 
S. pyogenes MGAS11027 
Streptococcus phage P9 
S. pyogenes MGAS10394   
S. pyogenes STAB14018   
S. pyogenes AP1 
S. pyogenes NCTC8198 
S. pyogenes ATCC 19615 
S. pyogenes MGAS1882 
S. pyogenes NGAS322 
S. pyogenes NGAS743 
Vibrio parahaemolyticus strain FDAARGOS_191 
S. pyogenes Alab49 
Vibrio parahaemolyticus strain FORC_008 
Vibrio parahaemolyticus strain ATCC 17802 
Vibrio alginolyticus NBRC 15630 ATCC 17749 
Lactobacillus paracllinoides strain TMW1-1995 
 
3.6.3    Characterization of cand34 deletion mutant 
To investigate the function of cand34, growth behavior of cand34 deletion mutant and 
complementation strain and overexpressed strain in THY broth and their virulence-
relevant properties were analyzed. 
3.6.3.1 Investigating the growth behavior  
To investigate whether the growth behavior of S. pyogenes M49 is affected by deletion 
of cand34 growth of WT, Δcand34, Δcand34::cand34 and M49/pAT19_cand34 strains 
were monitored in THY broth at 37°C and 5% CO2. The optical density was measured at 
600nm every hour to 24 hours. A similar growth behavior of all strains was observed 
(Figure 3-23).  
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Figure 3-23. Growth curve of WT, Δcand34, Δcand34:: cand34 and M49/pAT19_cand34 in 
THY-Medium.  
 
The growth rate (μ) and the doubling time of the strains were determined from the 
linear range of the exponential growth phase and are shown in Table 17. 
 
 
 
 
Table 17. Growth rate and doubling time of WT and recombinant cand34 strains 
(n=3). 
Strain Growth rate(h-1) Doubling time (h) 
WT 0.72±0.057 
 
0.96±0.057 
 
Δcand34 0.81±0.041 
 
0.87±0.045 
 
Δcand34:: cand34 0.62±0.2 
 
1.1±0.038 
 
M49/pAT19_cand34 0.62±0.067 
 
1.01±0.10 
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3.6.3.2 The influence of cand34 on adherence to and internalization into 
human keratinocytes  
To establish infection, the Streptococcus must firstly attach to the epithelium of the host 
cells. Interaction with the receptors on the cell suface leads to the streptococcal 
attachment to the epithelial cells. Internalization provides important protection against 
the immune response of the host as well as against treatment with antibiotics (Courtney 
& Podbielski, 2009). The influence of cand34 on adherence and internalization of S. 
pyogenes M49 was studied. As S. pyogenes M49 was isolated from skin, the human 
HaCaT keratinocyte cell line was used as described (2.2.14.1). 
 
 
 
 
 
Figure 3-24. The effect of cand34 on adherence and internalization of S. pyogenes on and into 
HaCaT cells. A: relative adherence of recombinant strains compared to WT (Kruskal Wallis test, 
multiple comparisons; not significant P ≥ 0.05, *** p ≤ 0.001, n=7). B: relative internalization of 
recombinant strains compared to the WT (n=5). The data are presented as the mean values ± 
standard deviation. 
A 
B 
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The relative adherence of S. pyogenes M49 and the recombinant strains to HaCaT cells 
was compared to the WT (Figure 3-24.A). Significant differences in the adherence 
behavior was determined between WT and cand34 deletion mutant. No significant 
difference was observed between deletion mutant and complementation. This means 
complementation strain could not restore the WT phenotype. The internalization of S. 
pyogenes M49 and its recombinant derivatives into HaCaT cells was compared (Figure 
3-24.B). No significant difference was observed between the WT and other strains.  
3.6.3.3 The survival of S. pyogenes M49 and Δcand34 in human blood 
Another relevant factor in the virulence of S. pyogenes is the ability of the microorganism 
to survive in human blood.  
To study the influence of cand34 on survival of S. pyogenes in human blood, WT, 
Δcand34, Δcand34::cand34 and M49/pAT19_cand34 were incubated in heparinized 
human blood (2.2.14.2) and the survival rate was assessed. The survival rates of the 
recombinant strains were plotted against the multiplication factor (Figure 3-25). Results 
indicate that the Δcand34 mutant has a significantly lower survival rate than the WT. 
Δcand34::cand34 and M49/pAT19_cand34 show no significant difference compare to 
the WT. 
 
Figure 3-25. Growth of WT, Δcand34, Δcand34::cand34 and M49/pAT19_cand34 strains in 
human blood. Δcand34 showed reduced growth compared to the WT. No significant difference 
was observed between WT and complementation strain and overexpression strain (Kruskal-
Wallis test, multiple comparisons; not significant P ≥ 0.05, ** p ≤ 0.01, n =7). The data are 
presented as the mean values ± standard deviation. 
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3.6.4   The role of cand34 in surviving under oxidative stress condition 
To investigate the influence of cand34 in surviving of S. pyogenes M49 under oxidative 
stress conditions, the following test was performed as explained (2.2.14.3). WT and 
Δcand34 were grown to the early exponential growth phase (OD600 ≈ 0.5) and different 
amounts of H2O2 were added to the cultures (in the absence of H2O2 as control and 0.5 
and 1 mM as tests). Bacteria were incubated at 37°C and 5% CO2 for 2 hours. Grown 
cells were thoroughly washed with PBS, serial dilutions were plated, and CFU were 
determined after 24h. Survival of the cand34 deletion mutant strain was significantly 
lower than the WT at 0.5 mM of H2O2 (Figure 3-26). 
  
 
 
 
 
Figure 3-26. Relative survival of S. pyogenes M49 and Δcand34 under oxidative stress 
conditions. (Two-way ANOVA, not significant P ≥ 0.05, *** p ≤ 0.001. n =3). The data are 
presented as the mean values ± standard deviation. 
 
3.6.5 Target prediction of sRNA cand34 
In silico analysis can be used to predict sRNA target genes. Possible targets of cand34 
were predicted using the online tools TargetRNA2 (Kery & Feldman, 2014), CobraRNA 
(Wright, et al., 2013) and RNA predator (Zhao, et al., 2008). Predicted targets via online 
tools are given in Appendix 7-13, Appendix 7-14, Appendix 7-15.  
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4 Discussion 
 Part I 
This study was performed to characterize the function of the putative Gly riboswitch 
(ribogly) in S. pyogenes M49 strain 591. The expression of the riboswitch region in this 
microorganism was detected by intergenic tiling array (Patenge, et al., 2012). Gly 
riboswitch in GAS M49 is located in the 5´-UTR of the Na+/Alanine symporter gene 
preceding the cation efflux system protein gene (Figure 1-7).  
Riboswitches sense specific ligands. Known bacterial riboswitches control the expression 
of the genes that are involved in the respective ligand’s transport or biosynthesis. 
Riboswitches regulate gene expression by different mechanisms which influence 
transcription termination, translation initiation, RNA stability and splicing. (Serganov & 
Nudler, 2013b; Mandal, et al., 2004).  
Luciferase reporter assays revealed that the expression of the Na+/Alanine symporter 
gene was induced in the absence of Gly or in the presence of low amount of Gly and was 
repressed in the presence of high Gly concentrations (Figure 3-4). RT-qPCR experiments 
revealed that upon increasing Gly concentrations, the full-length transcript level 
decreased drastically while ribogly transcript level remained constant (Figure 3-7). 
Northern blot analyses proved Na+/Alanine symporter gene repression in the presence of 
high Gly concentrations and suggested premature transcription termination (Figure 3-11).  
One explanation for these results is premature transcription termination. In 
transcriptional regulation by riboswitches, conformational change leads to the formation 
of either a stem-loop structure analogous to Rho-independent termination or anti-
terminator hairpin structure. The formation of a terminator leads to a transcription 
termination and short transcript will be derived. In S. pyogenes M49, in the presence of 
high concentrations of Gly transcription termination occurs and formation of the 
terminator inhibits elongation by RNA polymerase and only truncated transcript (ribogly) 
is detectable. In the absence of Gly or at low concentrations of Gly, anti-terminator 
hairpin structure is formed, and a full-length transcript will be produced. This kind of 
termination is similar to what happens in Rho-independent termination. It seems ribogly 
regulates transcription via controlling the formation of an intrinsic terminator.  
One example of this mechanism was observed in B. subtilis. Gly riboswitch in B. subtilis 
is composed of two similar aptamer domains; Type I and Type II followed by a single 
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expression platform (gcvT operon) (Phan & Schumann, 2007) (Mandal, et al., 2004).  In 
S. pyogenes one aptamer (type II) similar to the B. subtilis aptamers was predicted 
upstream of the Na+/Alanine symporter gene (Figure 4-1). A Gly riboswitch in V. cholera 
preceding VC1422 gene (Na+/Alanine symporter gene) also exhibits tandem architecture 
with two homologous aptamer domains followed by Na+/Alanine symporter gene. The 
ligand-binding pocket sequence in the Gly riboswitch in both B. subtilis and V. cholera 
is similar. Type I and type II aptamers are identified based on the variations in the 
sequences which flank conserved cores. Sequences that are represented in black and red 
are conserved (≥ 80% and ≥ 95%) and circles and black tick lines show less conserved 
sequences (Figure 4-1.A.B) (Mandal, et al., 2004).  
The secondary structure of the Gly riboswitch in S. pyogenes M49 was predicted by 
RNAfold on the RNA web server (Gruber, et al., 2008) and was illustrated via VARNA 
(Darty, et al., 2009) (Figure 4-1.C). It is composed of two aptamer domains; type I and 
type II. Type I is homologous to type I aptamer in V. cholera (a gram-negative bacterium) 
and type II aptamer is homologous to type II in both V. cholera and B. subtilis (a gram-
positive bacterium). 
Evolution is one explanation for this secondary structure. To adapt new niches, RNA 
evolved to function as a genetic information storage and catalyze chemical reactions 
(Gilbert, 1986; Serganov & Nudler, 2013b). Natural selection leads to alteration in RNA 
sequences into specific metabolite-binding domains to adapt to environmental stresses 
and signals (e.g. nutritional depletion) (Serganov & Nudler, 2013b). Both aptamers in the 
Gly riboswitch in S. pyogenes possess conserved nucleotides in the ligand-binding 
pocket, which were previously described (Esquiaqui, et al., 2014; Mandal, et al., 2004; 
Weinberg, et al., 2017). Conserved sequences form a precise sensor for a ligand and never 
change through evolution (Breaker, 2011).  
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Figure 4-1. The secondary structure schematics of Gly riboswitch in A) B. subtilis, B) V. 
cholerae, C) S. pyogenes. Type I aptamer of Gly riboswitch in S. pyogenes is homologous to type 
I aptamer of Gly riboswitch in V. cholera (a gram-negative bacterium) and type II aptamer is 
homologous to type II in both B. subtilis and V. cholera (a gram-positive bacterium). Gly 
riboswitch secondary structure was explained in detail in 3.1. 
 
In S. pyogenes M49 ribogly is preceding the Na+/Alanine symporter gene and induction 
is detectable at low Gly concentration (0.01 mM). In B. subtilis Gly riboswitch is 
preceding gcvT operon and induction happens at high concentration of Gly (10 mM). 
gcvT operon encodes the Gly cleavage system proteins and catalyzes the degradation of 
Gly (to 5,10-methylene-tetrahydrofolate, CO2, ammonia and NADH) for use of Gly as 
an energy source (Kikuchi, 1973; Mandal, et al., 2004). In the presence of high Gly 
concentration and binding to the aptamer domains, an anti-terminator structure is formed 
(Figure 4-2). Transcription is continued and expression of gcvT operon leads to the 
synthesis of the enzymes for Gly degradation. In absence of Gly, the transcription process 
is terminated prematurely and expression of gcvT operon is inhibited (Phan & Schumann, 
2007). The fact that putative Na+/Alanine symporter functions as an amino acid 
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transporter and gcvT operon functions for Gly degradation is consistent with the 
observations of their transcript levels in various amount of Gly. In B. subtilis when Gly 
concentration reaches to high level, a degradation system helps to adjust to the optimum 
condition. Na+/Alanine symporter is a member of Na+/Alanine symporter super family 
(SAF) and was studied in some microorganisms like Alteromonas haloplanktis (Reizer, 
et al., 1993). In this microorganism, the symporter transports alanine and glycine, Na+-
dependently. It has not been studied in S. pyogenes to date. The fact that Na+/Alanine 
symporter transcription is drastically limited in high Gly concentrations and increased in 
low amounts, suggests that it is involved in Gly transport in S. pyogenes too. 
 
  
 
Figure 4-2. Formation of an anti-terminator structure in Gly riboswitch in B. subtilis. Two 
aptamers control a single expression platform. 
 
An additional possibility for the continuous presence of ribogly in different concentration 
of Gly in contrast to the full-length transcript could be the high stability of its transcript. 
However, results of transcript stability test do not support this hypothesis. The ribogly 
transcript stability assay determined that short transcript (ribogly) is unstable in different 
concentrations of Gly and trace amounts were detected after one minute of stopping de 
novo synthesis of RNA in non-repressing (0.01 mM) and repressing (10 mM) level of 
Gly concentration. This fact implies that constant presence of ribogly is not due to the 
high stability of its transcript. 
The Na+/Alanine symporter transcript stability was rather high in non-repressing level 
(0.01 mM) of Gly and low in repressing levels (10 mM). ribogly is not stable under both 
conditions. These observations suggest that processing of the full-length transcript 
happens, and the processed Na+/Alanine symporter gene mRNA is more stable than the 
full-length transcript. A model of the full-length transcript processing in repressing and 
non-repressing conditions is provided in Figure 4-3. 
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The hypothesis is that at low Gly concentrations the full-length transcript undergoes 
processing. Ribogly and the coding transcripts (Na+/Alanine symporter and Efflux 
mRNA) are separated. Northern blot analysis of the coding transcript revealed a 300 
nucleotides band that according to this model represents the outcome of processing. 
Subsequently ribogly is degraded. In this model, ribogly could be a target of a 
ribonuclease. It is also possible that riboswitch RNA has auto-catalytic function as was 
observed in glmS riboswitch-ribozyme in B. subtilis (Collins, et al., 2007). A low 
concentration of Gly in the medium on one side induces the formation of an anti-
terminator structure and on the other side exposes a cleavage site downstream of the anti-
terminator. Separation leads to the stabilization of the Na+/Alanine symporter and Efflux 
mRNA.  
This observation proves that neither high stability nor processing of the full-length 
transcript, explains constant presence of ribogly (short transcript) but its continuous 
synthesis. A similar mechanism has been observed in B. subtilis, where in the absence as 
well as in the presence of Gly, the stability of riboswitch RNA was low (Phan & 
Schumann, 2007). In contrast to the situation in S. pyogenes, the full-length transcript 
was more stable in high Gly concentrations, compared to Gly deficient conditions (Figure 
3-13). 
A similar process has been reported for the Bacillus threonyl/tRNA synthetase gene 
(thrS). Expression of thrS is regulated by a T-box that responds to the limitation of 
threonine (Grundy, et al., 1993). A low concentration of threonine leads to a tRNA-
mediated anti-termination and results in expression of thrS. An additional control system 
for thrS expression is processing of the full-length transcript. In the absence or in the 
presence of limited amounts of threonine, the leader region of mRNA is processed 
between the T-box and the Rho-independent transcription terminator. The thrS mRNA is 
detected in cleaved form and processed transcript is stable (Condon, et al., 1996; Carona, 
et al., 2012). 
The same process was observed in Mg2+ riboswitch in Salmonella enterica serovar 
Typhimurium (Spinelli, et al., 2008). In the presence of high Mg2+ concentrations, besides 
transcription termination, RNA degradation by RNase E is an additional mechanism 
controlling mgtA expression that encodes Mg2+ transporter. 
In gram-positive bacteria, the glmS riboswitch-ribozyme in the 5′-UTR of the gene 
encoding glucosamine-6-phosphate (GlcN6P) synthetase, acts based on mRNA 
destabilization (Collins, et al., 2007). Its mechanism is based on metabolite sensing and 
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subsequently mRNA cleavage (Winkler, et al., 2004). Binding of GlcN6P to the 
riboswitch leads to an autocatalytic site-specific cleavage of glmS mRNA and creats 5´-
OH on the fragment that stimulates degradation of the downstream gene by RNase J 
(Collins, et al., 2007). RNase J1 and RNase J2 are essential ribonucleases for growth of 
S. pyogenes (Bugrysheva & Scott, 2010). To investigate the mechanism of processing in 
Gly riboswitch in S. pyogenes these two ribonucleases have high potential as a subject 
for further study. 
 
 
 
Figure 4-3. Model of the full-length transcript processing in low amount of Gly which leads to 
the removal of ribogly transcript. A) Degradation of the ribogly and the full-length transcript at 
10 mM. B) Stabilization of the symporter and the efflux mRNA by processing: the ribogly is 
removed and degraded (Figure 3-13). 
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 Part II 
In the second part, sRNA cand34 in S. pyogenes M49 strain 591 was studied. It was 
identified as CRISPR RNA in CRISPR system I-C. As described (1.8) CRISPR RNA is 
composed of short foreign DNA fragments (spacers) that are separated by repeat 
sequences. In one study, spacer analysis of a type II-A CRISPR-Cas system in isolates 
of S. agalactica determined that two spacers targeted two regions on its own chromosome 
(Stern, et al., 2010). Nowaza et. al suggested that the limited presence of CRISPR- 
systems in S. pyogenes strains have allowed the integration of virulence genes by phages 
into different S. pyogenes. This theory suggests that their ability to cause diseases can be 
related to the integrated prophages (Beres, et al., 2002; Beres & Musser, 2007). The full 
genome sequences of several strains of S. pyogenes genome showed the prophage regions 
possess variable virulence genes and extend pathogenic capacities (Fischetti, 2007). 
Inactivating the type II CRISPRCas system in Campylobacter jejuni revealed that the 
ability of this microorganism to infect the human peripheral nervous system (in Guillain-
Barré Syndrome) is drastically decreased (Louwen, et al., 2013). To study the potential 
involvement of CRISPR system in pathogenicity, they inactivated csn1 in the system, 
which effectively reduced virulence in Campylobacter jejuni isolates. This finding 
revealed a link between viral defence and virulence of C. jejuni and Guillain-Barré 
Syndrome.  
Δcand34 in S. pyogenes M49 was constructed to study a potential regulatory function and 
possible role of cand34 in virulence and metabolism. A quantification of cand34 
transcript levels in exponential phase via RT-qPCR in WT and the complementation 
strain showed drastic increase in the complementation strain. This effect can be caused 
by the high copy number of pAT19, which was used as shuttle vector in this experiment 
(Trieu-Cuot, et al., 1991).  
Investigating upstream and downstream genes transcript levels after deletion of cand34 
showed that ccdA, that is annotated as cytochrome C biogenesis protein gene was silent 
in WT but showed high-level of transcription in Δcand34. Measuring its transcript level 
in complementation strain revealed that cand34 in shuttle vector is not able to fully 
restore the transcript level of ccdA to the WT level. This phenomenon can be described 
by Primer sequences for amplifying flanking regions of cand34 to construct deletion 
mutant that were designed using NZ131 genome and not S. pyogenes M49 (because 
whole genome of S. pyogenes M49 is not sequenced to date). It is possible that at this 
region, difference in sequences causes interruption in deletion of cand34. This hypothesis 
Discussion  
 
- 86 - 
 
can explain the disability of cand34 in the complementation strain in restoring the 
transcript level of ccdA. Since the complementation strain does not complement ccdA, 
cand34 overexpression strain was used for the following experiments. Increased 
transcript level of cand34 in the overexpression strain could be used to study the effect 
of cand34 on virulence of S. pyogenes M49. 
A growth test was performed in THY to test comparability of the recombinant strains 
with WT. Disturbed growth behavior in constructed strains can influence the outcome of 
other experiments and distort their results.  
Because no significant difference was observed in growth behavior in strains they could 
be used for subsequent experiments.  
Survival of Δcand34 in human blood was significantly reduced compared to the WT. In 
the complementation strain, growth could be restored to the WT level. As discussed 
above, this phenotype can be attributed to cand34. Further study is needed to determine 
the cand34 transcript level in the WT growing in human blood.  
Investigating cand34 function in oxidative stress condition revealed that the cand34 
deletion mutant has less ability to survive in this condition. As the complementation 
strain was excluded from oxidative stress experiment because of small colony phenotype, 
it is not clear whether cand34 is responsible for decreased oxidative stress tolerance. As 
mentioned, ccdA was silent in WT, while in deletion mutant strain its transcript level 
dramatically increased and complementation strain was not able to return its transcript 
level to the WT. It might be proper a solution to construct ccdA deletion mutant and 
include it in the experiment beside cand34.  
ccdA has been also predicted in silico as a target for cand34 (Appendix 7-13, Appendix 
7-15) Prediction of its product interaction with other proteins (Szklarczyk, et al., 2015) 
showed that ccdA probably interacts with msrA (Figure 4-4).  
In silico target prediction (Appendix 7-15) suggests msrA as one possible target for 
cand34. msrA codes for methionine sulfoxide reductase which protects against oxidative 
stress. It has an important role as a repair enzyme for proteins that have been inactivated 
by oxidation. It catalyzes the oxidation-reduction of methionine sulfoxide to methionine 
(Cabreiro, et al., 2006). Regarding the observation in the oxidative stress assay (Figure 
3-26), the transcript level of msrA in strains needs to be determined. The location of msrA 
in S. pyogenes chromosome is presented in Figure 4-5. 
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Figure 4-4.  Prediction of ccdA interaction(s) with other genes. Among predicted genes msrA is 
seen which protect against oxidative stress.                        
https://string-db.org/cgi/input.pl?UserId=XnJ6BFyikDqU&sessionId=7lHSAPzFFJxe 
 
 
Figure 4-5. Pictorial representation o the location of CRISPR RNA, ccdA and msrA. 
https://www.ncbi.nlm.nih.gov/nuccore/NC_011375.1?report=graph# 
 
Further studies are needed to investigate the effect of cand34 on msrA transcript level via 
RT-qPCR under different conditions of oxidative stress. For a more precise experiment, 
pAT19 as shuttle vector in complementation strain should be replaced to decrease the 
high copy number of plasmid and restore the transcript level of cand34 to the WT level. 
The presence of ccdA deletion mutant in this experiment will be helpful.  
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5 Summary 
Part I: 
Riboswitches are non-coding RNAs that are induced by metabolites, ions or other 
environmental conditions and are mostly found within the 5´-UTR of mRNAs. They 
regulate the expression of downstream genes that are involved in transport or catabolism 
of the respective inducer. In this work, a putative glycine riboswitch (ribogly) located 
within the 5´-UTR of Na+/Alanine symporter gene was studied. Ribogly secondary 
structure is composed of two aptamer domains. Type I is similar to the type I aptamer 
domain in Gly riboswitch in Vibrio cholerae (a gram-negative bacterium) and type II is 
similar to type II in Bacillus subtilis (a gram-positive bacterium) and in Vibrio cholerae 
(Mandal, et al., 2004). Using a reporter gene system, it could be shown that ribogly is a 
glycine-dependent riboswitch. Reverse transcription followed by quantitative PCR 
revealed that in different concentrations of glycine ribogly is consistently transcribed 
while the transcription of the full-length mRNA decreased drastically at high amounts of 
glycine. Visualizing transcripts by Northern blotting suggests that in the absence of 
glycine or in the presence of a low glycine concentration, ribogly forms an anti-
terminator allowing synthesis of the full-length mRNA. In high glycine concentrations, 
a terminator is formed leading to transcription attenuation. Stopping de novo synthesis of 
RNA revealed that the full-length transcript is processed. Transcript stability assays 
showed that continuous presence of the ribogly is not caused by high stability of ribogly. 
Instead, the truncated ribogly transcript is synthesized continuously. Fusing the 
endogenous promoter of Na+/Alanine symporter gene to the reporter gene demonstrated 
that induction behavior in ribogly is not affected by the native promoter.  
Part II: 
In this part, a putative regulatory sRNA (cand34) in S. pyogenes M49 was characterized 
through virulence assays. A deletion mutant of cand34 was constructed. ccdA (upstream 
gene of cand34) which was silent in WT, was transcribed in Δcand34. The ectopic 
expression of cand34 was not able to reduce ccdA transcript level to the WT. One possible 
explanation is the damage of a regulatory element in the 5´ region of ccdA that has been 
caused by the deletion of cand34. cand34 deletion mutant showed a reduced growth in 
human blood than WT.  
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7 Appendix 
Appendix 7-1. Representation of 3 major types and 10 subtypes of known CRISPR system 
(Makarova, et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
 
- 99 - 
 
Appendix 7-2. A) Schematic of pFW11-luc2 plasmid. B) Restriction enzyme map in pFW11 
plasmid (Vincze, et al., 2003).
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ID   pFW11_luc2 (4210 bp) 
DE   MCSI: POS.1-44; LUC: POS.45-1694; aad9: POS.1828-2577;  
     MCSII: POS.2666-2741 
ID   pFW11_luc2 (4210 bp) 
DE   MCSI: POS.1-44; luc: POS.45-1694; aad9: POS.1828-2577;  
     MCSII: POS.2666-2741 
MSCI: TGTACAATTGCTAGCGTACGGCCGTCGACGTCCGGATCCTCGAGATGGAAGACGCCAAAAAC 
 
 
SQ   SEQUENCE   4210 BP; 1287 A; 866 C; 955 G; 1102 T; 0 OTHER; 
     TGTACAATTG CTAGCGTACG GCCGTCGACG TCCGGATCCT CGAGATGGAA GACGCCAAAA 
     ACATAAAGAA AGGCCCGGTG CCATTCTATC CGCTAGAGGA TGGAACCGCT GGAGAGCAAC 
     TGCATAAGGC TATGAAGAGA TACGCCCTGG TTCCTGGAAC AATTGCTTTT ACAGATGCAC 
     ATATCGAGGT GAACATCACG TACGCGGAAT ACTTCGAAAT GTCCGTTCGG TTGGCAGAAG 
     CTATGAAACG ATATGGGCTG AATACAAATC ACAGAATCGT CGTATGCAGT GAAAACTCTC 
     TTCAATTCTT TATGCCGGTG TTGGGCGCGT TATTTATCGG AGTTGCAGTT GCGCCCGCGA 
     ACGACATTTA TAATGAACGT GAATTGCTCA ACAGTATGAA CATTTCGCAG CCTACCGTAG 
     TGTTTGTTTC CAAAAAGGGG TTGCAAAAAA TTTTGAACGT GCAAAAAAAA TTACCAATAA 
     TCCAGAAAAT TATTATCATG GATTCTAAAA CGGATTACCA GGGATTTCAG TCGATGTACA 
     CGTTCGTCAC ATCTCATCTA CCTCCCGGTT TTAATGAATA CGATTTTGTA CCAGAGTCCT 
     TTGATCGTGA CAAAACAATT GCACTGATAA TGAACTCCTC TGGATCTACT GGGTTACCTA 
     AGGGTGTGGC CCTTCCGCAT AGAACTGCCT GCGTCAGATT CTCGCATGCC AGAGATCCTA 
     TTTTTGGCAA TCAAATCATT CCGGATACTG CGATTTTAAG TGTTGTTCCA TTCCATCACG 
     GTTTTGGAAT GTTTACTACA CTCGGATATT TGATATGTGG ATTTCGAGTC GTCTTAATGT 
     ATAGATTTGA AGAAGAGCTG TTTTTACGAT CCCTTCAGGA TTACAAAATT CAAAGTGCGT 
     TGCTAGTACC AACCCTATTT TCATTCTTCG CCAAAAGCAC TCTGATTGAC AAATACGATT 
     TATCTAATTT ACACGAAATT GCTTCTGGGG GCGCACCTCT TTCGAAAGAA GTCGGGGAAG 
     CGGTTGCAAA ACGCTTCCAT CTTCCAGGGA TACGACAAGG ATATGGGCTC ACTGAGACTA 
     CATCAGCTAT TCTGATTACA CCCGAGGGGG ATGATAAACC GGGCGCGGTC GGTAAAGTTG 
     TTCCATTTTT TGAAGCGAAG GTTGTGGATC TGGATACCGG GAAAACGCTG GGCGTTAATC 
     AGAGAGGCGA ATTATGTGTC AGAGGACCTA TGATTATGTC CGGTTATGTA AACAATCCGG 
     AAGCGACCAA CGCCTTGATG GACAAGGATG GATGGCTACA TTCTGGAGAC ATAGCTTACT 
     GGGACGAAGA CGAACACTGC TGCATAGTTG ACCGCTTGAA GTCTTTAATT AAATACAAAG 
     GAGACCAGGT GGCCCCCGCT GAATTGGAGT CGATATTGTT ACAACACCCC AACATCTTCG 
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     ACGCGGGCGT GGCAGGTCTT CCCGACGATG ACGCCGGTGA ACTTCCCGCC GCCGTTGTTG 
     TTTTGGAGCA CGGAAAGACG ATGACGGAAA AAGAGATCGT GGATTACGTC GCCAGTCAAG 
     TAACAACCGC CAAAAAGTTG CGCGGAGGAG TTGTGTTTGT GGACGAAGTA CCGAAAGGTC 
     TTACCGGAAA ACGCGACGCA AGAAAAATCA GAGAGATCCT CATAAAGGCC AAGAAGGGCG 
     GAAAGTCCAA ATTGTAAAAG CTTGATTTTC GTTCGTGAAT ACATGTTATA ATAACTATAA 
     CTAATAACGT AACGTAACGT AAAATTTGTT TGATTTGTCC AAAATATGGT ATAATAGGTA 
     CTAATCAAAA TAGTGAGGAG GATATATTTG AATACATACG AACAAATTAA TAAAGTGAAA 
     AAAATACTTC GGAAACATTT AAAAAATAAC CTTATTGGTA CTTACATGTT TGGATCAGGA 
     GTTGAGAGTG GACTAAAACC AAATAGTGAT CTTGACTTTT TAGTCGTCGT ATCTGAACCA 
     TTGACAGATC AAAGTAAAGA AATACTTATA CAAAAAATTA GACCTATTTC AAAAAAAATA 
     GGAGATAAAA GCAACTTACG ATATATTGAA TTAACAATTA TTATTCAGCA AGAAATGGTA 
     CCGTGGAATC ATCCTCCCAA ACAAGAATTT ATTTATGGAG AATGGTTACA AGAGCTTTAT 
     GAACAAGGAT ACATTCCTCA GAAGGAATTA AATTCAGATT TAACCATAAT GCTTTACCAA 
     GCAAAACGAA AAAATAAAAG AATATACGGA AATTATGACT TAGAGGAATT ACTACCTGAT 
     ATTCCATTTT CTGATGTGAG AAGAGCCATT ATGGATTCGT CAGAGGAATT AATAGATAAT 
     TATCAGGATG ATGAAACCAA CTCTATATTA ACTTTATGCC GTATGATTTT AACTATGGAC 
     ACGGGTAAAA TCATACCAAA AGATATTGCG GGAAATGCAG TGGCTGAATC TTCTCCATTA 
     GAACATAGGG AGAGAATTTT GTTAGCAGTT CGTAGTTATC TTGGAGAGAA TATTGAATGG 
     ACTAATGAAA ATGTAAATTT AACTATAAAC TATTTAAATA ACAGATTAAA AAAATTATAA 
     AAAAATTGAA AAAATGGTGG AAACACTTTT TTCAATTTTT TTGTTTTATT ATTTAATATT 
     TGGGAAATAT TCATTCTAAT TGGTAAGCGC GCCATGGGCC CTGCAGCATG CATATGCATC 
     CGGAGTTCCC GGGCGCCGGC CTAGGACTAG TGATCACCGG TCGCTCTTCC GCTTCCTCGC 
     TCACTGACGC GTAAAAAAGG CCCACAAAAG TGGGCCTTTT TTCTCGCTGC GCTCGGTCGT 
     TCGGCTGCGG CGAGCGGTAT CAGCTCACTC AAAGGCGGTA ATACGGTTAT CCACAGAATC 
     AGGGGATAAC GCAGGAAAGA ACATGTGAGC AAAAGGCCAG CAAAAGGCCA GGAACCGTAA 
     AAAGGCCGCG TTGCTGGCGT TTTTCCATAG GCTCCGCCCC CCTGACGAGC ATCACAAAAA 
     TCGACGCTCA AGTCAGAGGT GGCGAAACCC GACAGGACTA TAAAGATACC AGGCGTTTCC 
     CCCTGGAAGC TCCCTCGTGC GCTCTCCTGT TCCGACCCTG CCGCTTACCG GATACCTGTC 
     CGCCTTTCTC CCTTCGGGAA GCGTGGCGCT TTCTCATAGC TCACGCTGTA GGTATCTCAG 
     TTCGGTGTAG GTCGTTCGCT CCAAGCTGGG CTGTGTGCAC GAACCCCCCG TTCAGCCCGA 
     CCGCTGCGCC TTATCCGGTA ACTATCGTCT TGAGTCCAAC CCGGTAAGAC ACGACTTATC 
     GCCACTGGCA GCAGCCACTG GTAACAGGAT TAGCAGAGCG AGGTATGTAG GCGGTGCTAC 
     AGAGTTCTTG AAGTGGTGGC CTAACTACGG CTACACTAGA AGGACAGTAT TTGGTATCTG 
     CGCTCTGCTG AAGCCAGTTA CCTTCGGAAA AAGAGTTGGT AGCTCTTGAT CCGGCAAACA 
     AACCACCGCT GGTAGCGGTG GTTTTTTTGT TTGCAAGCAG CAGATTACGC GCAGAAAAAA 
Appendix 
 
- 102 - 
 
     AGGATCTCAA GAAGATCCTT TGATCTTTTC TACGGGGTCT GACGCTCAGT GGAACGAAAA 
     CTCACGTTAA GGGATTTTGG TCATGAGATT ATCAAAAAGG ATCTTCACCT AGATCCTTTT 
     AAATTAAAAA TGAAGTTTTA AATCAATCTA AAGTATATAT GAGTAAACTT GGTCTGACAG 
     TTACCAATGC TTAATCAGTG AGGCACCTAT CTCAGCGATC TGTCTATTTC GTTCATCCAT 
     AGTTGCCTGA CTCCCCGTCG TGTAGATAAC TACGATACGG GAGGGCTTAC CATCTGGCCC 
     CAGTGCTGCA ATGATACCGC GAGACCCACG CTCACCGGCT CCAGATTTAT CAGCAATAAA 
     CCAGCCAGCC GGAAGGGCCG AGCGCAGAAG TGGTCCGATA AACCCAGCGA ACCATTTGAG 
     GTGATAGGTA AGATTATACC GAGGTATGAA AACGAGAATT GGACCTTTAC AGAATTACTC 
     TATGAAGCGC CATATTTAAA AAGCTACCAA GAAAAAAAGC GGCCAAAAAG GCCTGGTGCC 
     ACCAGGCCAA AAAGGCCGCT TTTTTTCGAA GAGGATGAAG AGGATGAGGA GGCAGATTGC 
     CTTGAATATA TTGACAATAC TGATAAGATA ATATATCTTT TATATAGAAG ATTTTCGTTC 
     GTGAATACAT 
 
Appendix 7-3. pFW11 plasmid. 
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Appendix 7-4. Schematic of pAT18/19 plasmid. 
 
 
 
 
Appendix 7-5. luciferase gene sequence and the locations of designed primers. 
 
 
ATGGAAGACGCCAAAAACATAAAGAAAGGCCCGGTGCCATTCTATCCGCTAGAGGATGGAACCGCTGGAG
AGCAACTGCATAAGGCTATGAAGAGATACGCCCTGGTTCCTGGAACAATTGCTTTTACAGATGCACATAT
CGAGGTGAACATCACGTACGCGGAATACTTCGAAATGTCCGTTCGGTTGGCAGAAGCTATGAAACGATAT
GGGCTGAATACAAATCACAGAATCGTCGTATGCAGTGAAAACTCTCTTCAATTCTTTATGCCGGTGTTGG
GCGCGTTATTTATCGGAGTTGCAGTTGCGCCCGCGAACGACATTTATAATGAACGTGAATTGCTCAACAG
TATGAACATTTCGCAGCCTACCGTAGTGTTTGTTTCCAAAAAGGGGTTGCAAAAAATTTTGAACGTGCAA
AAAAAATTACCAATAATCCAGAAAATTATTATCATGGATTCTAAAACGGATTACCAGGGATTTCAGTCGA
TGTACACGTTCGTCACATCTCATCTACCTCCCGGTTTTAATGAATACGATTTTGTACCAGAGTCCTTTGA
TCGTGACAAAACAATTGCACTGATAATGAACTCCTCTGGATCTACTGGGTTACCTAAGGGTGTGGCCCTT
CCGCATAGAACTGCCTGCGTCAGATTCTCGCATGCCAGAGATCCTATTTTTGGCAATCAAATCATTCCGG
ATACTGCGATTTTAAGTGTTGTTCCATTCCATCACGGTTTTGGAATGTTTACTACACTCGGATATTTGAT
ATGTGGATTTCGAGTCGTCTTAATGTATAGATTTGAAGAAGAGCTGTTTTTACGATCCCTTCAGGATTAC
AAAATTCAAAGTGCGTTGCTAGTACCAACCCTATTTTCATTCTTCGCCAAAAGCACTCTGATTGACAAAT
Luc-check-rev CCA TGA TAA TAA TTT TCT GGA 
RT_Luc_for GAG ACA TAG CTT ACT GGG ACG 
RT_Luc_rev TAT CGA CTC CAA TTC AGC GGG 
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ACGATTTATCTAATTTACACGAAATTGCTTCTGGGGGCGCACCTCTTTCGAAAGAAGTCGGGGAAGCGGT
TGCAAAACGCTTCCATCTTCCAGGGATACGACAAGGATATGGGCTCACTGAGACTACATCAGCTATTCTG
ATTACACCCGAGGGGGATGATAAACCGGGCGCGGTCGGTAAAGTTGTTCCATTTTTTGAAGCGAAGGTTG
TGGATCTGGATACCGGGAAAACGCTGGGCGTTAATCAGAGAGGCGAATTATGTGTCAGAGGACCTATGAT
TATGTCCGGTTATGTAAACAATCCGGAAGCGACCAACGCCTTGATGGACAAGGATGGATGGCTACATTCT
GGAGACATAGCTTACTGGGACGAAGACGAACACTGCTGCATAGTTGACCGCTTGAAGTCTTTAATTAAAT
ACAAAGGAGACCAGGTGGCCCCCGCTGAATTGGAGTCGATATTGTTACAACACCCCAACATCTTCGACGC
GGGCGTGGCAGGTCTTCCCGACGATGACGCCGGTGAACTTCCCGCCGCCGTTGTTGTTTTGGAGCACGGA
AAGACGATGACGGAAAAAGAGATCGTGGATTACGTCGCCAGTCAAGTAACAACCGCCAAAAAGTTGCGCG
GAGGAGTTGTGTTTGTGGACGAAGTACCGAAAGGTCTTACCGGAAAACGCGACGCAAGAAAAATCAGAGA
GATCCTCATAAAGGCCAAGAAGGGCGGAAAGTCCAAATTG 
Appendix 7-6. pcrA, ribogly and Na+/Alanine symporter sequences and the position of 
predicted elements and designed primers:  
TTA: Start of the predicted first aptamer 
ACT: Start of the predicted second aptamer 
AAG: End of the second aptamer 
First Terminator 
Second Terminator 
T: Predicted transcriptional start site 
TTTTGGTTGACTTCATTCGTTTTTTGAGGTATGATAGTCC: predicted promoter 
 
Sequences and locations of designed primers within ribogly and Na+/Alanine symporter 
 
RT_ribogly_for CTGGAGAGACCTTATTAGGC 
 
RT_ribogly_rev GAGAGATTGAGCAGTATGCC  
 
T7.ribogly_rev cttaatacgactcactatagg GAGAGATTGAGCAGTATGCC                      
GlyLuc_Xho_rev CCT CGAGCT CCT AAA AGT CAT CGA AGA CG 
 
Ribo.prom. BamHl-fwd        TCGGATCCATGCGCTTCATCAACG    
 
Ribo.prom. xhol-rev             CCTCGAGAATTAGGACTATCATACCTC 
 
RT_AASymporter_for AATCAGCCTTCACTCCGACAGC 
 
RT_AASymporter-rev ACTCATTGGAGAAGACACCGCG 
 
AAsymporter.fwd4 GGACGGGGATTTACCTTACC 
 
T7.AASymporter.rev4 cttaatacgactcactataggCAGTTCCGACAGTAGCGGC 
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>CP000829.1:1000027-1002349 Streptococcus pyogenes NZ131, complete 
genome 
CCTCGTATCCCTTTTCATCAAGCAAATCATTTTTAGCGTTTGAAATAGTTCCTAAAATAGAACGTTCATT
CCACTTTTTAGGGTCTATATTTAATTGTTTTAAAATGCGCTTCATCAACGTTCGTTGCTCACCTGGATCC
ACGATTGTGAAGTTTCGGTTGTAACCAATGTGATCAGCCTCACGACGCAGAATCCGTACACACATGGAGT
GAAAGGTAGCAATTAAGGTATCTTTAGTAGCTGGATTTAAGGCCAAGGCCCTTTCTTTCATTTCACGCGC
AGCCTTATTAGTAAAGGTAATAGCTAAAATATTCCAAGGATTGACAAATTTTTCATCAATTAAATAGGCA
ATACGATGGGTCAGTACCCTTGTTTTACCAGAACCAGCCCCCGCCATAATCAATAAGGGGCCTTCAGTTG
TTTGAACAGCTTGTGCCTGCCGATCATTCATTCCATTTAATAAAGGATTCATGCTTTCTCCTTAATCTCG
TTCAGTGACATCTCTTTTATCAACCTTAAAATTATATCATGTTTCCAAGAAAAATAGCAAAGAAGACCCC
AAAAGTAAAGAGATTCCTTTTTTCTAGTTTAGGATCAGATATTTAAAAATAATAGCGATTTCTTAAAGCA
TTCCTTATTTTTTTGCTATTTTGGTTGACTTCATTCGTTTTTTGAGGTATGATAGTCCTAATTTAATAAA
CCGAATGATGTCATGCAGGAGAAGAATTTTTTTCGCCGAAGGAGTTATACTCTCAGGTGTTCAGTTTTTG
AACGGGACTGTTTGATGGACGGACTTCTGGAGAGACCTTATTAGGCGCCGAAGGGGCAAGGCATACTGCT
CAATCTCTCAGGCAAAAGGACAGAAGGTAAAATACAAACACCATTAAGAACAGTCTTAGTCTTTTTTGTG
TTTGCTGTTTTATCATTGCTTCAGAAGTTGTCTCAAAGAAAGAGATAGCTTTTTTCTTTTGGCGTCTTCG
ATGACTTTTAGGAGAGAAAGAATGATAGCACTCGTTAAATTAATTGATAACCTTGTTTGGGGACCGCCCC
TCTTAATTTTATTGGTTGGGACGGGGATTTACCTTACCAGTCGTTTAGGATTAATTCAAATCTTAAAACT
ACCAAGAGCCTTTAAACTCATTTTTTCAGATGACGAAGGACATGGAGATATTTCATCCTTTGCTGCTCTT
GCAACTGCCCTTGCCGCTACTGTCGGAACTGGTAACATTGTTGGGGTTGCCACTGCTATCAAGTCTGGTG
GTCCTGGAGCGCTCTTTTGGATGTGGGTTGCCGCTTTTTTTGGAATGGCCACTAAGTACGCTGAAGGGGT
ACTAGCGATTAAATACCGTACAAAGGATGCCAACGGTCATATTTCTGGTGGTCCTATGTACTATATTGTT
AATGGCATGGGGACAAAATGGAAACCCTTAGCCATTCTTTTTGCGGGTTCAGGGATCCTAGTTGCCCTAT
TTGGAATAGGAACCTTTGCTCAAGTGAACTCGATCACCTCGTCTTTAGGTCATAGCTTTGGCTTATCCCC
ACAAATGGTCAGTATTGTTTTAGCTATCTTTGTGGCTGCCATTATTTTTGGTGGCATTCATTCCATTTCC
AAAGTGGCTGAAAAAGTCGTTCCTTTTATGGCTATTTTTTATATTCTATCTAGTTTAGCAGTTATTTTTA
GTCACTACCAGCAGCTACTTCCTGTTATTCGTTTAGTCTTTCAATCAGCCTTCACTCCGACAGCTGCTAT
TGGGGGCTTTGCTGGAAGTCTCATGAAGGATGCCATTCAAAAAGGAATTGCACGCGGTGTCTTCTCCAAT
GAGTCTGGACTAGGATCTGCACCTATTGCTGCAGCAGCAGCTAAAACCAATGAACCCGTGGAGCAGGGAC
TGATCTCCATGACAGGAACTTTTATTGATACGATTATTATCTGTACCCTAACCGGCCTATCTATTTTAGT
AACAGGCCAATGGACTGGGCAGCTCGAAGGGGCTCCTCTGACCCAATCTGCCTTTGCCACTGTGTTTGGA
AATTTAGGGACTTTTGGCCTAACCTTTTCCCTAGTTCTCTTCGCCTTTACAACGATTTTAGGATGGAGTT
ATTATGGAGAACGCTGCTTTGAATTCCTCTTTGGCATTACACATCTCACCTACTTCCGTATTGTCTTTAT
CTTAATGGTAGGCCTAGGAGGCTTCCTTAAGTTAGAACTAATTTGGGTTTTGGCTGATATTGTCAATGGT
TTAATGGCACTTCCTAACCTGATTGCCCTCCTAGCTCTCTCGCCAGTTGTTATTTTAGAAACCAAGCATT
ACTTTATTAAGTAA 
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Appendix 7-7. Cation efflux system protein (spy49-1009) sequence and the locations of 
designed primers. 
Ffflux.joint.rev GATTGGCATCGGCTGGTTGGC 
Efflux.fwd      GTCTCAACGAGCTAGGACC 
Efflux.rev GGCAGGCTCAACGTGAATG 
 
>CP000829.1:1002469-1003704 Streptococcus pyogenes NZ131 
ATGACACAGGATCCGATTGCAAATTTAAAACTAGCCAGAAAGGGCCCAATCGTTAGTATTATTGTCTACT 
TGTCGCTTAGTGTTGCCAAATTATTAGCTGGTTATTTGTTAAATGCAAGTTCCCTTATTGCTGATGGATT 
TAACAATTTATCGGATATTGTGGGAAATGTAGCCCTGCTTATTGGTCTTCACTTAGCTAGCCAACCAGCC 
GATGCCAATCATAAATTTGGTCATTGGAAAATTGAAGACTTATCCAGCCTTGTCACTTCTTTTATTATGT 
TTCTTGTAGGTTTCCAAGTACTGATTCACACAATTAAAAGTATCTTTAGTGGTCAGCAAGTTGATATTGA 
CCCTCTTGGGGCTATTGTCGGTATCGTTTCAGCTTTTGTTATGTTAGGGGTTTATGTCTTTAACAAACGT 
CTTTCCAAACGTGTAAAATCCAGTGCCTTAGTCGCTGCTTCTAAGGATAATCTAGCTGATGCTGTTACTT 
CTATCGGAACATCAATTGCTATTATAGCAGCTTCTTTGCATTTACCAGTTATCGATCATATAGCTGCTAT 
GATCATTACGTTCTTTATTCTTAAAACAGCTTTTGATATCTTTATGGAAAGTTCGTTTAGTTTATCTGAT 
GGATTTGATAGCCGTCATTTGAAAAAATCCGAAAAAGCCATTTTAGAAATCCCTAAAATTGTCGCCGTTA 
AGTCTCAACGAGCTAGGACCTATGGTAGCAATGTCTATCTTGATATTGTACTTGAAATGAATCCTGATCT 
TTCAGTCTATGAAAGTCACTCTATTACAGAGAAAGTGGAGCAGTTATTGAGTGACCAATTTTCTATTTAT 
GACATTAACATTCACGTTGAGCCTGCCATGATTCCCGAAGAAGAGATTTTTGATAATGTCGCCAAAAAGC 
TCTACCGCTACGAAAAATTAATTTGGAGTAAGGTTCCTGACTATGACCACTACATTGCTAAGTCTTTCCA 
ACTGATTGATGCGAATGGCCAAACAGTTAACTATGAACAATTTTGGAACCAAGAAATTTATTATCCAAGT 
AACTTCAACCATTTTCAGATTGAATCCATTAGTCAAAAAACGATGTTGGTAACTTACCAATTAAATGGCA 
ATCAACGTACCAGTATTTGGAGGCGTCATGAATCTTGGTCCTTACTCTTCCACCAAATTACCCCTATCGC 
TAAGAGACAATTACATCACACACACTATCGTATTGTAAAAATGTAA 
Appendix 7-8. Sequencing result of S. pyogenes M49/pFW11- promoterribogly-luc2 
transformant. luc-check.rev primer. 
Streptococcus pyogenes NZ131, complete genome  
Sequence ID: CP000829.1Length: 1815785Number of Matches: 1 
Related Information 
Range 1: 1000135 to 1000719  
Alignment statistics for match #1 
Score Expect Identities Gaps Strand 
1075 bits(582) 0.0 584/585(99%) 0/585(0%) Plus/Minus 
     
Query  430      AATTAGGACTATCATACCTCAAAAAACGAATGAAGTCAACCAAAATAGCaaaaaaaTAAG  489 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1000719  AATTAGGACTATCATACCTCAAAAAACGAATGAAGTCAACCAAAATAGCAAAAAAATAAG  1000660 
 
Query  490      GAATGCTTTAAGAAATCGCTATTATTTTTAAATATCTGATCCTAAACTAGAAAAAAGGAA  549 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1000659  GAATGCTTTAAGAAATCGCTATTATTTTTAAATATCTGATCCTAAACTAGAAAAAAGGAA  1000600 
 
Query  550      TCTCTTTACTTTTGGGGTCTTCTTTGCTATTTTTCTTGGAAACATGATATAATTTTAAGG  609 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1000599  TCTCTTTACTTTTGGGGTCTTCTTTGCTATTTTTCTTGGAAACATGATATAATTTTAAGG  1000540 
 
Query  610      TTGATAAAAGAGATGTCACTGAACGAGATTAAGGAGAAAGCATGAATCCTTTATTAAATG  669 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1000539  TTGATAAAAGAGATGTCACTGAACGAGATTAAGGAGAAAGCATGAATCCTTTATTAAATG  1000480 
 
Query  670      GAATGAATGATCGGCAGGCACAAGCTGTTCAAACAACTGAAGGCCCCTTATTGATTATGG  729 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1000479  GAATGAATGATCGGCAGGCACAAGCTGTTCAAACAACTGAAGGCCCCTTATTGATTATGG  1000420 
 
Query  730      CGGGGGCTGGTTCTGGTAAAACAAGGGTACTGACCCATCGTATTGCCTATTTAATTGATG  789 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1000419  CGGGGGCTGGTTCTGGTAAAACAAGGGTACTGACCCATCGTATTGCCTATTTAATTGATG  1000360 
 
Query  790      AAAAATTTGTCAATCCTTGGAATATTTTAGCTATTACCTTTACTAATAAGGCTGCGCGTG  849 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
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Sbjct  1000359  AAAAATTTGTCAATCCTTGGAATATTTTAGCTATTACCTTTACTAATAAGGCTGCGCGTG  1000300 
 
Query  850      AAATGAAAGAAAGGGCCTTGGCCTTAAATCCAGCTACTAAAGATACCTTAATTGCTACCT  909 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1000299  AAATGAAAGAAAGGGCCTTGGCCTTAAATCCAGCTACTAAAGATACCTTAATTGCTACCT  1000240 
 
Query  910      TTCACTCCATGTGTGTACGGATTCTGCGTCGTGAGGCTGATCACATTGGTTACAACCGAA  969 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1000239  TTCACTCCATGTGTGTACGGATTCTGCGTCGTGAGGCTGATCACATTGGTTACAACCGAA  1000180 
 
Query  970      ACTTCACAATCGTGGATCCAGGTGAGCAACGAACGTTGATGACGC  1014 
                |||||||||||||||||||||||||||||||||||||||||| || 
Sbjct  1000179  ACTTCACAATCGTGGATCCAGGTGAGCAACGAACGTTGATGAAGC  100013 
 
Appendix 7-9. Sequencing result of Na+/Alanine symporter and cation efflux system junction 
fragment. AA.Efflux.joint.fwd primer. 
Streptococcus pyogenes NZ131, complete genome  
Sequence ID: CP000829.1Length: 1815785Number of Matches: 1 
Related Information 
Range 1: 1002342 to 1002688  
Alignment statistics for match #1 
Score Expect Identities Gaps Strand 
630 bits(341) 6e-177 346/348(99%) 2/348(0%) Plus/Plus 
     
Query  8        TTATAGT-AACATGACGTTAGTACTACCCAGTTATACCTAGTCTTCTTCTGCCAAGTTCA  66 
                ||| ||| |||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1002342  TTA-AGTAAACATGACGTTAGTACTACCCAGTTATACCTAGTCTTCTTCTGCCAAGTTCA  1002400 
 
Query  67       AGACGCTAGGCTTTTTTCTTAAGCCCCTTTTTATGGTATAATATAAAGTTGAAATCAAAG  126 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1002401  AGACGCTAGGCTTTTTTCTTAAGCCCCTTTTTATGGTATAATATAAAGTTGAAATCAAAG  1002460 
 
Query  127      GAGTTATTATGACACAGGATCCGATTGCAAATTTAAAACTAGCCAGAAAGGGCCCAATCG  186 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1002461  GAGTTATTATGACACAGGATCCGATTGCAAATTTAAAACTAGCCAGAAAGGGCCCAATCG  1002520 
 
Query  187      TTAGTATTATTGTCTACTTGTCGCTTAGTGTTGCCAAATTATTAGCTGGTTATTTGTTAA  246 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1002521  TTAGTATTATTGTCTACTTGTCGCTTAGTGTTGCCAAATTATTAGCTGGTTATTTGTTAA  1002580 
 
Query  247      ATGCAAGTTCCCTTATTGCTGATGGATTTAACAATTTATCGGATATTGTGGGAAATGTAG  306 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1002581  ATGCAAGTTCCCTTATTGCTGATGGATTTAACAATTTATCGGATATTGTGGGAAATGTAG  1002640 
 
Query  307      CCCTGCTTATTGGTCTTCACTTAGCTAGCCAACCAGCCGATGCCAATC  354 
                |||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1002641  CCCTGCTTATTGGTCTTCACTTAGCTAGCCAACCAGCCGATGCCAATC  1002688 
 
 
 
Appendix 7-10. Sequencing result of 3´flanking region of cand34 in WTΔcand34 using Spec-
weg-for primer. 
Streptococcus pyogenes NZ131, complete genome 
Sequence ID: CP000829.1Length: 1815785Number of Matches: 1 
Range 1: 1200583 to 1201475 
Score 
Expect Identities Gaps Strand 
1633 bits(884) 0.0 890/894(99%) 1/894(0%) Plus/Minus  
 
Query  119      TGCGCCACTAGCTTTCGGTAAACTAAGGGTAACTTAAGAGAGGAGTTATTTATGACACTA  178 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1201475  TGCGCCACTAGCTTTCGGTAAACTAAGGGTAACTTAAGAGAGGAGTTATTTATGACACTA  1201416 
 
Query  179      TCACTTGTATTAATGGTATCGGTTTTTGGGGCAGGCTTGTTATCATTTTTCTCTCCGTGT  238 
                |||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1201415  TCACTTGTAT-AATGGTATCGGTTTTTGGGGCAGGCTTGTTATCATTTTTCTCTCCGTGT  1201357 
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Query  239      ATCTTTCCGGTCCTTCCTGTCTATTTAGGCATTTTACTGGATGCAGATGATTCAAAGACG  298 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1201356  ATCTTTCCGGTCCTTCCTGTCTATTTAGGCATTTTACTGGATGCAGATGATTCAAAGACG  1201297 
 
Query  299      ATTACTATATTTGGTAAAAAACTCTATTGGTATGGCATTGTCAAAACCTTAGCCTTTATT  358 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1201296  ATTACTATATTTGGTAAAAAACTCTATTGGTATGGCATTGTCAAAACCTTAGCCTTTATT  1201237 
 
Query  359      TTTGGTCTATCTACTATTTTTGTGATTTTAGGTTACGGGGCTGGTTTTTTAGGAAATATC  418 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1201236  TTTGGTCTATCTACTATTTTTGTGATTTTAGGTTACGGGGCTGGTTTTTTAGGAAATATC  1201177 
 
Query  419      CTTTATGCGGTATGGTTTCGGTACTTACTGGGAGCCGTGGTCATTATCTTGGGGATTCAT  478 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1201176  CTTTATGCGGTATGGTTTCGGTACTTACTGGGAGCCGTGGTCATTATCTTGGGGATTCAT  1201117 
 
Query  479      CAGATGGGCCTCATTACCATTAAGAGCTTACAATTTCAAAAATCACTGACTTTCCATAAT  538 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1201116  CAGATGGGCCTCATTACCATTAAGAGCTTACAATTTCAAAAATCACTGACTTTCCATAAT  1201057 
 
Query  539      AACAAGAATCGCAACGGTTTGTTCAATGCATTTATCCTTGGTTTAACCTTTAGCTTTGGT  598 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1201056  AACAAGAATCGCAACGGTTTGTTCAATGCATTTATCCTTGGTTTAACCTTTAGCTTTGGT  1200997 
 
Query  599      TGGACGCCTTGTGTGGGACCTGTTTTGAGTTCTGTTCTAGCTTTGGTGGCTTCAGGGGGA  658 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1200996  TGGACGCCTTGTGTGGGACCTGTTTTGAGTTCTGTTCTAGCTTTGGTGGCTTCAGGGGGA  1200937 
 
Query  659      AATGGTGCCTGGCAAGGTGGCGTTTTGATGATTATTTATACTCTTGGATTGGGCATTCCT  718 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1200936  AATGGTGCCTGGCAAGGTGGCGTTTTGATGATTATTTATACTCTTGGATTGGGCATTCCT  1200877 
 
Query  719      TTCCTGCTTATCTCTTTTGCGTCAGGCATTGTTTTGAAACAGTTTAACAAGCTCAAACCC  778 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1200876  TTCCTGCTTATCTCTTTTGCGTCAGGCATTGTTTTGAAACAGTTTAACAAGCTCAAACCC  1200817 
 
Query  779      CACATGCTTTTACTGAANAAAGTAGGAGGCGTTCTGATTATAGTCATGGGAATCTTGCTT  838 
                ||||||||||||||||| |||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1200816  CACATGCTTTTACTGAAAAAAGTAGGAGGCGTTCTGATTATAGTCATGGGAATCTTGCTT  1200757 
 
Query  839      ATGACAGGAACCTTAAATAACTTAGCACAACTTTTTGGATAAAGGAGAAACACAATGAAN  898 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct  1200756  ATGACAGGAACCTTAAATAACTTAGCACAACTTTTTGGATAAAGGAGAAACACAATGAAA  1200697 
 
Query  899      AAAGGACTATTAGTAACAACTGGTTTGGCTTGTCTCGGGCTACTAACTGCTTGCTCAACC  958 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1200696  AAAGGACTATTAGTAACAACTGGTTTGGCTTGTCTCGGGCTACTAACTGCTTGCTCAACC  1200637 
 
Query  959      CAAGACAATATGGCTAANAAGGAAATAACTCAGGACAAGATGAGCATGGCAGCT  1012 
                ||||||||||||||||| |||||||||||||||||||||||||||||||||||| 
Sbjct  1200636  CAAGACAATATGGCTAAAAAGGAAATAACTCAGGACAAGATGAGCATGGCAGCT  1200583 
 
 
Appendix 7-11. Sequencing result of 5´flanking region of cand34 in WTΔcand34 using MCSI-
for primer. 
Streptococcus pyogenes NZ131, complete genome 
Sequence ID: CP000829.1Length: 1815785Number of Matches: 1 
Range 1: 1202004 to 1202863 
Score 
 
Expect 
 
Identities 
 
Gaps 
 
Strand 
1585 bits(858) 0.0 859/860(99%) 0/860(0%) Plus/Minus  
 
Query  59       CTTCCAAGGTCGGAGTAAACGACCACCCTTAGATTGTGTTAATGCCCTCTTGTCTTTTGG  118 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1202863  CTTCCAAGGTCGGAGTAAACGACCACCCTTAGATTGTGTTAATGCCCTCTTGTCTTTTGG  1202804 
 
Query  119      TTACAGTTTACTGACCTTTGAATGTCAATCTGCCTTGGAAGCTGTCGGATTAGACAGTTA  178 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1202803  TTACAGTTTACTGACCTTTGAATGTCAATCTGCCTTGGAAGCTGTCGGATTAGACAGTTA  1202744 
 
Query  179      CGTTGGTTTCTTTCACACGGATCGTCCTGGGCGTGCTAGTTTAGCGCTTGATTTAGTTGA  238 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1202743  CGTTGGTTTCTTTCACACGGATCGTCCTGGGCGTGCTAGTTTAGCGCTTGATTTAGTTGA  1202684 
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Query  239      AGAGTTCCGCTCATATATTGTAGATCGTTTTGTCTTTTCATTAATTAATAAAGGACAACT  298 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1202683  AGAGTTCCGCTCATATATTGTAGATCGTTTTGTCTTTTCATTAATTAATAAAGGACAACT  1202624 
 
Query  299      TCAGAAAAAACACTTTGAGGTTAAAGAAAATGGTAGTATTTTATTGACGGAAAATGGCAG  358 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1202623  TCAGAAAAAACACTTTGAGGTTAAAGAAAATGGTAGTATTTTATTGACGGAAAATGGCAG  1202564 
 
Query  359      AGCTATTTTTATTGATTTGTGGCAGAAGCGTAAGCATACTGAGGTAGAACATCCTTTTAC  418 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1202563  AGCTATTTTTATTGATTTGTGGCAGAAGCGTAAGCATACTGAGGTAGAACATCCTTTTAC  1202504 
 
Query  419      AAAAGAAAAAGTAAAACTTATGTTATTACCCTATGTACAAGCGCAGCTTTTAGCTAAGGC  478 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1202503  AAAAGAAAAAGTAAAACTTATGTTATTACCCTATGTACAAGCGCAGCTTTTAGCTAAGGC  1202444 
 
Query  479      CATACGAGGAGATTTAGAAAGCTATCCACCTTTTATGGTTTAGGAGATGTTATATGATGG  538 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1202443  CATACGAGGAGATTTAGAAAGCTATCCACCTTTTATGGTTTAGGAGATGTTATATGATGG  1202384 
 
Query  539      TTTTAGTCACTTATGATGTAAATACGGAAACACCTGCTGGTAGAAAAAGATTGCGTCATG  598 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1202383  TTTTAGTCACTTATGATGTAAATACGGAAACACCTGCTGGTAGAAAAAGATTGCGTCATG  1202324 
 
Query  599      TTGCCAAACTCTGTGTGGACTATGGGCAACGTGTTCAAAATTCTGTTTTTGAATGTTCTG  658 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1202323  TTGCCAAACTCTGTGTGGACTATGGGCAACGTGTTCAAAATTCTGTTTTTGAATGTTCTG  1202264 
 
Query  659      TGACACCCGCAGAATTTGTGGATATAAAGCACCGCTTAACACAAATCATTGATGAGAAAA  718 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1202263  TGACACCCGCAGAATTTGTGGATATAAAGCACCGCTTAACACAAATCATTGATGAGAAAA  1202204 
 
Query  719      CTGATAGTATTCGCTTTTATTTATTGGGGAAAAATTGGCAGAGGCGTGTGGAAACACTTG  778 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1202203  CTGATAGTATTCGCTTTTATTTATTGGGGAAAAATTGGCAGAGGCGTGTGGAAACACTTG  1202144 
 
Query  779      GTCGCTCAGACAGCTATGACCCAGATAAAGGTGTCTTATTATTGTAAAAATCTCTTGTGC  838 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1202143  GTCGCTCAGACAGCTATGACCCAGATAAAGGTGTCTTATTATTGTAAAAATCTCTTGTGC  1202084 
 
Query  839      GAAGCTAGCTTTCACAGAAACACCTTGCTTGCTCGCGCAAAAATAACTTAAAAAAGAAGC  898 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1202083  GAAGCTAGCTTTCACAGAAACACCTTGCTTGCTCGCGCAAAAATAACTTAAAAAAGAAGC  1202024 
 
Query  899      GAAATGGAGATAANAAGGCT  918 
                ||||||||||||| |||||| 
Sbjct  1202023  GAAATGGAGATAAAAAGGCT  1202004 
 
 
 Appendix 7-12. Sequencing result of cand34 in pAT19-cand34. 
A: using Compl _M16/c34_Bam_fwd primer. 
 
Streptococcus pyogenes NZ131, complete genome 
Sequence ID: CP000829.1Length: 1815785Number of Matches: 12 
Range 1: 1201501 to 1201949  
Score Expect Identities Gaps Strand 
708 bits(383) 0.0 429/451(95%) 3/451(0%) Plus/Plus 
     
Query  27       CTTGAATTTGATACGCTATCAGATAAATGGTTGACTAAAGGCATGTAAAAACCCGACCTC  86 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1201501  CTTGAATTTGATACGCTATCAGATAAATGGTTGACTAAAGGCATGTAAAAACCCGACCTC  1201560 
 
Query  87       TCTTTTAATGAGGTCAGGTTCATCTTTCAATCCACTCACCCATGAAGGGTGAGACAAGAT  146 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1201561  TCTTTTAATGAGGTCAGGTTCATCTTTCAATCCACTCACCCATGAAGGGTGAGACAAGAT  1201620 
 
Query  147      GACACTGGTACTGCACATGTCGATTTAAAAATTTCAATCCACTCACCCATGAAGGGTGAG  206 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1201621  GACACTGGTACTGCACATGTCGATTTAAAAATTTCAATCCACTCACCCATGAAGGGTGAG  1201680 
 
Query  207      ACAGATCTTAAAATGGATTCTTCTTCAGATATTTTTGATTTCAATCCACTCACCCATGAA  266 
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                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1201681  ACAGATCTTAAAATGGATTCTTCTTCAGATATTTTTGATTTCAATCCACTCACCCATGAA  1201740 
 
Query  267      GGGTGAGACGATAACAGTTGCTTTAGTCGATAAGTCGATTAGCGATTTCAATCCACTCAC  326 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1201741  GGGTGAGACGATAACAGTTGCTTTAGTCGATAAGTCGATTAGCGATTTCAATCCACTCAC  1201800 
 
Query  327      CCATGAAGGGTGAGACATTATGTTTTGCCACATGAGAAAGTAAAAAATGGAATTTCAATC  386 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1201801  CCATGAAGGGTGAGACATTATGTTTTGCCACATGAGAAAGTAAAAAATGGAATTTCAATC  1201860 
 
Query  387      CACTCACCCATGAAGGGTGAGACGCTGTGACATTGCGGGATGTAATCAAAG-TAAAAAAT  445 
                ||||||||||||||||||||||| |  | | | | ||  |   || |   | |  |  || 
Sbjct  1201861  CACTCACCCATGAAGGGTGAGACTCCCTTATAAT-CGACAAA-AAGCGCCGATTGATTAT  1201918 
 
Query  446      TTCAATCCACTCACCCATGAAGGGTGAGACT  476 
                ||||||||||||||||| ||||||||||||| 
Sbjct  1201919  TTCAATCCACTCACCCACGAAGGGTGAGACT  1201949 
 
B: using Compl _M16/c34_Sall_rev primer 
Streptococcus pyogenes NZ131, complete genome  
Sequence ID: CP000829.1Length: 1815785 
Related Information 
Range 1: 1201501 to 1201949  
Score Expect Identities Gaps Strand 
708 bits(383) 0.0 429/451(95%) 3/451(0%) Plus/Minus 
     
Query  301      AGTCTCACCCTTCATGGGTGAGTGGATTGAAATTTTTTA-CTTTGATTACATCCCGCAAT  359 
                ||||||||||||| |||||||||||||||||||  |  | |   | ||   |  || | | 
Sbjct  1201949  AGTCTCACCCTTCGTGGGTGAGTGGATTGAAATAATCAATCGGCGCTT-TTTGTCG-ATT  1201892 
 
Query  360      GTCACAGCGTCTCACCCTTCATGGGTGAGTGGATTGAAATTCCATTTTTTACTTTCTCAT  419 
                 | |  | |||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1201891  ATAAGGGAGTCTCACCCTTCATGGGTGAGTGGATTGAAATTCCATTTTTTACTTTCTCAT  1201832 
 
Query  420      GTGGCAAAACATAATGTCTCACCCTTCATGGGTGAGTGGATTGAAATCGCTAATCGACTT  479 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1201831  GTGGCAAAACATAATGTCTCACCCTTCATGGGTGAGTGGATTGAAATCGCTAATCGACTT  1201772 
 
Query  480      ATCGACTAAAGCAACTGTTATCGTCTCACCCTTCATGGGTGAGTGGATTGAAATCAAAAA  539 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1201771  ATCGACTAAAGCAACTGTTATCGTCTCACCCTTCATGGGTGAGTGGATTGAAATCAAAAA  1201712 
 
Query  540      TATCTGAAGAAGAATCCATTTTAAGATCTGTCTCACCCTTCATGGGTGAGTGGATTGAAA  599 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1201711  TATCTGAAGAAGAATCCATTTTAAGATCTGTCTCACCCTTCATGGGTGAGTGGATTGAAA  1201652 
 
Query  600      TTTTTAAATCGACATGTGCAGTACCAGTGTCATCTTGTCTCACCCTTCATGGGTGAGTGG  659 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1201651  TTTTTAAATCGACATGTGCAGTACCAGTGTCATCTTGTCTCACCCTTCATGGGTGAGTGG  1201592 
 
Query  660      ATTGAAAGATGAACCTGACCTCATTAAAAGAGAGGTCGGGTTTTTACATGCCTTTAGTCA  719 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1201591  ATTGAAAGATGAACCTGACCTCATTAAAAGAGAGGTCGGGTTTTTACATGCCTTTAGTCA  1201532 
 
Query  720      ACCATTTATCTGATAGCGTATCAAATTCAAG  750 
                ||||||||||||||||||||||||||||||| 
Sbjct  1201531  ACCATTTATCTGATAGCGTATCAAATTCAAG  1201501 
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Appendix 7-13. Target prediction of sRNA can34 using the online tool CobraRNA 
(Wright, et al., 2013). 
Rank CopraRNA 
p-value 
Locus Tag Gene 
Name  
Energy 
[kcal/mol]  
PositionmRNA  Position 
sRNA 
Annotation 
1. 1.557e-10 spy49_rs05965 N/A -24.93 1 -- 20 69 -- 88 cytochrome C biogenesis 
protein CcdA 
 
2. 0.0008724 spy49_rs06360 N/A -15.54 136 -- 151 233 -- 
248 
NAD(+) synthetase 
 
3. 0.0009724 spy49_rs07985 N/A -15.59 260 -- 290 97 -- 126 peptide deformylase 
 
 
4. 0.001523 spy49_rs04125 glmM -15.25 232 -- 247 232 -- 
248 
phosphoglucosamine 
mutase 
 
5. 0.00157 spy49_rs04330 N/A -15.69 143 -- 153 32 -- 42 spermidine/purescine 
ABC transporter 
permease 
 
6. 0.002337 spy49_rs02545 N/A -14.76 244 -- 254 238 -- 
248 
PTS beta-glucoside 
transporter subunit 
EIIBCA 
 
7. 0.002864 spy49_rs06845 N/A -14.30 187 -- 221 115 -- 
144 
aspartyl/glutamyl-
tRNA(Asn/Gln) 
amidotransferase subunit 
C 
 
8. 0.004982 spy49_rs05985 N/A -13.33 16 -- 68 98 -- 156 type I-C CRISPR-
associated protein 
Cas7/Csd2 
 
9. 0.005282 spy49_rs00965 N/A -12.99 172 -- 193 119 -- 
140 
L-xylulose 5-phosphate 
3-epimerase 
 
10. 0.007091 spy49_rs01155 N/A -13.21 42 -- 54 75 -- 87 DNA repair protein RadA 
 
 
Appendix 7-14. Target prediction of the sRNA cand34 using the online tool TargetRNA2 (Kery 
& Feldman, 2014). 
Rank p-
value 
Energy 
[kcal/mol] 
Position 
mRNA 
Position 
sRNA 
gene Synonym Annotation 
1. 0.005 -12.65 (-70) - (-61) 54-45 pyrC Spy49_0718 dihydroorotase 
 
2. 0.006 -12.43 1-13 12-1 - Spy49_1488c Small terminase 
 
3. 0.014 -10.97 (-1) - 12 56-43 rpmF Spy49_1770 50S ribosomal protein L32 
 
4. 0.015 -10.85 (-5) - 7 47- 36 - Spy49_1556c DAK2 domain-containing 
protein 
 
5. 0.025 -9.85 (-34) - (-19) 279- 264 rpsE Spy49_0065 30S ribosomal protein S5 
 
6. 0.028 -9.61 (-48) - (-34) 36- 22 exoA Spy49_0334C 3-exo-deoxyribonuclease 
 
7. 0.033 -9.28 (-76) - (-68) 47- 39 hutG Spy49_1731 Formimidoylglutamase 
 
8. 0.036 -9.08              1-10 42-33 - Spy49_0953c hypothetical protein 
 
9. 0.039 -8.89 (-9) - 6 15-2 - Spy49_0018 glycerol-3-phosphate 
acyltransferase PlsX 
 
10. 0.044 -8.62 (-70) - (-57) 270- 256  Spy49_0946 DNA-binding protein 
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Appendix 7-15.Target prediction of the sRNA cand34 using the online tool RNApredator (Zhao, 
et al., 2008). 
Rank Energy 
[kJ/mol] 
z-
Score 
mRNA 
[Start] 
mRNA 
[End] 
sRNA Gene 
Annotation 
Accession 
1. -29.12 -9.34 -153 -124 1-30 Cytochrome c type biogenesis protein Spy49 NC_011375 
2. -16.66 -3.75 -187 -172 32-47 Aspartate carbamoyltransferase Spy49 NC_011375 
3. -16.16 -3.52 223 243 31-51 D lactate dehydrogenase Spy49 NC_011375 
4. -16.07 -3.48 19 36 233-
250 
NAD synthetase Spy49 NC_011375 
5. -15.58 -3.26 638 659 119-
140 
Hexulose 6 phosphate synthase Spy49 NC_011375 
6. -15.41 -3.19 -58 -48 32-42 Spermidine Putrescine ABC transporter 
permease component potC Spy49 
 
NC_011375 
7. -15.25 -3.12 733 743 32-42 Spermidine Putrescine ABC transporter 
permease component potB Spy49 
 
NC_011375 
8. -15.15 -3.07 1133 1148 32-47 Putative uracil permease Spy49 NC_011375 
9. -14.99 -3 1249 1265 35-53 Putative cationic amino acid transporter protein 
Spy49 
 
NC_011375 
10. -14.99 -3 53 81 116-
144 
Aspartyl tRNA(Asn) amidotransferase subunit C 
Spy49 
 
NC_011375 
11. -14.90 -2.96 809 829 299-
325 
Putative protoporphyrinogen oxidase Spy49 
 
NC_011375 
12. -14.83 -2.93 943 964 300-
323 
hypothetical protein Spy49 1048c Spy49 
 
NC_011375 
13. -14.67 -2.86 384 401 244-
261 
hypothetical protein Spy49 1765c Spy49 
 
NC_011375 
14. -14.42 -2.74 1382 1400 233-
251 
Putative salivaricin A modification enzyme; 
amino acid dehydration Spy49 
 
NC_011375 
15. -14.41 -2.74 342 355 265-
278 
LSU ribosomal protein L18p (L5e) Spy49 
 
NC_011375 
16. -14.30 -2.69 -186 -175 35-47 Seryl tRNA synthetase Spy49 NC_011375 
17. -14.25 -2.67 102 125 32-53 Putative Holliday junction resolvase Spy49 
 
NC_011375 
18. -14.08 -2.59 -192 -173 232-
251 
hypothetical protein Spy49 1390c Spy49 
 
NC_011375 
19. -14.00 -2.55 836 847 35-46 Two component system histidine kinase Spy49 
 
NC_011375 
20. -13.89 -2.51 117 139 32-53 Glycerol uptake facilitator protein Spy49 
 
NC_011375 
21. -13.88 -2.5 976 991 38-53 GTP binding and nucleic acid binding protein 
YchF Spy49 
 
NC_011375 
22. -13.85 -2.49 813 828 238-
253 
DNA polymerase III delta prime subunit Spy49 
 
NC_011375 
23. -13.83 -2.48 1218 1239 232-
255 
hypothetical protein Spy49 1238 Spy49 
 
NC_011375 
24. -13.76 -2.45 753 768 38-52 Penicillin binding protein 7 precursor (PBP 7) (D 
alanyl D alanine endopeptidase) Spy49 
 
NC_011375 
25. -13.69 -2.42 -199 -177 301-
324 
Transcriptional regulator; DeoR family Spy49 
 
NC_011375 
26. -13.62 -2.38 954 968 38-52 Putative esterase Spy49 
 
NC_011375 
27. -13.52 -2.34 1686 1705 32-53 Putative heavy metal transporting ATPase Spy49 NC_011375 
28. -13.47 -2.32 2343 2355 241-
253 
DNA mismatch repair protein MutS Spy49 
 
NC_011375 
29. -13.44 -2.3 -106 -90 35-53 Histidine ammonia lyase Spy49 
 
NC_011375 
30. -13.43 -2.3 292 310 32-51 hypothetical protein Spy49 0961c Spy49 
 
NC_011375 
31. -13.43 -2.3 67 76 299-
308 
Putative chromosome segregation SMC Spy49 
 
NC_011375 
32. -13.41 -2.29 -123 -109 236-
250 
ComX2 alternate sigma factor Spy49 
 
NC_011375 
33. -13.40 -2.29 466 483 35-51 Peptide methionine sulfoxide reductase msrA 
Spy49 
 
NC_011375 
34. -13.39 -2.28 716 733 116-
133 
Putative positive transcriptional regulator Spy49 
 
NC_011375 
35. -13.27 -2.23 628 646 35-52 hypothetical protein Spy49 1801c Spy49 NC_011375 
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36. -13.22 -2.21 29 43 37-51 Putative copper transporting ATPase Spy49 
 
NC_011375 
37. -13.21 -2.2 739 753 34-47 hypothetical protein Spy49 1266c Spy49 
 
NC_011375 
38. -13.21 -2.2 160 179 32-51 hypothetical protein Spy49 0160 Spy49 NC_011375 
39. -13.13 -2.16 -15 -7 300-
308 
UDP N acetylglucosamine 1  
carboxyvinyltransferase Spy49 
 
NC_011375 
40. -13.12 -2.16 -33 -20 265-
278 
SSU ribosomal protein S5p (S2e) Spy49 
 
NC_011375 
41. -13.12 -2.16 117 127 43-53 Immunogenic secreted protein Spy49 
 
NC_011375 
42. -13.03 -2.12 -136 -118 300-
318 
hypothetical protein Spy49 0347 Spy49 
 
NC_011375 
43. -13.03 -2.12 28 44 231-
248 
Phosphoglucosamine mutase Spy49 
 
NC_011375 
44. -12.99 -2.1 841 862 31-50 Probable regulatory protein Spy49 
 
NC_011375 
45. -12.99 -2.1 1115 1125 299-
309 
Putative rhamnosyltransferase Spy49 
 
NC_011375 
46. -12.96 -2.09 43 53 238-
248 
Beta glucoside permease IIABC component 
Spy49 
 
NC_011375 
47. -12.94 -2.08 518 539 30-49 Antirepressor Spy49 
 
NC_011375 
48. -12.88 -2.05 2089 2101 235-
247 
Extracellular hyaluronate lyase Spy49 
 
NC_011375 
49. -12.86 -2.04 426 439 33-46 Probable dipeptidase Spy49 
 
NC_011375 
50. -12.81 -2.02 -29 -8 119-
140 
Hexulose 6 phosphate isomerase Spy49 
 
NC_011375 
51. -12.75 -1.99 98 115 37-53 Putative ATP dependent exonuclease; subunit A 
Spy49 
 
NC_011375 
52. -12.71 -1.98 305 318 313-
325 
Putative peptidoglycan branched peptide 
synthesis protein; serine/alanine adding enzyme 
Spy49 
 
NC_011375 
53. -12.67 -1.96 864 875 35-47 Aerobic glycerol 3 phosphate dehydrogenase 
Spy49 
 
NC_011375 
54. -12.62 -1.94 -58 -34 235-
259 
Putative secreted protein Streptputative secreted 
protein Spy49 
 
NC_011375 
55. -12.60 -1.93 112 121 1-10 hypothetical protein Spy49 0777 Spy49 
 
NC_011375 
56. -12.57 -1.91 393 411 32-52 Transcriptional regulator; GntR family Spy49 
 
NC_011375 
57. -12.52 -1.89 56 66 238-
248 
hypothetical protein Spy49 1218c Spy49 
 
NC_011375 
58. -12.51 -1.89 -83 -62 232-
255 
Alpha mannosidase Spy49 
 
NC_011375 
59. -12.48 -1.87 238 249 243-
254 
Putative efflux protein Spy49 
 
NC_011375 
60. -12.46 -1.86 1026 1043 35-51 Amidophosphoribosyltransferase Spy49 
 
NC_011375 
61. -12.45 -1.86 -14 6 299-
325 
Sua5/YciO/YrdC family protein Spy49 
 
NC_011375 
62. -12.43 -1.85 341 355 241-
255 
hypothetical protein Spy49 0801 Spy49 
 
NC_011375 
63. -12.43 -1.85 263 283 299-
325 
Iron sulfur cluster assembly protein SufD Spy49 
 
NC_011375 
64. -12.42 -1.85 2285 2304 299-
325 
Putative DNA mismatch repair protein Spy49 
 
NC_011375 
65. -12.40 -1.84 -31 -17 233-
248 
hypothetical protein Spy49 0352c Spy49 
 
NC_011375 
66. -12.31 -1.8 159 175 243-
259 
hypothetical protein Spy49 1435c Spy49 
 
NC_011375 
67. -12.30 -1.79 40 49 1-10 hypothetical protein Spy49 0756 Spy49 
 
NC_011375 
68. -12.28 -1.78 267 283 33-51 Ribonuclease HII Spy49 
 
NC_011375 
69. -12.28 -1.78 49 56 300-
307 
hypothetical protein Spy49 1497c Spy49 
 
NC_011375 
70. -12.27 -1.78 358 373 32-47 hypothetical protein Spy49 1229c Spy49 
 
NC_011375 
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71. -12.24 -1.77 642 653 315-
326 
Transmembrane histidine kinase CsrS Spy49 
 
NC_011375 
72. -12.23 -1.76 132 154 65-88 Putative transcriptional regulator Spy49 
 
NC_011375 
73. -12.18 -1.74 674 701 300-
325 
hypothetical protein Spy49 0740 Spy49 NC_011375 
74. -12.16 -1.73 360 369 1-10 Lactate oxidase Spy49 
 
NC_011375 
75. -12.15 -1.73 115 127 34-46 Putative PTS dependent galactosamine IID 
component Spy49 
 
NC_011375 
76. -12.13 -1.72 -169 -161 32-40 Low molecular weight protein tyrosine 
phosphatase Spy49 
 
NC_011375 
77. -12.12 -1.71 963 974 67-78 Two component sensor histidine kinase Spy49 
 
NC_011375 
78. -12.08 -1.69 381 402 301-
322 
hypothetical protein Spy49 0642 Spy49 
 
NC_011375 
79. -12.08 -1.69 273 281 300-
308 
ComX1 Alternate Sigma Factor Spy49 
 
NC_011375 
80. -12.07 -1.69 352 363 66-77 Glyoxalase family protein Spy49 
 
NC_011375 
81. -12.05 -1.68 884 902 32-47 hypothetical protein Spy49 0623 Spy49 
 
NC_011375 
82. -12.04 -1.68 421 430 244-
253 
Endonuclease III Spy49 
 
NC_011375 
83. -12.01 -1.66 256 275 35-53 SSU ribosomal protein S2p (SAe) Spy49 
 
NC_011375 
84. -12.00 -1.66 493 507 244-
258 
Protein dltB Spy49 
 
NC_011375 
85. -11.97 -1.64 96 117 31-51 Putative permease Spy49 
 
NC_011375 
86. -11.92 -1.62 431 452 30-53 Protein dltD precursor Spy49 
 
NC_011375 
87. -11.91 -1.62 440 448 300-
308 
Recombination protein Spy49 
 
NC_011375 
88. -11.89 -1.61 632 643 242-
253 
Alcohol dehydrogenase Spy49 
 
NC_011375 
89. -11.88 -1.6 183 208 301-
325 
hypothetical protein Spy49 1380c Spy49 
 
NC_011375 
90. -11.87 -1.6 35 48 36-48 Regulatory protein spx Spy49 
 
NC_011375 
91. -11.82 -1.58 1187 1207 303-
324 
Putative ABC transporter Spy49 
 
NC_011375 
92. -11.80 -1.57 -174 -164 241-
251 
Beta glucosidase Spy49 
 
NC_011375 
93. -11.79 -1.56 1694 1700 300-
306 
Putative ABC transporter; ATP binding protein 
Spy49 
 
NC_011375 
94. -11.78 -1.56 190 202 238-
250 
Acetyl CoA acetyltransferase Spy49 NC_011375 
95. -11.78 -1.56 685 705 238-
258 
Laminin binding surface protein Spy49 
 
NC_011375 
96. -11.77 -1.55 545 559 244-
257 
Sugar ABC transporter; permease protein Spy49 
 
NC_011375 
97. -11.77 -1.55 709 717 32-40 Putative multi drug resistance efflux pump Spy49 
 
NC_011375 
98. -11.77 -1.55 44 66 32-51 Ribonuclease Z Spy49 
 
NC_011375 
99. -11.75 -1.55 111 120 239-
248 
hypothetical protein Spy49 1343c Spy49 NC_011375 
100. -11.75 -1.55 56 73 238-
258 
Zinc binding protein adcA precursor Spy49 NC_011375 
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Abreviations 
aad9 resistance gene for spectinomycin 
Ala Alanine 
bp base pair 
°C Celcius / centigrade 
CaCl2 Calcium Chloride 
CFU Colony Forming Unit 
CO2 carbondioxide 
cDNA Conmlementary DNA 
DMEM    Dulbecco’s Modified Eagle’s Medium 
DNA deoxyribonucleic acid 
dNTP dideoxynucleoside triphosphate 
E. coli  Escherichia coli 
EDTA Ethylene Diamine Tetraacetic Acid 
FCS  Fetal Calf Serum 
GAS    Group A Streptococcus 
Gly Glycine 
h hour 
LB       Luria Bertani 
luc  luciferase 
Mg Magnesium 
min  minute 
mM  millimolar 
n nano (10-9) 
NaCl sodium chloride 
NaOH sodium hydroxide 
nm nometer 
OD Optical Density 
PBS  Phosphate Buffered Saline 
PCR Polymerase Chain Reaction 
pH power of Hydrogen 
RLU  Relative Light Unit 
RNA ribonucleic acid 
rpm revolutions per minute 
RT-qPCR Revers Transcriptase- quantitative PCR  
S Second 
S. pyogenes Streptococcus pyogenes 
Ser Serine 
THB  Todd Hewitt Broth 
THY  Todd Hewitt Yeast 
Tween 20  polyoxyethylene sorbital monolaurate 
UV Ultraviolet 
WT  Wild Type 
µ micro (10-6) 
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